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Abstract  
 
CD4
+
 T cells play protective roles against viral, bacterial, fungal and parasitic infections. 
This protective ability results from the capacity of CD4
+ 
T cells to differentiate into various effector 
T helper subsets which have been extensively described in recent literature. T helper cells aid 
pathogen killing either directly, by secreting potent pro-inflammatory cytokines such as tumour 
necrosis factor (TNF) or indirectly, by providing help to B cells in order to promote class switching 
or secreting cytokines such as interferon gamma (IFNγ) to activate macrophages to enhance their 
microbicidal activity. CD4
+
 T cells have a unique characteristic to be plastic, depending on the 
tissue environment (cytokines and chemokines), expression of master transcription factors, nature 
of the invading pathogen and the current immune status of the host (immunocompetent vs 
immunocompromised). Generation of T-helper 1 (Th1) CD4
+
 T cells requires expression of the 
master transcription factor T bet and cytokines interleukin (IL)-12, IFNγ and TNF. Studies have 
identified the protective ability of Th1 cells in Plasmodium and Leishmania infections and the more 
recent self-regulatory Th1 cells, known as Tr1 cells have been shown to limit immunopathology via 
production of IL-10 in addition to IFNγ. While no single master transcription factor has been 
identified for Tr1 cells, Blimp1, c-maf, Ahr and Egr2 have been reported to induce IL-10 
production in Tr1 cells. In an effort to understand what dictates the emergence of Th1 versus Tr1 
cells in various disease settings, the latest approaches have focused on deciphering the 
transcriptional landscape of these cells. Our studies have focused on the downstream effect of the 
generation of these responses in the context of parasitic infections, namely Plasmodium and 
Leishmania which represent inflammatory environments in the host and can potentially be adapted 
to gain a better understanding of chronic inflammatory diseases. 
 
Here we identify a dominant type I interferon (IFN) response that appears to suppress CD4
+
 
T cell responses in human volunteers experimentally challenged with blood-stage Plasmodium 
falciparum (P. falciparum) infection. Using gene array studies to identify a type I IFN signature and 
peripheral blood mononuclear cells (PBMC’s) for functional validation studies, we found that type I 
IFN’s suppressed CD4+ T cell-derived IFNγ production. Additionally, type I IFN’s appeared to be 
required for IL-10 production and generation of Tr1 cells. Linear regression analysis showed that 
high IL-10 levels were strongly associated with high parasitemia, as determined by area under the 
parasitemia curve (AUC).  
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Collectively, these results indicate that type I IFN’s promote the generation of Tr1 cells which may 
potentially suppress anti-parasitic responses during human malaria. 
 
To study the generation of Tr1 cells in greater detail, we employed a mouse model of 
Plasmodium and Leishmania infections with a specific focus on the transcriptional regulator 
Blimp1. Many studies have shown positive associations between Blimp1 and IL-10 and this was 
confirmed in our models of experimental Plasmodium and Leishmania infections, where IL-10
+ 
CD4
+
 T cells and Tr1 cells (IL-10
+IFNγ+) expressed the highest levels of Blimp1. To determine a 
role for Blimp1 in controlling parasite growth, T cell specific Blimp1 deficient mice infected with 
Plasmodium or Leishmania exhibited significantly reduced parasite burdens throughout the course 
of infection and this was associated with enhanced Th1 responses and severely impaired Tr1 
responses in both models. Additionally, we noted that IL-12 was required for the generation of Tr1 
cells and Blimp1 expression in these cells, thus supporting the notion that Tr1 cells arise from 
terminally differentiated Th1 cells. Interestingly, TNF producing CD4
+
 T cells had a lower Blimp1 
expression profile, compared to IL-10 producing CD4
+
 T cells, potentially indicating a negative 
association where Blimp1 was suppressing TNF during infection. TNF controls parasite growth in 
Leishmania infections, but has also been shown to mediate splenic pathology via the killing of 
marginal zone macrophages (MZM’s) leading to a breakdown in tissue architecture. Strikingly, we 
observed a significant increase in TNF producing CD4
+
 T cells in the T cell specific Blimp1 
deficient mice which was associated with extensive splenomegaly, a characteristic feature observed 
in patients with visceral leishmaniasis (VL). Importantly, Blimp1 transcripts were also found to be 
up-regulated in VL patients, indicating the clinical relevance of Blimp1 during infection. We sought 
to determine the mechanism by which Blimp1 was regulating pathology in the spleen. Firstly, we 
confirmed that the loss of MZM’s in the T cell specific Blimp1 deficient mice was due to a lack of 
IL-10, where T cell-specific IL-10 deficient mice also displayed the same phenotype of MZM loss, 
and this process appeared to be TNF dependent. In support of IL-10 mediating protection against 
MZM loss, we were able to show that IL-10 signalling in T cells and myeloid-derived populations 
was a requirement for protection against TNF-mediated destruction. In summary, our data reveals a 
novel mechanism where Blimp1 induced IL-10 production by Tr1 cells limits pathology during 
infection. These findings have wider implications for other inflammatory diseases. 
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1.1 INTRODUCTION  
 
 
Throughout history, humans have evolved to adapt and survive outbreaks and pandemics, 
including the bubonic plague (1347 - 1351) that resulted in 75 million deaths and the Spanish flu 
(1918 -1919) which caused an estimated 50 million deaths
1, 2
. More recently, the human 
immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) pandemic which 
began in 1981 is still a major global health concern, along with other infectious diseases including 
malaria, tuberculosis and leishmaniasis
3, 4, 5
. Just as our immune system has changed through 
evolution, pathogens have co-evolved alongside us, and the interplay between hosts and pathogens 
have shaped the immunological landscape and diseases seen today.  
 
 
Parasitic diseases such as malaria and leishmaniasis are associated with potent inflammatory 
responses that attempt to eliminate parasites from the host, but can result in host tissue damage. 
Parasites have evolved to evade immune surveillance and cause immunosuppression of the host by 
inducing immunoregulatory networks that contribute to parasite persistence. Over time, chronic 
infection results in extensive immune dysfunction in the host. During infection, immunoregulatory 
networks serve to minimise inflammation-induced damage of host tissues, thus preserving the 
structural integrity of essential organs, including the brain, lungs, liver and spleen. Architectural 
integrity, particularly in the spleen, is important, since it is a site for the generation of immune 
responses, filtering of the blood and removal of foreign matter. The spleen is home to specialised 
cell populations such as macrophages, dendritic cells (DC’s), T and B cells which traffic throughout 
this secondary lymphoid organ. Interactions between these cell populations dictate the type and 
magnitude of immune responses that emerge during infection.  
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Histopathological changes in the brain or spleen of individuals with malaria or 
leishmaniasis, respectively, are examples of the consequences of immune dysfunction as a result of 
exacerbated inflammatory immune responses to parasites. While there is currently no effective 
vaccine available against these parasitic diseases, there is an urgent need to develop targeted 
therapeutic strategies to treat these diseases. A more comprehensive understanding of anti-parasitic 
immune responses, as well as how immunoregulatory networks are established, is necessary for the 
design and development of such strategies. Furthermore, the development of therapeutic 
interventions against parasite-induced inflammation has the potential to be used against other 
chronic inflammatory diseases, such as rheumatoid arthritis, Crohn’s disease, psoriasis, 
inflammatory bowel disease and ulcerative colitis.  
 
This thesis reports on the establishment of immunoregulatory networks in malaria and 
leishmaniasis, and how these networks serve to limit host pathology, but also contribute to parasite 
persistence. The findings presented in this thesis offer insights into mechanisms that underpin 
inflammation-induced pathology in a broad range of other infectious and non-infectious diseases. 
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1.2 LITERATURE REVIEW  
 
1.2.1 Malaria 
 
Malaria has pervaded human civilization for at least 4000 years and still remains a global 
health challenge today
6
. The World Health Organisation (WHO), reported 198 million malaria cases 
world-wide that resulted in 584,000 deaths in 2013
7
.  An estimated 90% of all malaria-related 
deaths occurred in young children under the age of five in sub-Saharan Africa
7
 (Fig 1). The 
geographical distribution of malaria coincides with lower income countries and communities
7
, and 
the global cost of malaria is estimated to be at least $12 billion (USD) each year, according to the 
Centers for Disease Control and Prevention (CDC)
8
.  
 
 
Figure 1: Countries with ongoing transmission of malaria in 2013. 
 
Figure source: Adapted from WHO World Malaria Report 2014
7
 from the national malaria control 
programme reports. 
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Malaria control and elimination strategies, including vector control (insecticide-treated bed 
nets or indoor residual spraying), chemoprevention (used on pregnant women and young children), 
rapid diagnosis and artemisinin-based combination therapy (ACT), have all been shown to 
contribute to reduced mortality rates
9, 10, 11
. However, the limited efficacy of the recently tested 
RTS/S/AS01 (Appendix 1) vaccine
12
, along with increased drug resistance, highlights the urgent 
need for the development of novel strategies to combat the devastating effects of this disease. 
 
1.2.2 Plasmodium species  
 
Malaria-related deaths are caused by protozoan parasites of the genus Plasmodium. Six 
species have been identified to cause disease in humans, including P. falciparum, P. vivax, P. 
malariae, P. ovale wallickerie, P. ovale curtisii and a sixth species, P. knowlesi which is a zoonotic 
infection also infecting monkeys in South-East Asia
7
. The most life-threatening of these is P. 
falciparum, which contributes to the majority of all malaria-related deaths due to its prevalence in 
the African continent
7
. In comparison to P. falciparum, P. vivax displays a wider geographic spread, 
due to its ability to survive at higher altitudes, as well as grow in the Anopheles mosquito at cooler 
temperatures and also because it has a dormant liver-stage (hypnozoite) that allows it to remain as a 
potential reservoir for infection for long periods of time
7
.  
 
1.2.3 Plasmodium life cycle 
 
 Plasmodium spp. are eukaryotic apicomplexan intracellular parasites transmitted by the bite 
of an infected female Anopheles mosquito
13
. Infection of the human host begins when a female 
Anopheles mosquito injects sporozoites during a blood-meal
14
 (Fig 2). The liver stage of the 
lifecycle takes place when circulating sporozoites migrate to the liver to invade hepatocytes and 
develop into schizonts
14, 15
. The liver-stage is transient, causes no pathology and can  last between 
7-10 days in humans and 2 days in mice
16
. The blood-stage of infection is triggered by the release 
of 30,000 – 40,000 merozoites (from liver schizonts) that invade red blood cells (RBC’s), and then 
undergo repeated cycles of replication causing RBC’s to rupture17 that can result in the development 
of clinical symptoms, including: fever, chills, fatigue and nausea. Complications of P. falciparum 
infections result in severe anaemia, respiratory distress syndrome and cerebral malaria
18, 19, 20
. Left 
untreated, Plasmodium infections can lead to multi-organ failure in a matter of days
21, 22
.  
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Figure 2: Life cycle of the malaria parasite. 
 
1) A female Anopheles mosquito injects sporozoites during a blood meal. Sporozoites travel to the liver to 
invade hepatocytes. 2) Liver stage: within 5-16 days in humans, sporozoites divide and release merozoites 
into the bloodstream 3) Merozoites go onto invade RBC’s and undergo asexual replication, where they then 
release 30-40,000 merozoites per RBC into the bloodstream to infect new RBC’s. This blood-stage of 
infection gives rise to clinical symptoms and complications if left untreated. 4) Instead of asexual replication, 
some merozoite-infected RBC’s develop into male and female gametocytes (sexual forms). 5) Gametocytes 
are taken up by another mosquito during a blood meal, and within the mosquito gut, gametocytes develop 
into gametes. Male and female gametes fuse (zygote) and develop into ookinetes that then become oocysts 
which line the mid-gut of the mosquito. 6) Each oocyst grows and divides to produce many sporozoites that 
are released into the mosquito’s body cavity which then travel to the salivary glands. The transmission cycle 
is complete once the mosquito injects sporozoites into another human during a blood meal. Figure source: 
Adapted from NIAID https://www.niaid.nih.gov/topics/Malaria/Pages/lifecycle.aspx. 
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1.2.4 Malaria pathogenesis 
 
The WHO defines severe malaria as severe anaemia, cerebral malaria, respiratory distress 
syndrome, liver dysfunction, renal failure, haemoglobinuria and/or metabolic acidosis
18, 19, 21, 23, 24
. 
Two processes involved in the pathogenesis of severe malaria include microvascular obstruction 
leading to hypoxia, as well as immunopathological processes. Haemorrhaging associated with the 
sequestration of pRBC’s, leukocytes and increased blood brain barrier permeability, has been 
observed in human and mouse cerebral malaria syndromes. The P. falciparum membrane protein 
(PfEMP)-1 is an adhesion protein involved in antigenic variation and cytoadhesion of pRBC’s to 
the microvasculature of the brain, as well as other host cells
25, 26
. PfEMP1 is an important virulence 
factor, encoded by approximately sixty var genes that are regularly switched on, one at a time to 
generate antigenic variation of pRBC’s, thus evading detection27. pRBC’s sequester to the brain 
vascular endothelium via PfEMP1-mediated interactions with a number of adhesion molecules 
including vascular cell adhesion molecule (VCAM)-1 and intercellular adhesion molecule (ICAM)-
1
28, 29
.  
 
1.2.5 Immunity to malaria 
 
Individuals that are repeatedly exposed to malaria develop natural acquired immunity, also 
known as premonition, which is characterised by low parasite burden and tolerance to symptoms of 
severe disease
30, 31
. However, these individuals are only partially protected from disease 
manifestations, and the little protection that is acquired, rapidly wanes in the absence of re-infection 
and sterilising immunity is never fully achieved
32, 33, 34
. Immunity to blood-stage parasites is 
primarily mediated by humoral immune responses
35. Studies in the early 1960’s showed that 
passive transfer of human serum from naturally immune adults containing parasite-specific 
immunoglobulin (Ig)-G antibodies could protect children from clinical symptoms
36
. Cellular and 
innate immune responses play an important role in limiting parasite growth; however, inflammation 
associated with these responses can also cause disease
37, 38, 39
. Given that the adaptive immune 
system has evolved with a number of potent regulatory mechanisms, it is not clear why these 
mechanisms are not sufficient to prevent immune-mediated pathology in the host.  
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The spleen orchestrates many immune responses against Plasmodium infections and usually 
increases in size, which is initially due to changes in the vasculature
40
, but shortly thereafter 
lymphoid and reticuloendothelial hyperplasia occurs
40
. During Plasmodium infections, the spleen 
removes damaged RBC’s and pRBC’s from the bloodstream, as well as being a site where 
Plasmodium-specific T and B cell responses are generated within specialised regions of the organ
41, 
42, 43, 44
. 
 
The protective and pathogenic roles of CD4
+
 T cells during Plasmodium infection have been 
reported in human and mouse studies
37, 45, 46, 47, 48, 49, 50
. Plasmodium induces potent inflammatory 
responses in the form of cytokine production by various immune cells, including interferon-gamma 
(IFNγ), tumour necrosis factor (TNF) and interleukin (IL)-1251, 52, 53. CD4+ T cell derived IFNγ is 
critical for controlling parasite growth and the generation of parasite-specific antibody responses are 
required for protection against re-infection
49, 54, 55, 56
. However, in severe malaria models, CD4
+
 T 
cells contribute to immunopathology
37
 and the mechanisms that drive this pathological response are 
poorly understood. CD4
+
, CD8
+
 T cells, gamma delta (γδ) T cells and Natural Killer (NK) cells 
produce IFNγ during Plasmodium infections52, 57, 58, 59. Despite reports on a protective role for IFNγ 
during human and mouse Plasmodium infections, the exacerbated immunopathology associated 
with elevated IFNγ levels suggests both protective and pathogenic cellular sources of IFNγ. Studies 
in mice 
60
 and humans
61, 62
 have shown that the presence of poly-functional CD4
+
 T cells producing 
IFNγ, IL-2 and TNF simultaneously, better correlates with protection, compared to single cytokine 
producing CD4
+
 T cells. Similar results have been reported during Leishmania major, 
Mycobacterium tuberculosis, and HIV infections
60, 63, 64, 65, 66
. Thus, the quality of the T cell 
response is critical in determining disease outcome and is of paramount importance in vaccine 
efficiency. Recently, type I interferons (IFN’s) were reported to suppress protective CD4+ T cell-
derived IFNγ production via CD8α- DC’s in a severe malaria model67, 68. This is but one of many 
examples of immune regulatory factors that can influence parasite-specific CD4
+
 T cell 
development and thus disease outcome in malaria. 
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1.2.6 Experimental malaria models   
 
Infection of mice with Plasmodium parasites have served as experimental malaria models 
which have made significant contributions to our understanding of disease progression and 
generation of immune responses. Four Plasmodium species are commonly used in laboratories 
around the world, including, P. berghei ANKA (PbA), P. chabaudi chabaudi AS (PcAS), P. yoelii 
(YM-non-lethal and 17XNL-lethal) and P. vinckei [reviewed in
69, 70, 71, 72
]. While not all aspects of 
P. falciparum pathophysiology can be modelled using these experimental malaria models, they have 
provided valuable insights into host-parasite interactions and the generation of immune responses. 
An alternative approach is the development of humanised mouse models to study P. falciparum 
infection; however, the limitations associated with any experimental model still remain
73
. The 
challenge associated with the continued use of experimental malaria models is to ensure better 
translation of experimental findings into effective treatments for malaria. 
 
1.2.6.1 Uncomplicated malaria  
 
C57BL/6J mice injected intravenously (i.v.) with PcAS develop mild, uncomplicated 
malaria infections, where peripheral parasitemia reaches its peak 7-8 days post infection (p.i.) and is 
largely resolved by 12-13 days p.i.
72
. Symptoms of PcAS-infected mice include: ruffled fur, 
anaemia, weight loss and haemoglobinuria, which is generally observed 8-9 days p.i.. However, 
mice are generally able to resolve the infection and establish immunity to re-infection
72
. Interleukin 
(IL)-10 production by type I regulatory (Tr1) CD4
+
 T cells has recently been shown to be important 
for the prevention of immune-mediated pathology in this model
74, 75
. Cell adoptive transfer 
experiments have demonstrated that the initial wave of parasitemia is controlled by CD4
+
 T-helper 
1 (Th1) cells
45
, whereas resolution of infection occurs as a result of CD4
+
 follicular T-helper (Tfh) 
cell-mediated help in the generation of antibody responses
76
. Tfh cells provide help to B cells by 
promoting proliferation, survival, class-switch recombination, plasma cell differentiation, somatic 
hyper-mutation, adhesion and attraction [reviewed in
77
]. It is through these processes that Tfh cells 
have been shown to be essential for antibody production and germinal centre formation which leads 
to the production of high-affinity antibodies and memory B cells
77
. A recent study found that 
inducible T-cell co-stimulator (ICOS) was not required for Tfh induction during PcAS infection or 
production of isotype-switched antibodies but is necessary for the maintenance of a sustained high-
affinity, protective antibody response
78
.  
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The involvement of ICOS in providing help to B cells, involves the induction of Bcl-6 expression
79
 
or protecting Bcl-6 from ubiquitin-mediated degradation
80
, as well as promoting the mobilisation 
and entry of Tfh cells into B cell follicles
81
. Additionally, a role for IL-21 signalling was shown to 
be involved in orchestrating co-operation between T and B cell responses during PcAS infections
82
. 
1.2.6.2 Severe malaria  
 
 PbA-infected mice rapidly develop severe neurological symptoms including coma, paralysis 
and convulsions 6-7 days p.i., and has been commonly employed to model the pathogenesis of 
severe malaria symptoms observed in humans infected with P. falciparum. Five years ago, the 
relevance of this particular model was questioned
83
, resulting in a debate amongst the malaria 
research community. Notably, the terms ‘severe’ and ‘cerebral’ have been used interchangeably 
when describing the pathogenesis of malaria, however, severe malaria, as defined by the WHO has 
a range of clinical syndromes which do not result in coma
21
. Therefore, a consistent definition of 
disease is required when interpreting findings from studies on severe malaria. Evidence of brain 
pathology in PbA-infected mice includes inflammation in the brain, breakdown of the blood-brain 
barrier (BBB)
84
 and up-regulation of ICAM-1 and VCAM-1 on brain endothelium
85
. Numerous 
studies have identified a role for CD8
+
 cytotoxic T cells in the immunopathology of the brain via 
perforin/granzyme B dependent mechanisms
86, 87, 88, 89
. Numerous features of the PbA model 
recapitulate the severe symptoms observed in humans with cerebral malaria, severe anaemia, 
metabolic acidosis, liver dysfunction and respiratory distress
84, 90, 91, 92, 93
. 
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1.2.7 Leishmaniasis  
 
Leishmaniasis has emerged as the one of the most prevalent parasitic diseases world-wide 
after malaria and filariasis
94
. The three main forms of leishmaniasis include cutaneous leishmaniasis 
(CL), the most common form classified by self-resolving, localised cutaneous lesions. In some 
instances, parasites disseminate throughout the skin resulting in multiple non-ulcerative nodules 
(also known as diffuse cutaneous leishmaniasis, DCL). A second form of disease occurs when 
parasites grow in macrophages in the lymphatics, contributing to nasobronchial and buccal mucosal 
tissue destruction, also known as mucocutaneous leishmaniasis (ML). This affects mucus secreting 
membranes of the nose, mouth and throat. The third, and most deadly form of disease is visceral 
leishmaniasis (VL), also known as kala-azar
5, 95
. The WHO estimates 310 million people to be at 
risk of infection
96
 and 1 million cases of CL have been reported in the last 5 years
96
. 
 
VL is a parasitic disease that mainly affects the spleen, liver and bone marrow
97
. An 
estimated 1.3 million cases, results  in up to 30,000 deaths occur annually according to the latest 
WHO estimates
96
. VL is endemic in 76 countries, but more than 90% of cases occur in India, 
Bangladesh, Ethiopia, Sudan and Brazil
96
 (Fig 3). Clinical features of VL include persistent low-
grade fever, pancytopenia, hypergammaglobulinemia, hepatosplenomegaly resulting in progressive 
distension of the abdomen and cachexia
97
. Immunocompromised individuals have a greater risk of 
developing VL and relapse is not uncommon after drug treatment
98, 99
.  Recent efforts have focused 
on treatment regimens against VL in HIV/VL co-infected individuals, since people living with HIV 
have a much higher risk of developing active disease
100
. In addition, VL-mediated immune 
dysfunction accelerates progression to AIDS
101
. However, the toxicity associated with anti-
leishmanial drugs, their long treatment course and cost, as well as lack of a vaccine to prevent VL, 
has renewed efforts to combat this neglected parasitic disease
100
. The main focus of recent studies 
include the development of novel, targeted therapies involving drug in conjunction with 
immunotherapy to enhance anti-parasitic responses to prevent disease
102
. 
 
Chapter 1 
 
 41758573  38 
 
Figure 3: Global distribution of VL in 2013. 
 
Figure source: Adapted from WHO Leishmaniasis control programme: Annual report 2013
103
. 
 
1.2.8 Leishmania species  
 
Leishmania spp belongs to the group of flagellated Kinetoplastidae and 7 main species 
transmitted by Phelbotomine sandflies have been identified to cause disease in humans, including L. 
mexicana, L. amazonensis, L. tropica and L. major which cause CL, L. braziliensis which causes 
MCL, and L. donovani and L. infantum which cause VL
99, 104
.   
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1.2.9 Leishmania life cycle 
 
Leishmania parasites exist in two developmental stages: the flagellated, motile promastigote 
form and the non-motile amastigote form. The promastigote is found within the infected female 
Phelobotomine sandfly which progresses to the non-dividing, infectious ‘metacyclic’ promastigote 
form that is transmitted during a blood meal
104, 105
. Injected promastigotes replicate within host 
mononuclear phagocytes as amastigotes, which do not have an exterior flagellum (Fig 4)
104, 105
. 
Parasites can survive within the phagolysomes of these cells by resisting digestion by lysosomal 
enzymes. Within the host cell they multiply until the cell ruptures, allowing parasites that invade 
other macrophages
104, 105
. When a female sandfly takes up infected macrophages during a blood 
meal, amastigotes convert into the promastigote form within the mid-gut of the sandfly, thus 
completing the transmission cycle (Fig 4)
104, 105
. 
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Figure 4: Lifecycle of the Leishmania parasite. 
 
a) A female Phelobotomine sandfly injects the infective metacyclic promastigotes during a blood meal. b) 
The metacyclic promastigotes are taken up by phagocytes such as macropahges. c) Once inside the 
macrophage, the metacyclic promastigotes develop into their aflagellate amastigote form and undergo 
numerous cycles of replication causing the host cell to rupture and release amastigotes into the environment, 
so that they can be phagocytosed by other un-infected macrophages. d) Infected macrophages are taken up 
by another sandfly during a bloodmeal and amastigotes are converted into promastigotes within the mid-gut 
of the sandlfy, thus completing the transmission cycle. Adapted from Paul Kaye & Phillip Scott, 2011, 
Nature Reviews Microbiology 9, 604–615, permission number 3766460241587.   
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1.2.10 Immunopathology in VL 
 
Experimental VL induced by infecting C57BL/6J mice with L. donovani results in 
dissemination of parasites throughout the viscera where the liver, spleen and bone marrow are the 
key sites of infection
106
. Injected L. donovani amastigotes are preferentially taken up by tissue-
resident macrophages such as marginal zone macrophages (MZM’s) and marginal zone 
metallophilic macrophages (MMM’s) in the spleen, stromal macrophages in the bone marrow and 
Kupffer cells (KC’s) in the liver107. Immune responses to L. donovani are tissue-specific, with 
hepatic infection being acute and transient whereas chronic infection becomes established in the 
spleen and bone marrow. The reasons for parasite persistence in the spleen and bone marrow remain 
unclear. 
 
In experimental VL, liver parasite burdens peak at 14-21 days p.i., and begin to decline by 
28 days p.i., and are largely resolved within 6-8 weeks p.i.
106
. Parasite clearance in the liver is 
driven by the formation of inflammatory granulomas around infected KC’s, the activation of CD4+ 
T cells to produce TNF and IFNγ which signal to macrophages to kill parasites via inducible nitric 
oxide synthase (iNOS) and reactive oxygen species (ROS)
108, 109, 110
. CD4
+
 T cells control parasite 
growth in the liver
111, 112
, whereas CD8
+
 T cells are required for protection from reinfection
109
. 
CD4
+
 T cell-derived IL-2, IL-12, IFNγ, TNF, lymphotoxin (LT) and granulocyte/macrophage 
colony-stimulating factor (GM-CSF) are required for effective granuloma formation around 
infected KC’s110, 113, 114, 115, 116, 117, 118.  
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The spleen is a unique, highly organised secondary lymphoid organ. The vascular networks 
of the spleen are arranged such that the branching arterial vessels are sheathed with lymphoid tissue 
and terminate in an avenous sinusoidal system, which is encapsulated by a fibrous capsule that 
supports the larger vasculature
119
 (Fig 5a). This intricate system of interconnected vascular 
networks divide the spleen into two main compartments, known as the red pulp and white pulp 
regions, which are separated by a specialised collection of cells comprising the marginal zone 
(MZ)
119
 (Fig 5b). The red pulp is important for the removal of pathogens and old RBC’s from the 
circulation, as well as for recycling iron
119
. Within the white pulp, the branching arterial vessels are 
surrounded by B and T cell areas which are maintained by the chemokines. CXCL13 is produced by 
CD35
+
 follicular DC’s (FDC’s) and stromal cells, and is important for maintenance of B cell 
zones
120
. In contrast, CCL19 and CCL21 (produced by stromal cells) are involved in recruiting T 
cells and DC’s to T cell zones121, 122. CXCL13, CCL19 and CCL21 expression is regulated by LT-
α1β2 and TNF
123
.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Structure of the spleen. 
 
a) Structural layout of the spleen b) layout of white pulp regions in mice (left) and humans (right). 
Figure source: Reina E. Mebius & Georg Kraal, 2005 Nature Reviews Immunology 5, 606-616, 
permission number 3766781021951. 
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The close interaction between haematopoietic cells and the circulation makes for an efficient 
immune surveillance system
119
. The structure of the spleen facilitates this interaction through the 
MZ which acts as a transit area for cells entering the white pulp via the bloodstream
119, 124
, and thus 
allows for T and B cell interactions to take place. The MZ is home to various specialised cell 
populations which assist in the maintenance of the splenic architecture and in particular two subsets 
of macrophages. MMM’s line the inner border of the MZ, adjacent to the white pulp and the 
MZM’s reside at the outer boundary of the MZ, adjacent to the red pulp (Fig 6)119, 125, 126, 127. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Layout of cells residing in the MZ of the spleen. 
 
a) MZM’s form the outer ring of macrophages b) MMM’s form the inner ring around the white pulp. 
Figure source adapted from: Reina E. Mebius & Georg Kraal, 2005 Nature Reviews Immunology 5, 606-616, 
permission number 3766781021951. 
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In contrast to the response to infection in the liver during experimental VL, a chronic 
infection is established in the spleen and is thought to result in impaired immune responses
128
. 
Furthermore, TNF-mediated destruction of the splenic architecture consequently impedes 
lymphocyte trafficking through the spleen, and thus T cell priming is signficantly reduced
129
. 
Elevated levels of TNF in the spleen are associated with the induction of IL-10
130
 which impedes 
anti-parasitic immunity and consequently allows parasites to persist. It is unclear why the anti-
parasitic action of TNF is beneficial in the liver and aids control of parasite growth, yet exacerbates 
the inflammatory response in the spleen leading to architectural destruction and immunological 
dysfunction
128
. 
 
TNF and its related cytokine LTα are both required for initial parasite control in the liver 
during L. donovani infection
118
, yet exhibit distinct roles despite their structural similarities as 
members of the TNF superfamily
131
. Specifically, LTα is required for leukocyte migration from the 
perivascular areas (surrounding the hepatic portal vein) of the liver to infected KC’s118. In contrast, 
TNF was needed for leukocyte recruitment to the liver, but critically, was required for the survival 
of L. donovani infected mice
118
.  
 
Splenomegaly is also a feature of VL in humans and dogs. During L. donovani infection, 
TNF plays a critical role in vascular and architectural remodelling of the MZ of the spleen
129, 132
, 
including expansion of the red pulp vascular system, neovascularisation of the white pulp and 
remodelling of stromal cell populations that define T and B cell areas
133
.   
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1.2.11 Inflammation  
1.2.11.1 TNF  
 
TNF was first discovered in 1975, and is a key inflammatory cytokine for control of 
intracellular pathogen growth, as well as normal physiological functions in homeostasis and 
health
134
.   Various cells are able to produce TNF during infection, including monocytes, 
macrophages, DC’s, B cells and T cells135, 136, 137, 138. The inflammatory action of TNF occurs via 
two transmembrane receptors; tumour necrosis factor receptor (TNFR)-1 which is expressed 
ubiquitously on all cell types and TNFR2 which is preferentially expressed by cells of 
haematopoietic origin, as well as endothelial cells and can be induced upon cell activation
139, 140
. 
The pro-inflammatory and programmed cell death pathways activated by TNF via TNFR1 are 
associated with tissue injury
131, 141, 142
. Signalling via TNFR2 promotes tissue repair and 
angiogenesis
142, 143, 144
.  Excessive TNF production has been linked to rheumatoid arthritis and other 
autoimmune diseases
145
. The soluble form of TNF (sTNF) is found in blood plasma and confers 
TNF with potent endocrine function and an ability to act at distant physiological sites away from the 
site of synthesis
146
. 
 
 
 All major anti-TNF agents bind to soluble and membrane-bound forms of TNF with high 
affinity and specificity, thus preventing TNF from binding to TNFRs
137
. Anti-TNF agents like 
Enbrel
TM
 are widely used to treat rheumatoid arthritis, ankylosing spondylitis and plaque 
psoriasis
137
, however, immunosuppression is a major issue for patients receiving anti-TNF 
treatment
137
. Therefore, it is imperative to understand how TNF is regulated in these settings in 
order to provide better therapeutic options for these diseases.   
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1.2.11.2 IFNγ 
 
 IFNγ is predominantly known to aid Th1 cell differentiation, stimulate antigen presentation 
via MHCI and MHCII as well as induce inflammatory responses against intracellular pathogens 
such as Plasmodium and Leishmania [reviewed in
147, 148
]. One of the most important effects of IFNγ 
on macrophages is the activation of microbicidal effector functions
149, 150
. Earlier reports have 
shown that TNF is produced by L. major amastigote-infected macrophages and IFNγ dramatically 
enhances TNF secretion, suggesting that both TNF and IFNγ act synergistically to enhance the 
killing actions by macrophages
151
. IFNγ is also involved in orchestrating the trafficking of 
lymphocytes to sites of inflammation through up-regulating the expression of CXCL10, MCP-1, 
MIG, MIP-1α/β, CCL5, ICAM-1 and VCAM-1147. TNF and IL-1β synergistically regulate many of 
these molecules
148
.  
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1.2.12 Immunoregulation  
 
1.2.12.1 CD4
+
 T cell differentiation  
 
CD4
+
 T cells play key roles in protection against Plasmodium, Leishmania, Mycobacterium 
and HIV infections
63, 152, 153, 154
.  The diverse nature of these pathogens requires CD4
+
 T cells to 
differentiate into specialised subsets and respond accordingly to the invading pathogen (Fig 7). 
While the field of CD4
+
 T cell biology has progressed rapidly, increasing our understanding of the 
types of CD4
+ 
T cell responses required to provide protection against infectious diseases will aid the 
development of immune therapies and vaccines against diseases such as malaria and leishmaniasis.  
 
The differentiation pathways of the various Th subsets of CD4
+
 T cells continues to expand, since 
their initial discovery 29 years ago by Mosmann and Coffman
155
. Th cells were first characterised 
by their cytokine profiles which determined their function, however since then, the identification of 
master transcription factors for each subset re-defined the roles of Th1, Th2, Th17, Tfh and Treg 
(regulatory) cells (Fig 7). Upon encountering antigen, CD4
+ 
T cells acquire their effector function 
via the integration of signals from professional antigen presenting cells (APC’s), such as DC’s, as 
well as the local cytokine environment
156
. The integration of these signals activates or represses 
master transcription factors such as T cell-specific T-box (Tbet), “G-A-T-A” sequence binding 
protein 3 (GATA3), RAR-related orphan receptor gamma-T (RORγT), B-cell cll/lymphoma 6 (Bcl-
6) and Forkhead box P3 (Foxp3) which drive and sustain the specialised functions exhibited by 
Th1, Th2, Th17, Tfh and Treg cells, respectively
156
.  
 
Th1 cell differentiation is driven by the master transcription factor Tbet (encoded by the tbox21 
gene) to produce Th1-signature cytokines, including IFNγ, TNF, LTα and IL-2 in order to promote 
cell-mediated immunity against intracellular pathogens such as Plasmodium and Leishmania
156, 157
.  
 
Th2 cells are programmed by the master transcription factor GATA3 and typically produce IL-4, 
IL-5, IL-13 and IL-10 to mediate humoral immune responses and resistance against extracellular 
pathogens, such as helminths
158, 159
. 
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The Th17 cell differentiation pathway is driven by RORγT to induce IL-17 production by Th17 
cells which are important for protection against bacterial and fungal pathogens such as Klebsiella 
pneumoniae, Citrobacter rodentium and Candida albicans
160
. Th17 cells typically produce IL-17A, 
IL-17F and IL-22 as signature cytokines, mediating neutrophil infiltration into peripheral tissues
156, 
161
. Furthermore, Th17 responses are important in several autoimmune disease pathologies
162
.  
 
The discovery of Tfh cells brought about new insights into the development of antibody responses. 
Tfh cells assist B cell-mediated immune responses, including class switching, and germinal centre 
formation
163
. Tfh cells express PD1, SLAM, CXCR5, ICOS and their differentiation is driven by 
the master transcription factor Bcl-6
164, 165
. Tfh cells typically produce IL-21 in addition to other 
cytokines produced by Th2 cells. IL-21 production acts in an autocrine manner, that along with IL-
6, transforming growth factor beta (TGFβ) and Bcl-6 promotes Tfh differentiation164, 165. Although 
all CD4
+
 T cells migrate to follicular regions of the spleen, Tfh cells preferentially reside there due 
to the continuous expression of the CXCR5 chemokine receptor
164
.  
 
Recent findings using comparative analysis methods between the genome-wide landscapes 
of various transcription factors have identified a new layer of complexity that complements the 
plasticity and functional diversity of CD4
+
 T cells in the face of disease. For example, the discovery 
of IL-10-producing Th1 cells, commonly referred to as Tr1 cells, has challenged the concept of a 
single transcription factor solely driving the differentiation of a single Th subset.  
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Figure 7: CD4
+
 T cell differentiation pathways. 
 
Depending on the nature of the invading pathogen, local tissue environment and expression of master 
transcription factors, CD4
+
 T cells can differentiate into various Th subsets (Th1, Th2, Th17 and Tfh) that act 
to limit pathogen spread and confer protection, provide help to CD8
+
 T cells to exert their cytotoxic effects 
or activate immunoregulatory mechanisms (Treg cells) that prevent immunopathology in the host. Figure 
drawn by: S. Ng, Immunology and Infection Laboratory, QIMR Berghofer. 
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1.2.12.2 Treg cells 
 
The selection and deletion of self-reactive T cells occurs in the thymus and allows for the 
generation of potent immune responses with minimal damage to ‘self’. However, in rare instances, 
self-reactive T cells enter the periphery, but are suppressed by a process known as peripheral 
tolerance
166
. In 1993, Powrie et al., demonstrated the regulatory ability of T cells (which would be 
later known as regulatory T cells or Tregs) in a series of adoptive transfer experiments
167
. 
CD45RB
lo 
(regulatory) or CD45RB
hi 
CD4
+
 T cells were transferred into severe combined 
immunodeficient (SCID) mice, where they observed that the mice that received the CD45RB
lo 
CD4
+
 T cells did not develop colitis or wasting disease
167
. Later in 1995, Sakaguchi et al., went on 
to show that the suppressive ability of Treg cells was conferred by the expression of high levels of 
the interleukin 2-receptor alpha chain (IL-2Rα, CD25)168. Then in 2003, several groups identified 
the master transcription factor, Foxp3, as the driver of Treg cell differentiation and their suppressive 
abilities
169, 170, 171
. Treg cells can be classified into thymus-derived natural Tregs (nTregs) which 
control auto-reactivity, and peripherally-generated inducible Tregs (iTregs) which are thought to 
regulate immunity to tumours or invading pathogens [reviewed in
172, 173, 174
].  
 
Mechanisms of Treg cell suppression include cell-cell contact via cytotoxic T-lymphocyte-
associated protein (CTLA)-4, lymphocyte-activation gene (LAG)-3 or galectin-1, the production of 
immunoregulatory cytokines and suppressing effector T cell responses via IL-2 sequestration
175, 176, 
177, 178, 179
 (Fig 8). The phenotypic and functional diversity of Treg cells is broad and determined by 
the expression of molecules other than Foxp3. For example, in inflammatory settings, Tregs often 
employ the same transcriptional machinery as their target cells, thereby copying the migratory and 
tissue localising behaviour such that they are able to modulate specific Th cell subsets
180, 181, 182, 183, 
184, 185
. 
 
Activation of effector T cells requires  T cell receptor – major histocompatibility complex 
(TCR-MHC) engagement, as well as co-stimulatory signals from the APC, where CD28 on the T 
cell interacts with CD80 or CD86 on the APC
186, 187
. Cell-cell contact suppression involves the 
down-regulation of CD80 and CD86 on APC’s during interaction between CTLA4 expressing T 
cells and APC’s188, 189. Therefore, in the absence of co-stimulatory signals, T cells go into a state of 
anergy and are unable to respond to stimuli
190
.   
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Treg cells produce immunoregulatory cytokines such as IL-10 and TGFβ as another means 
of suppressing effector T cell responses. IL-10 suppresses the ability of APC’s to stimulate T cells 
via the inhibition of co-stimulatory signals
191
. Furthermore, Treg-derived IL-10 is critical for 
limiting inflammation-induced tissue pathology and in particular, suppressing Th17 inflammatory 
responses
192. Similar functions have been reported for TGFβ, including the promotion of Treg cells 
in combination with IL-2
193
.  
 
Treg cells sequester IL-2 by up-regulating their expression of IL-2Rα and thus compete with 
activated T cells (which also express IL-2Rα) to consume IL-2 for their own proliferation, 
maintenance and induction of IL-10
194
. The down-regulation of IL-2Rα expression on activated T 
cells, decreases their IL-2 responsiveness and thus their survival in the surrounding environment is 
also decreased
194
. 
 
  
Figure 8: Mechanisms of Treg-mediated suppression. 
 
Three main mechanisms that Treg cells use to exert their suppressive functions include, contact dependent, 
secretion of soluble factors (IL-10 and TGFβ) or sequestration of IL-2. Figure source adapted from: Lauren E 
Mays and Youhai H Chen, 2008 Cell Research 17: 904–918, permission number 3767561095697. 
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1.2.12.3 Tr1 cells 
 
Tr1 cells were first identified in 1988 in SCID patients and were associated with high levels 
of IL-10 production
195, 196
. In 1997, Groux et al., found that IL-10 producing CD4
+
 T cells in both 
humans and mice were a distinct subset of T cells that were antigen-specific, exhibited 
immunosuppressive functions and were capable of mediating immune tolerance
197
. Since then, Tr1 
cells have been characterised on the basis of their effector cytokine profile, whereby they secrete 
IL-10 in large amounts and IFNγ in variable amounts, simultaneously198, 199. Gene expression 
profiling experiments demonstrated that CD49b and LAG3 co-expression is specific to Tr1 cells in 
humans and mice
200
. Tr1 mediated suppression mechanisms include cell-cell contact suppression 
via CTLA4 or programmed cell death protein (PD)-1, secretion of IL-10, TGFβ, granzyme B and 
perforin, as well as disrupting the metabolic states of effector T cells via CD39 and CD73
201, 202
. 
 
The important immunoregulatory functions of Tr1 cells have been widely reported and they 
are being tested as an alternative immunotherapeutic approach in cases where Treg cell based 
therapies are not feasible
203, 204
. Tr1 cells are Tbet
+
 Foxp3
-
 CD4
+
 T cells that co-produce the effector 
cytokines IL-10 and IFNγ simultaneously205. While no single transcription factor has been 
identified for Tr1 differentiation, it is thought that Tr1 cells derive from a common Th1 lineage, and 
under inflammatory conditions, acquire a self-regulating ability to produce IL-10 in addition to 
IFNγ. The induction of Tr1 cells begins with IL-27 production by APC’s, such as DC’s and 
macrophages which stimulates IL-21 production by CD4
+
 T cells and acts in an autocrine manner 
for IL-10 producing Th1 cells
206, 207
. IL-27 induces the transcription factors c-Maf and aryl 
hydrocarbon receptor (Ahr) via STAT1 and STAT3-dependent mechanisms into order to activate 
il10 and il21 gene expression (Fig 9)
206, 208, 209, 210
. Importantly, the critical role for IL-27 in the 
induction of Tr1 cells in Plasmodium and Leishmania, Toxoplasma and Mycobacterium infections 
have been reported
74, 208, 211, 212, 213
. Furthermore, the predominant source of IL-10 in Plasmodium 
and Leishmania infections is derived from Th1 cells
205, 214
. 
 
While c-Maf and Ahr are required for inducing IL-10 production, the transcriptional regulator, B-
lymphocyte induced maturation protein (Blimp)-1 also plays a role in the induction of IL-10. Treg 
cells require Blimp1 in order to produce IL-10
181
 and more recently, IL-10 production by Th1 cells 
was reported to be Blimp1-dependent (Fig 9)
215, 216, 217
. 
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Figure 9: Induction of IL-10 producing Th1 cells.  
 
Three mechanisms of IL-10 induction in Th1 cells, 1: IL-27 produced by APC’s (macrophages and DC’s) 
activates c-Maf and Ahr transcription factors in Th1 cells via STAT1 and STAT3-dependent mechanisms to 
dive IL-10 transcription which then regulates Th1 responses and suppresses macrophages and DC’s, 2: IL-27 
signalling activates the early growth response (Egr)-2 transcription factor to induce Blimp1 to bind to the 
il10 locus. 3: c-Maf and Ahr activates IL-21 to maintain IL-10 production by Th1 cells, in an autocrine 
manner. Figure source: Engwerda CR, Ng SS and Bunn PT, 2014, Front. Immunol.5:498. doi: 
10.3389/fimmu.2014.00498, open-access article under the  Creative Commons Attribution License (CC BY). 
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1.2.12.4 IL-10 
 
IL-10 was first identified 26 years ago and has shaped our current understanding of immune 
regulation in the context of inflammation, autoimmunity, infectious diseases and pathology
218
. IL-
10 is produced by T cells, B cells, macrophages, DC’s and epithelial cells219 and is induced in 
response to excessive inflammation in order to prevent tissue damage
201, 220
. The immunoregulatory 
abilities of IL-10 involve the suppression of TNF and nitric oxide (NO) resulting in an overall 
reduced capacity of macrophages to activate their microbicidal mechanisms
219
. IL-10 can also 
inhibit the antigen-presentation abilities of APC’s, inhibit DC maturation (via the down-regulation 
of co-stimulatory signals) and inhibit IL-12 production which is required for the activation of Th1 
cells
219
. Thus, the regulation of IL-10 is critical during infection, since its expression is detrimental 
and promotes pathogen survival in Leishmania
214, 221
, Mycobacterium tuberculosis
222
 and 
Candida
223
 infections, whereas lack of IL-10 correlates with fatal outcomes in Plasmodium
74, 224
, 
Toxoplasma gondii
225
 and Listeria monocytogenes
226
 infections [reviewed in
205
].   
 
In humans, a shift from an inflammatory response towards a persistent anti-inflammatory response 
may provide one explanation as to why individuals living in malaria endemic areas have reduced 
frequencies of severe malaria episodes
227, 228
. Field studies have shown that the proportion of IL-10 
responders increases with age, and is inversely correlated with severe malaria cases
229, 230
. More 
recently, it was demonstrated that the ability of PBMC’s (isolated from individuals from a low 
endemic area who had a documented clinical record of P. falciparum or P. vivax in the last 6 years) 
to respond to IL-10 was maintained with no significant decline over 6 years, whereas the response 
to IFNγ rapidly decreased over time231. However, the induction of IL-10 production, particularly by 
Tr1 cells, may offer an explanation into the limited efficacy rate of the current RTS,S/AS01 
vaccine, where immunoregulatory mechanisms are induced instead of anti-parasitic responses. 
Therefore, while inflammatory responses are regulated, the induction of these immunoregulatory 
mechanisms may cause an impediment of parasite control and instead promote parasite 
persistence
47, 232
.  
 
 
 
 
 
 
Chapter 1 
 
 41758573  55 
 
While Treg cell-derived IL-10 plays a suppressive role, the frequency of Tregs were not 
elevated in the blood and did not accumulate in the spleen during active VL
233
, suggesting a 
minimal role for Tregs in VL. Additionally, antigen-specific IFNγ responses were not restored 
when Treg cells were depleted
233
. Interestingly, Tr1 cells are the predominant source of IL-10 
during Leishmania, as well as Plasmodium infections
47, 75, 205, 212, 214, 233, 234, 235
. 
 
Since IL-10 plays an immunosuppressive role in humans and mice with VL
236, 237
, IL-10 
blockade represents a logical therapeutic approach
238
. However, releasing the brake on potent anti-
parasitic responses could result in inflammation-induced pathology, leading to immune dysfunction. 
Therefore, a better understanding of IL-10 regulation is required to maximise its therapeutic 
potential. 
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1.2.12.5 Blimp1 
 
Blimp1 encoded by prdm1, functions as a transcriptional regulator by creating a more 
closed/repressive chromatin structure
239, 240, 241
. Initially reported to play a key role in plasma cell 
differentiation
242, 243
, recent reports have identified a wider role for Blimp1 in various immune cell 
subsets including, DC’s, NK cells, CD8+ and CD4+ T cells (Fig 10)217, 244, 245, 246, 247. Blimp1 is 
expressed by B cells, T cells, granulocytes, macrophages, epithelial cells and germ cells
248
. 
 
The five C2H2 zinc finger motifs in the C-terminus of Blimp1 contain DNA-binding sites. 
The consensus-binding site for Blimp1 is very similar to interferon regulatory factor (IRF)-1 and 
IRF2, and therefore, competes with these transcription factors to bind to the IFNβ promoter249. 
Blimp1 also contains a proline-rich region N-terminal to the zinc fingers and PR domain conserved 
between Blimp1 and the Rb-binding protein RIZI (encoded by prdm2)
250
. Both the proline-rich 
region and zinc fingers are required for transcriptional repression, where groucho transcription 
factors (hGroucho) and histone deacetylases (HDACs) 1 and 2 associate to form a co-repressor 
complex at this site
241, 250
.  
 
Blimp1 has been reported to solely function as a transcriptional repressor, but a study which showed 
Blimp1 could directly bind to a conserved region in intron 1 of the il10 locus, has suggested that it 
may also play a positive role in gene expression
181
. One of the most important findings pertaining to 
Blimp1 has been its relation to IL-10
216, 251
. Recent studies have implicated an important role for 
Blimp1 in driving CD4
+
 T cell differentiation, where Treg cells require Blimp1 and IRF4 in order to 
produce IL-10
181
. More recently, Blimp1 has been shown to drive the differentiation of Tr1 cells in 
various disease settings
215, 216, 251
. IL-12-induced Blimp1 expression in Tr1 cells via a STAT4 
dependent manner
216
, supports the emerging concept that Tr1 cells differentiate from a Th1-related 
lineage. Tr1 cells are induced in inflammatory conditions and while the transcriptional program/s 
they employ to produce IL-10 is not restricted to a single transcription factor, Tr1 cells respond to 
environmental signals and thus, their adaptive abilities are well-suited during infection, where the 
environment is constantly changing. Given the broad role of Blimp1 in various immune cells, it also 
highlights the potential for Blimp1 to regulate mechanisms of IL-10 induction by other cells, in 
addition to CD4
+
 T cells.  
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While the transcriptional requirements for Tr1 cell induction have been reported and their 
immunoregulatory functions validated, the combined effect of these has not been studied in the 
context of infectious or inflammatory diseases. This is of paramount importance if 
immunoregulatory networks involving IL-10 and Tr1 cells are to be employed in therapeutic 
settings. 
 
 
 
Figure 10: Diverse role of Blimp1 in immune cells.  
 
Timeline of the expanding roles of Blimp1 from 2003 – 2014. Figure drawn by: S. Ng, Immunology and 
Infection Laboratory, QIMR Berghofer 
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1.2.12.6 Type I IFN’s 
 
In human malaria studies, host genetic factors play a central role in resistance mechanisms 
against malaria infection
252, 253
. Cytokines and their receptors, such as type I IFN alpha receptor 
(IFNαR)-1 and IFNαR2 have been shown to be involved in malaria pathogenesis, where an 
association between two polymorphisms in the IFNαR1 gene  and  increased risk of severe malaria 
was identified
252
. Furthermore, whole brain transcriptional responses during PbA infection in 
genetically resistant and susceptible mouse strains resulted in the identification of differentially 
expressed genes, implicated in interferon-regulated processes. Thus, IFN-dependent transcriptional 
programs may play a role in the pathogenesis of severe malaria syndromes
254
. In viral infections, 
type I IFN’s induce the expression of a wide array of genes that prevent viral spread and replication. 
IFNα and IFNβ are early innate cytokines known to affect DC function in viral infections, whereby 
type I IFN’s can act in an autocrine manner to induce DC maturation in vivo. Type I IFN’s  have 
been shown to suppress CD4
+
 T cell-dependent parasite control during blood-stage Plasmodium 
infection
67
. Recent studies have shown that type I IFN’s signalling directly, modulates the function 
of CD8α- cDC’s during severe blood-stage Plasmodium infection, and by doing so, limits their 
ability to drive IFNγ production by Th1 cells68. This provides a cellular mechanism to explain how 
CD4
+
 T cell responses are impaired by type I IFN’s during systemic disease. 
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1.3 DEVELOPMENT OF HYPOTHESIS AND AIMS 
 
The human immune system in all its complexity has evolved to fight against some of the 
worst plagues and pandemics known to mankind. Given this, it is no wonder that CD4
+
 T cells 
exhibit great functional diversity and plasticity in order to fight pathogens of varying virulence and 
complexity. Plasmodium and Leishmania parasites have continued to evade immune surveillance 
mechanisms and instead hijack the host’s immune system for their own survival. The limited 
efficacy of the RTS,S/AS01 vaccine and increased toxicity of anti-leishmanial drugs highlights the 
need for novel strategies for modulating immune responses that ultimately provide long-term 
protection. Importantly, the translation of this research into therapies that extend beyond parasitic 
diseases has the potential to offer novel ways to treat a broad range of inflammatory diseases.  
 
Based on the above background information, the following hypothesis has been formulated 
for testing in this thesis: 
 
CD4
+
 T cell responses are suppressed during Plasmodium and Leishmania infections via 
mechanisms involving the early development of immune regulatory mechanisms involving IL-10. 
Furthermore, anti-parasitic CD4
+
 T cell responses can be improved to control infection without 
causing disease by targeting Tr1 cells that develop during infection.  
 
This hypothesis was tested by addressing specific aims as follows: 
 
Chapter 3: Investigates the role of type I IFN’s and suppression of CD4+ T cell responses during P. 
falciparum infections. 
 
Chapter 4: Investigates the role of Blimp1 in CD4
+
 T cell responses during Plasmodium infections. 
 
Chapter 5: Describes the mechanism by which Blimp1-dependent IL-10 production by Tr1 cells 
limits TNF-mediated tissue pathology during Leishmania infections. 
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This chapter describes the generic materials and methods used in Chapters 3, 4 and 5. 
Materials and methods specific to each chapter have been included separately within each chapter. 
 
2.1 BUFFERS AND MEDIA  
 
All buffers and media were prepared under sterile conditions and filtered before use 
 
RPMI/PS: 990ml Roswell Park Institute Medium (QIMR Berghofer Medical Research Institute, 
QLD, Australia), 10ml Penicillin (100 U/ml) /Streptomycin (100µg/ml) (Life Technologies, 
Scoresby, VIC, Australia) 
 
RPMI/PS+: 990ml Roswell Park Institute Medium (QIMR), 10ml Penicillin/Streptomycin Plus 
(Life Technologies), 2mM L-glutamine (QIMR), 40mM HEPES (QIMR) 
 
FACS buffer: 5g AlbuMAX® II Lipid-Rich Bovine Serum Albumin (Life Technologies), 500μl 
Sodium Azide (QIMR), 500ml 1x PBS (QIMR) 
 
FACS block buffer: 50ml 24G2 supernatant (QIMR), 50ml Fetal Bovine Serum (Life 
Technologies) 
 
MACS buffer: 5g AlbuMAX® II Lipid-Rich Bovine Serum Albumin (Life Technologies), 5ml 
0.5M EDTA (QIMR), 495ml Dulbecco’s PBS (Life Technologies) 
 
Freezing Medium: 10% DMSO (Sigma-Aldrich, Castle Hill, NSW, Australia), 90% Fetal Bovine 
Serum (Life Technologies) 
 
Complete Media: 45 ml RPMI 1640 (Life Technologies), 5ml Fetal Bovine Serum (Life 
Technologies), 20μl Gentamicin (50mg/ml, Sigma-Aldrich) 
 
LV9 Assay Medium: 395ml RPMI (QIMR), 100ml Fetal Bovine Serum (Life Technologies), 5ml 
Penicillin/Streptomycin Plus (Life Technologies) 
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2.2 MICE  
 
The following strains of mice were used for experiments (details are provided in each respective 
chapter): 
 
 C57BL/6J = Wild type (WT) 
 C57BL/6J.IFNγR-/- = Interferon Gamma Receptor deficient 
 
 C57BL/6J.Prdm1gfp+ (GFP reporters) 
 
 C57BL/6J.Lck-Cre+ x Prdm1fl/fl = Prdm1ΔT (Cre positive) T cell specific Blimp1 deficient  
 C57BL/6J.Lck-Cre- x Prdm1fl/fl = Prdm1fl/fl (Cre negative) littermate controls 
 
 C57BL/6J.Foxp3-Cre+ x Prdm1fl/fl = Prdm1ΔF (Cre positive) Treg cell specific Blimp1 
deficient  
 C57BL/6J.Foxp3-Cre- x Prdm1fl/fl = Prdm1fl/fl (Cre negative) littermate controls 
 
 C57BL/6J.Lck-Cre+ x Il10fl/fl = Il10ΔT (Cre positive) T cell specific IL-10 deficient  
 C57BL/6J.Lck-Cre- x Il10fl/fl = Il10fl/fl (Cre negative) littermate controls 
 
 C57BL/6J.Lck-Cre+ x Il10Rfl/fl = Il10RΔT (Cre positive) T cell specific IL-10R deficient  
 C57BL/6J.Lck-Cre- x Il10Rfl/fl = Il10Rfl/fl (Cre negative) littermate controls 
 
 C57BL/6J.LysM-Cre+ x Il10Rfl/fl = Il10RΔM (Cre positive) Myeloid-derived specific IL-10R 
deficient  
 C57BL/6J.LysM-Cre- x Il10Rfl/fl = Il10Rfl/fl (Cre negative) littermate controls 
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2.3 PARASITES AND INFECTIONS  
 
2.3.1 Preparing PcAS parasites for infection 
 
Cryopreserved stabilate of PcAS parasites was thawed on ice for 2-3 minutes. 12% (w/v) 
NaCl solution in MilliQ water (0.2x the initial frozen volume) was added drop-wise to the stabilate 
to wash any excess glycerolyte solution. Stabilate was placed back on ice for 5 minutes. 1.6% (w/v) 
NaCl solution in MilliQ water (10x the initial frozen volume) was added drop-wise and then 
centrifuged at 338xg (Eppendorf Centrifuge 5810R) for 10 minutes at 4°C. Supernatant was 
carefully removed using a Pasteur pipette and the red blood cell pellet was then gently resuspended 
in 500µl PBS. 200µL of this inoculum was then injected into a C57BL/6J mouse i.v. via the lateral 
tail vein. Parasites were detectable in this passage mouse after 3-4 days post injection, where 
parasitemia had reached 3-5%. At this time point, the passage mouse was subsequently euthanized 
via CO2 asphyxiation and approximately 0.5-1ml of blood was collected via cardiac puncture into a 
10ml conical tube containing 5ml of RPMI/PS + 5U/ml of heparin. An additional 5ml of RPMI/PS 
was added and then centrifuged at 338 x g for 7 minutes at room temperature. Supernatant was 
carefully removed and the RBC pellet was resuspended in 1ml of RPMI/PS. A 1:1000 dilution of 
the 1ml preparation was then prepared for RBC counts in a 0.1% Trypan Blue solution in PBS 
(0.4%, MP Biomedicals Pty Ltd, Seven Hills, NSW, Australia). RBC concentration was adjusted to 
5x10
5
 pRBC’s/ml in RPMI/PS, to inject 200µl per mouse (final concentration: 1x105 
pRBC’s/mouse) i.v. 
 
2.3.2 Preparation of PbA parasites for infection 
 
Cryopreserved PbA stabilate was thawed at room temperature and 200µl was subsequently 
injected into a C57BL/6J mouse i.p. Parasites were detectable in this passage mouse after 4 days 
post injection, where parasitemia had reached 1-3%. At this time point, the passage mouse was 
subsequently euthanized via CO2 asphyxiation and parasite inoculum was prepared as above (2.3.1). 
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2.3.3 Preparation of Leishmania parasites for infection 
 
L. donovani (LV9 strain) amastigotes were harvested from the spleen of a chronically 
infected C57BL/6J.RAG1
-/-
 mouse. A single cell suspension was prepared by homogenization of 
the spleen in RPMI/PS and then centrifuged at 128xg for 5 minutes at room temperature to remove 
any debris. Supernatant (containing parasites) was decanted into a separate tube and centrifuged at 
1800xg for 15 minutes at room temperature. 1ml of RBC Lysis buffer (Sigma-Aldrich) was added 
to the pellet and incubated for 5 minutes at room temperature. 49ml of RPMI/PS was then added to 
wash the lysis buffer and centrifuged at 1800xg for 15 minutes at room temperature. The pellet 
containing the parasites was washed twice more by decanting the supernatant and adding 50ml 
RPMI/PS and centrifuging as above. Parasites were then resuspended in 10ml RPMI/PS and then 
passed through a blunt 26” gauge needle and 10ml syringe in order to minimise parasite clumping. 
Parasites were counted using the Helber counting chamber (Weber Scientific, Teddington, UK). 
Concentration was adjusted to 1x10
8
 parasites/ml in RPMI/PS and 200µl (final concentration: 2x10
7
 
parasites/ml) was injected per mouse i.v. via the lateral tail vein. 
 
2.4 COLLECTION OF MOUSE SAMPLES  
 
At indicated time points, Plasmodium or Leishmania infected mice were euthanized by CO2 
asphyxiation and blood, spleens and livers were subsequently harvested and processed. 
 
Blood was collected via cardiac puncture using 27” gauge insulin syringes (QIMR) into 1ml 
eppendorf tubes. Blood was then centrifuged at 775xg (Eppendorf Centrifuge 5418) for 10 minutes 
at 4°C.  200µl of serum was collected and transferred to a 96 well U-bottom plate, sealed with 
parafilm and stored at -20°C until required for analysis. 
 
2.4.1 Collection of samples from Plasmodium infected mice  
 
Spleens were collected into 10ml RPMI/PS. 
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2.4.2 Collection of samples from L. donovani infected mice  
 
Spleens were harvested and a section of the spleen was collected into 4% (w/v) 
Paraformaldehyde (PFA, MP Biomedicals Pty Ltd, Seven Hills, NSW, Australia) for microscopy. A 
small section of the end of the spleen was cut laterally to make multiple impression smears on glass 
slides in order to determine parasite burden and a third piece was collected into 10ml RPMI/PS for 
flow cytometry. 
 
Livers were perfused via the hepatic portal vein with 10ml of 1x PBS using a 26”gauge 
needle (QIMR). A portion of the liver from the left lateral lobe was cut laterally to make multiple 
impression smears on glass slides to determine parasite burdens. The remainder of the liver was 
collected into 5ml of 2% FBS solution in PBS for flow cytometry. 
 
2.5 PROCESSING OF MOUSE SAMPLES FOR FLOW CYTOMETRIC ANALYSIS 
 
Spleens were passed through a BD Falcon-100μm cell strainer (BD Biosciences, San Jose, 
CA, USA) to obtain a single cell suspension. Splenocyte suspensions were then centrifuged at 338xg 
for 7 minutes at room temperature. To obtain the splenic mononuclear cells, supernatants were 
decanted; pellets were resuspended in 1ml of RBC lysis buffer (Sigma-Aldrich) and incubated at 
room temperature for 8 minutes to ensure complete lysis of RBC’s. 9ml of RPMI/PS was added to 
wash lysis buffer and then centrifuged at 338xg for 7 minutes at 4°C, to inhibit any further lysis. 
Supernatants were decanted and pellets were resuspended in a final volume of 10ml RPMI/PS for 
counting. Splenic mononuclear cells were then counted on a haemocytometer 
(BLAUBRAND
®
counting chamber Neubauer, Blackburn, VIC, Australia) after a 1:5 to 1:20 
dilution in 0.1% Trypan Blue solution in PBS (0.4%, MP Biomedicals Pty Ltd).  
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Livers were passed through a SEFAR- 200µm metal mesh (SEFAR Pty Ltd, Meadowbrook, 
QLD, Australia) and strainer to obtain a single cell suspension. Hepatocyte suspensions were then 
washed with 2%FBS in PBS and centrifuged twice at 338xg for 7 minutes at room temperature. To 
obtain hepatic mononuclear cells, supernatants were decanted; pellets were resuspended in 25ml of a 
33% (v/v) Percoll (VWR International, Tingalpa, QLD, Australia) density gradient solution and 
centrifuged for 578xg for 15 minutes at room temperature. After centrifugation, the hepatocyte layer 
was removed using pasteur pipettes, while the hepatic mononuclear cell pellet was resuspended in 
1ml of RBC Lysis buffer (Sigma-Aldrich) and incubated for 5 minutes at room temperature. 9ml of 
RPMI/PS was added to wash lysis buffer and then centrifuged at 338xg for 7 minutes at 4°C, to 
inhibit any further lysis. Supernatants were decanted and pellets were resuspended in a final volume 
of 0.5 - 3ml RPMI/PS for counting. Hepatic mononuclear cells were then counted on a 
haemocytometer (BLAUBRAND
®
counting chamber Neubauer) after a 1:20 dilution in 0.1% Trypan 
Blue solution in PBS (0.4%, MP Biomedicals Pty Ltd). 
 
2.6 FLOW CYTOMETRY 
2.6.1 Surface staining  
 For surface staining 1-2x10
6 
cells per well were plated into a 96 well U-bottom plate. Cells 
were centrifuged at 338xg for 3 minutes at 4°C, supernatant was decanted and 225µl of HBSS 
(Hank’s Balanced Salt Solution, Life Technologies) was added per well and centrifuged at 338xg for 
3 minutes at 4°C. 2.5µg/ml (50µl final volume) of LIVE/DEAD® Fixable Aqua dead cell stain (Life 
Technologies) diluted in HBSS was added per well and incubated for 15-20 minutes at room 
temperature, protected from light. 170µl of HBSS was added per well and centrifuged at 338xg for 3 
minutes at 4°C. Supernatant was decanted and 100µl of FACS block (QIMR) was added per well 
and incubated on ice for 10 minutes on ice, protected from light in order to block non-specific Fc-
mediated interactions. Cells were washed and 2.5-5µg/ml (50µl final volume) of primary surface 
antibodies (e.g. CD4, TCRβ) was added per well and incubated for 15-20 minutes on ice, protected 
from light. Primary antibodies were either directly conjugated to a fluorophore (e.g. CD49d PeCy7) 
or biotinylated (e.g. CD49d biotin, followed by Streptavidin PeCy7). Cells were washed twice by 
adding 150-200µl of FACS buffer (QIMR) and centrifuging at 338xg for 3 minutes at 4°C.  
Supernatants were decanted and cells were resuspended in a final volume of 100µl of 1% PFA (MP 
Biomedicals Pty Ltd), stored at 4°C and protected from light until acquisition on a Fortessa 5 (BD 
Biosciences). Samples were generally acquired within 12-24 hours post staining.  
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2.6.2 Intracellular cytokine staining (ICCS) 
 
For intracellular cytokine staining, 1-2x10
6 
cells per well were plated into a 96 well U-
bottom  plate and incubated for 3 hours at 37°C in 10µg/ml Brefreldin A (10mg/mL, Sigma Aldrich) 
diluted in 5% FBS in RPMI/PS, to prevent the secretion of cytokines from the cell. For the detection 
of IL-10, 25ng/ml phorbol 12-myristate 13-acetate (PMA, 1mg, Sigma-Aldrich)  and 500ng/ml 
Ionomycin calcium salt (1mg, Sigma-Aldrich)  was added in addition to the Brefeldin A to re-
stimulate cells to produce IL-10. After the 3 hour incubation, cells were centrifuged at 338xg for 3 
minutes at room temperature. Supernatant was decanted and 225µl of HBSS was added per well for 
washing. 2.5µg/ml (50µl final volume) of LIVE/DEAD® Fixable Aqua dead cell stain (Life 
Technologies) diluted in HBSS was added per well and incubated for 15-20 minutes at room 
temperature, protected from light. Cells were then treated with FACS block for 10 minutes on ice 
and subsequently stained for surface markers with primary antibodies for 15-20 minutes on ice.  
Cells were then washed with FACS buffer prior to fixation with either 100µl of BD cytofix buffer 
(BD Biosciences) if only detecting cytokines or  100µl of 1x eBioscience fixation/permeabilisation 
buffer staining kit (4x, Jomar Bioscience, Kensington, SA, Australia) if detecting transcription 
factors in addition to intracellular cytokines. Cells were incubated in each respective cytofix buffer 
for 20 – 30 minutes on ice, protected from light. After fixation, 100µl of 1x BD permeabilisation 
buffer (10x, BD Biosciences) or 100µl of 1x eBioscience permeabilisation buffer (10x, Jomar 
Bioscience) was added per well and cells were then centrifuged at 338xg for 3 minutes at 4°C. Cells 
were washed a second time with 1x permeabilisation buffer and centrifuged at 338xg for 3 minutes 
at 4°C. 2.5-5µg/ml (50µl final volume) of intracellular surface antibodies (e.g. IFNγ, Tbet) were 
added per well and incubated for 45-60 minutes on ice, protected from light.  
 
Cells were subsequently washed twice with 150-200µl of 1x permeabilisation buffer and centrifuged 
at 338xg for 3 minutes at 4°C. Cells were resuspended in a final volume of 100µl of 1% PFA (MP 
Biomedicals Pty Ltd), stored at 4°C and protected from light until acquisition on a Fortessa 5 (BD 
Biosciences). Samples were generally acquired within 12-24 hours post staining.  
 
Acquisition of all samples was performed on a Becton Dickson Fortessa 5 (BD Biosciences) and the 
data acquired using FACS DIVA software (BD Biosciences) was analysed on FlowJo software v9 
and v10.0.7 (Treestar, Ashland, OR, USA). 
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2.7 ASSESSMENT OF SUPERNATANT AND SERUM CYTOKINE LEVELS 
 
Culture supernatants and serum from blood collected via cardiac bleeds were processed for 
cytokine analysis. A Flex set cytometric bead array (CBA) Kit (BD, Franklin Lakes, NJ, USA) was 
used to quantify cytokine levels (pg/mL) in culture supernatants or serum. Briefly, standards were 
prepared by serial dilutions (0-5000pg/mL) and subsequently the master mix containing antibody-
coated beads along with the detection reagent (PE) was plated into a 96 V-bottom well-plate and 
standards and serum samples were added and incubated in the master mix for 2 hours at room 
temperature. Samples were then washed with the BD wash buffer and then acquired on a HTS 
system plate reader on the Fortessa 5 Flow cytometer (BD Biosciences) according to the 
manufacturer’s instructions. Analysis was performed using FCAP Array v3.0 (Soft Flow, 
Minnesota, USA) 
 
2.8 STATISTICAL ANALYSIS  
 
All statistical methods have been reported separately in each chapter. 
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3.2 INTRODUCTION  
 
Malaria represents a major global health burden, but the most recently tested RTS,S/AS01 
vaccine has limited efficacy that wanes relatively quickly
12, 255
. Since its development began in 
1984, the RTS,S/AS01 vaccine has progressed to show protection in young children in 2004 and 
infants in 2007 in malaria endemic regions
256, 257
. However, the maximum efficiency achieved with 
the RTS,S/AS01 vaccine is a modest 46% in recent Phase III clinical trials
12
. The limited vaccine 
efficacy highlights the urgent need for the development of novel therapeutic strategies, as well as 
developing a better understanding for this low efficacy rate. Although sterilising immunity is rarely 
achieved, if at all, a high degree of immune responsiveness resulting in low levels of parasitemia 
and an asymptomatic carrier status is a minimum requirement for malaria elimination programs
6, 
258
. While potent immune responses limit parasite growth, immunoregulatory networks are essential 
for protection against clinical disease caused by excessive inflammation. Therefore, host survival is 
dependent on the fine balance achieved between these two processes. 
 
An effective vaccine induces a combination of cellular and humoral immune responses to provide 
protection. Until very recently, registered vaccines with high efficacy records have been developed 
without a clear understanding of their mechanism of protection
259
. Early protection offered by a 
majority of existing vaccines is dependent on antibody responses, and therefore the efficacy of 
various vaccines under trial, including the RTS,S/AS01 vaccine, is determined by measuring 
antibodies in response to immunisation
259
. This is primarily due to past studies which demonstrated 
that the administration of concentrated human serum immunoglobulin could prevent and attenuate 
measles
260
. Similarly, passive serum transfer studies from immune adults to malaria-infected 
children resulted in parasite clearance and disease recovery
36
. However, the immunogenicity of 
antigens in vaccines poses a challenge that goes beyond the antibody response itself and therefore a 
greater understanding of immune responses against the pathogen in question is required
259
. 
Differentiating between immune responses that contribute to protection versus disease is imperative 
for better vaccine development and efficacy.  In an effort to identify immune correlates of 
protection achieved by the current RTS,S vaccine, many groups have studied antibody levels as a 
measure of vaccine efficacy in addition to identifying immune correlates of protection. White et al., 
used mathematical modelling to predict that RTS,S-induced protection from infection is dependent 
on both anti-CSP antibodies and CSP-specific CD4
+
 T cells, with antibodies playing a dominant 
role in preventing infection
261
.  
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It is important to note however, identifying immune correlates of protection in individuals living in 
malaria endemic areas is further confounded by whether the vaccine itself  or naturally acquired 
responses account for protection from infection in older children and adults
262
. Furthermore, it is 
becoming increasingly apparent that the magnitude of antibody responses is insufficient to explain 
overall efficacy and as such, recent vaccine studies are now investigating the quality and specificity 
of antibody responses
263
. However, there is still debate regarding the rapid waning of protection in 
the absence of parasite exposure
32, 258, 264, 265, 266
. Nonetheless, various studies have indicated that 
once established, clinical immunity can in fact be long-lasting, particularly in trans-migrant 
populations and/or may vary depending on the parasite antigen; the immune response was generated 
against
267, 268, 269, 270, 271
. However, it still remains to be shown how and why if there is no or 
minimal defect in the generation and maintenance of humoral immune responses, then what is the 
underlying cause of the observed limited efficacy of the current RTS,S vaccine formulation? Thus, 
it will be important to identify the mechanisms that govern the induction and maintenance of 
humoral immunity, particularly in the vaccine setting. 
 
The blood-stages of the malaria parasite Plasmodium induce a pro-inflammatory cascade 
that contributes to parasite clearance, but in the absence of immunoregulatory mechanisms, can lead 
to immunopathology
37, 74
.  Early reports demonstrated a protective role for CD4
+
 T cells during 
Plasmodium infections, but more recent studies have also reported on the pathogenic roles of CD4
+
 
T cells and their contribution to disease
37, 45, 67, 68
. The pro-inflammatory cytokine IFNγ has been 
shown to play protective roles in experimental malaria models, during uncomplicated and severe 
malaria. CD4
+
 T cell derived IFNγ, in particular, is required for anti-parasitic immunity via the 
activation of macrophages, NK cells and differentiation of Th1 cells
45, 50, 54
. Recent studies have 
shown that type I IFN’s suppress CD4+ T cell-derived IFNγ production, via DC’s in a model of 
severe malaria
67, 68
.  
 
In addition to suppressing CD4
+
 T cell responses, type I IFN’s  have been shown to induce 
IL-10 production in monocytes/macrophages, DC’s, B and T cells, via STAT3-dependent or  
independent pathways
272, 273
. The induction of type I IFN responses by Plasmodium species may be 
beneficial to the parasite, given the observed suppression of anti-parasitic CD4
+ 
T cell responses
67, 
274
. The suppression of T cell responses during parasitic infections, allows for the preferential 
emergence or induction of immunoregulatory networks that can allow parasites to persist and cause 
disease. 
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CD4
+
 CD25
+ 
Foxp3
+ 
Treg cells are well known for their suppressive and immunoregulatory 
functions. While it is thought that these Treg cells are present and poised to limit damage to the host 
tissue caused by inflammation, this provides a simplistic picture which is in fact more complicated 
than previously thought. Given that cell-mediated immune responses play a dual role during malaria 
infections, whereby inflammation ultimately serves to limit parasite growth, but in doing so, 
contributes to pathogenesis and disease
37
. The potential involvement of Treg cells in promoting and 
orchestrating a balance between these two processes is still under intense investigation. Earlier 
studies have shown in experimental models
275
 as well as humans
235
 associations between Treg cell 
frequencies and reduced parasite-specific IFNγ memory responses. Recent studies however, have 
found very little evidence of associations between CD4
+ 
Foxp3
+
 Treg cell frequencies and 
protection against severe malaria
276, 277
. Boyle et al., demonstrated a trend toward reduced risk of 
symptomatic malaria once infected with P. falciparum, amongst children with lower Treg cell 
frequencies
276
. This suggests that chronic malaria exposure may potentially alter Treg homeostasis, 
and thus impact the development of anti-malarial immunity in naturally exposed populations
276
. 
Furthermore, a recent study showed that neither Treg cell frequencies (CD4
+ 
CD25
+ 
Foxp3
+
 
CD127
lo
) or absolute numbers were associated with malaria-related symptoms
277
. Unlike naturally 
occurring Treg cells which develop in the thymus, induced Treg cells are derived from conventional 
CD4
+
 T cells which acquire their suppressive abilities upon activation [reviewed in
278, 279
]. 
Therefore, while the role of Treg cells remains to be further elucidated during Plasmodium 
infections, the involvement of other regulatory mechanisms, such as those involving IL-10 have 
been recently reported to play a role in Plasmodium infections.  
 
Regulation of IL-10 induction, production and activity in CD4
+
 T cells depends on local 
signals received by activated CD4
+
 T cells in inflamed tissue [reviewed in
280
]. The emergence of 
IFNγ+ IL-10+ CD4+ (Tr1) T cells in Plasmodium infections has been recently reported47, 232, 235, 281. 
Portugal et al., suggested that upon re-exposure, children acquire exposure-dependent 
immunoregulatory responses to regulate inflammation while enhancing anti-parasitic responses
232
. 
Jagannathan et al., proposed that while Tr1 cells displayed immunoregulatory characteristics and 
their emergence was largely dependent upon recent malaria exposure, they were not associated with 
protection from future disease, after controlling for prior malaria incidence
47
. Studies have shown 
that in naturally exposed populations, the effector phenotype of P. falciparum-specific CD4
+
 T cells 
is largely influenced by age and transmission intensity
48
. In areas of high transmission, higher 
frequencies of Tr1 cells were observed in children, whereas adults displayed higher frequencies of 
IFNγ+ TNF+ CD4+ T cells48. Interestingly, in areas of low transmission, both children and adults had 
higher frequencies of IFNγ+ TNF+ CD4+ T cells48.  
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This suggests that the emergence of immunoregulatory networks depends on the level of exposure 
to malaria parasites, with high exposure early in life possibly requiring the establishment of these 
networks to protect from inflammation caused by infection.  
 
While the generation of cellular immunity against Plasmodium species contributes to the control of 
parasite growth, the induction of humoral immunity is required for long-term protection against 
malaria. Follicular T helper (Tfh) cells play critical roles in generating long lived antibody 
responses
165, 282, 283, 284
. Children in areas of high transmission rates of P. falciparum tend to have 
short-lived antibody responses to malaria
285, 286
. Obeng-Adjei et al., recently showed that 
stimulation of PBMC’s with P. falciparum antigen results in the production of Th1 cytokines and 
preferential activation of a ‘Th1-like’ CXCR3+ Tfh subset, which was less efficient than the 
CXCR5
+ 
Tfh population in helping B cells
287
. It was suggested that this response to parasite antigen 
might contribute to the limited efficacy of the RTS,S/AS01 vaccine.  
 
Moreover, in the human setting, the role of IFNγ, particularly in endemic regions is more 
complicated with regards to whether it plays protective, redundant or pathogenic roles. Evidence of 
a protective role for CD4
+
 T cell derived IFNγ has largely been based on associations between IFNγ 
levels and protection from disease
35, 288, 289, 290
. This includes data from high versus low 
transmission areas, studies comparing  immune responses in infants and young children versus 
adults, as well as investigations on the presence of other infections or complications such as HIV, 
tuberculosis and salmonella infections
48, 291, 292, 293, 294
. However, the magnitude of immune 
responses generated in response to parasite antigen in healthy volunteers versus individuals living in 
malaria endemic areas is unknown and may provide valuable insights into the limited efficacy of 
the current RTS,S/AS01 vaccine. Therefore, we studied CD4
+
 T cell responses following first 
exposure to P. falciparum infection in a series of controlled human malaria infection (CHMI) 
studies.  
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CHMI’s have been employed to test drugs and vaccines in an effort to gain a better 
understanding of protective immune responses against malaria
295
. CHMI’s provide a unique 
situation where the generated immune responses are independent of previous or multiple exposures 
and thus represents a system where primary immune responses to malaria can be studied. 
Furthermore, this system may potentially be informative for gaining a better understanding of the 
immune responses observed during primary/early exposures (such as those observed in very young 
children living in malaria endemic areas). While the immune responses observed in adults may be 
considered to be more developed, these studies are nonetheless a stepping stone to understanding 
first/early exposures to Plasmodium infections. CHMI’s can be divided into two systems including, 
sporozoite-induced malaria infection (SIM) and induced blood-stage malaria infection (IBSM)
296
. 
The CHMI studies described in this Chapter comprise of IBSM’s, since it is the blood-stage of 
infection that is responsible for causing symptoms, disease and death, if left untreated. The IBSM 
system allows for the safe testing of anti-malarial drugs and compounds, as well as vaccine 
efficacy
296
. 
 
The limited efficacy of the RTS,S/AS01 vaccine has prompted investigation into 
interactions between the host and malaria parasites, and how this may impede the generation of  
immune responses that should provide long-term protection. In addition, there is an urgent need to 
identify reliable correlates of protective immune responses in malaria endemic regions. The 
RTS,S/AS01 vaccine was designed  to target free sporozoites and intra-hepatic stages of the 
parasites,  and by doing so, prevent the development of blood-stages responsible for all clinical 
symptoms of malaria. A blood-stage vaccine may extend the protection offered by pre-erythrocytic 
vaccines, but in order for these to be developed, a better understanding of host immune responses 
that control blood-stage malaria is needed. 
 
This Chapter examines the development of host immune responses, including the emergence 
of immunoregulatory networks, following first exposure to P. falciparum in a series of CHMI 
studies. 
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3.3 MATERIALS AND METHODS 
 
The material and methods presented here are specific to this chapter 
 
3.3.1 CHMI 
 
The studies described here comprise a series of sub-studies performed in conjunction with a 
main study (controlled, non-randomised interventional trials) aimed at characterising the 
effectiveness of various newly discovered anti-malarial compounds/drugs (Table 1 and 2) against 
early blood-stage P. falciparum infection in healthy individuals. The main study was undertaken by 
Professor James McCarthy (QIMR Berghofer Medical Research Institute) in association with Q-
Pharm Pty Ltd (QIMR Berghofer) under approval of the QIMR Berghofer Human Research Ethics 
Committee (QIMR-HREC). HREC study numbers: P1444, P1470, P1530, P2012 and P2066.  
ANZCTR Trial IDs: ACTRN12612000323820, ACTRN12612000814875, 
ACTRN12613000565741, ACTRN12613001040752 and NCT02281344. All participants involved 
in the sub-study provided written consent to participate. The sub-study involved the collection of 
blood (20-40ml) at various time points including: day 0 (before challenge), day 7, day 14 and day 
28-35 post challenge (Fig 1), in order to assess cellular immune responses (see 3.3.2 and 3.3.3) and 
or collecting samples for gene array studies (see 3.3.6). Participants were healthy males and females 
aged between 16 and 55 with no prior exposure to malaria or malaria endemic regions. All 
participants were infected i.v. with P. falciparum (clone 3D7, drug sensitive strain) which results in 
IBSM. Real-time quantitative PCR (qPCR), as described by Rockett et al., was used to monitor 
peripheral parasitemia twice daily beginning at 4 days post challenge and subsequently monitored 
every 2 hours for the first 12 hours after drug treatment
297
. Drug was administered once parasitemia 
had exceed  1,000 parasites/ml and participants were monitored closely on-site (Q-Pharm). While 
this was a controlled human malaria infection, some participants did report symptoms of headaches, 
nausea, vomiting and increased body temperature which are all characteristic symptoms induced by 
the blood-stages of P. falciparum  infection.  
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Figure 1: Blood collection at indicated time-points during CHMI studies 
 
20-40ml of blood was collected from participants before infection (day 0). Participants were then infected 
with 1,800 – 2,800 pRBC’s (P. falciparum, 3D7 clone) i.v. on day 0. 20-40ml of blood was collected at day 
7 (day of admission – treated with experimental drug), 14 and 28 or 35 (end of study – treated with rescue 
drug, Riamet®) post challenge. At each time-point, PBMC’s were isolated and cultured in the presence of 
nRBC’s or pRBC’s for 24-72 hours and Brefeldin A was added for the last 3 hours of culture. 
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Table 1: Cohorts used in Gene array studies n= 33 
Year of study Cohort Subject Age (years) Gender Drug, Dose 
2012 QP12C02 C1 S001 31 M Larium®, Mefloquine 
(5mg/kg) S006 23 M 
S011 26 M 
2012 QP12C02 C2 S015 20 F Larium®, Mefloquine 
(10mg/kg) S016 27 M 
S017 22 F 
S018 24 F 
S019 20 F 
S020 24 F 
S022 23 M 
S025 25 M 
2012 QP12C02 C3 S028 28 F Larium® Mefloquine 
(15mg/kg) S032 27 F 
S033 28 M 
S035 25 M 
S036 25 F 
S038 37 M 
S041 25 F 
S042 34 M 
2012 QP12C10 C1 S005 22 F OZ439, 100mg  
S009 23 M 
S011 28 F 
S012 25 M 
S013 32 F 
S017 16 M 
S018 34 M 
2012 QP12C10 C2 S024 20 M OZ439, 100mg 
S026 27 M 
S027 27 F 
S028 27 M 
S029 35 M 
S031 23 F 
S032 23 M 
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Table 2: Cohorts used in microarray validation n=18* and PBMC assay studies n= 35 § 
Year of study Cohort Subject Age (years) Gender Drug, Dose 
2013 QP13C14 C1*,§ S001 25 M Ferroquine, 800mg 
S002 22 M 
S003 24 F 
S007 22 F 
S008 27 M 
S009 41 F 
S010 26 F 
2013 QP13C05 C1* S003 19 M Piperaquine, Piperaquine 
phosphate (960mg) S008 21 M 
S012 20 M 
S013 27 M 
2013 QP13C05 C2* S016 26 F Piperaquine, Piperaquine 
phosphate (640mg) S017 25 M 
S018 23 M 
S019 19 M 
S022 24 M 
S024 31 M 
S025 25 M 
2014 QP13C05 3A§ S030 25 M Piperaquine, Piperaquine 
phosphate (480mg) S033 21 F 
S035 23 M 
S036 26 F 
S037 21 F 
2014 QP13C05 3B§ S045 18 M Piperaquine, Piperaquine 
phosphate (480mg) S050 22 F 
S052 32 F 
S057 23 M 
2014 QP14C11§ S001 29 M MMV390048, 20mg 
S002 28 M 
S005 29 M 
S006 24 M 
S008 23 M 
S011 19 M 
2015 QP14C12 C1§ S018 37 M OZ439 (200mg) DSM265,  
(100mg) S019 55 M 
S020 22 M 
S017 25 M 
S011 21 F 
S021 19 F 
S007 24 F 
2015 QP14C12  C2§ S028 27 F OZ439 (200mg) DSM265,  
(50mg) S029 23 M 
S022 24 F 
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3.3.2 Human Peripheral Blood Mononuclear cell (PBMC) isolation  
 
Human PBMC’s were isolated by Ficoll-gradient separation from whole blood. Briefly, 20-
40ml of blood was collected into Lithium Heparin tubes (BD Biosciences, San Jose, CA, USA)  
from participants of the following cohorts: QP13C14 Cohort 1 (2013, Ferroquine, n=5), QP13C05 
Cohort 3A (2014, Piperaquine, n=5), QP13C05 Cohort 3B (2014, Piperaquine, n=4), QP14C11 
Cohort 1 (2014, MMV390048, n=6), QP14C12 Cohort 1 (2015, OZ439 DSM265, n=7), QP14C12 
Cohort 2 (2015, OZ439 DSM265, n=3). Whole blood was inverted gently a few times prior to 
centrifugation at 784 xg for 10 minutes at room temperature to remove 1-2ml of plasma that was 
stored at -20°C to -80°C until required. After plasma removal, 25ml of sterile 1x PBS (QIMR 
Berghofer) was added and tubes were inverted gently a few times to ensure a homogenous mixture. 
13ml of Ficoll-Paque
TM
 PLUS (GE Healthcare, Silverwater, NSW, Australia) was layered gently 
under the blood and centrifuged at 392xg for 30 minutes at room temperature without brake. After 
centrifugation the buffy coat was collected and PBMC’s were washed with 50ml of 1x PBS, 
centrifuged at 392xg for 10 minutes at 4°C. The PBMC pellet was then re-suspended in 4ml 
complete media (Chapter 2, 2.1). Cells were diluted 1:10 in 0.1% Trypan Blue in PBS (0.4%, MP 
Biomedicals Pty Ltd, Seven Hills, NSW, Australia) and counted on a haemocytometer 
(BLAUBRAND
®
counting chamber Neubauer, Blackburn, VIC, Australia). 
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3.3.3 PBMC Assay  
 
For fresh isolation, PBMC’s were isolated as described in 3.3.2, counted on a 
haemocytometer and then adjusted to a concentration of 2x10
6
 cells/ml, in complete media.  
For cryopreserved samples (field samples collected from Timika, Indonesia), each vial underwent a 
“quick thaw” procedure (37°C for 5 minutes in a water bath). Once samples were thawed, complete 
media was added drop-wise (1ml), followed by the addition of 9ml of media. Cells were centrifuged 
for 600xg for 7 minutes at room temperature. Cells were then counted and viability of the cells was 
determined on a haemocytometer (BLAUBRAND
®
counting chamber Neubauer), after a 1:10 
dilution in 0.1% Trypan Blue in PBS (0.4%, MP Biomedicals Pty Ltd). All samples were adjusted to 
a concentration of 2x10
6
cells/ml, in complete media. Patient clinical data for samples from Timika 
is shown in Table 3. 
 
Table 3: Timika patient clinical data  
*Pf: All patients were P. falciparum positive 
 
 
All Pf* Age (years) Gender Weight (kg) Ethnicity Treatment 
 43 F 55 Non-Papuan Artekin® (Dihydroartemisinin 
and Piperaquine) 
43 M 51 Non-Papuan Coart® (Artemether and 
Lumefantrine) 
30 M 45 Highland Coart® 
25 M 46 Non-Papuan Coart® 
27 M 49 Highland Coart® 
35 F 71 Non-Papuan Coart® 
37 M 55 Non-Papuan Artekin® 
20 M 59 Highland Artekin® 
36 M 59 Highland Coart® 
20 M 49 Highland Coart® 
33 M 47 Non-Papuan Coart® 
40 F 55 Highland Cq+SP (Chloroquine and 
sulfadoxine-pyrimethamine) 
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Normal red blood cells (nRBC’s) and parasitised red blood cells (pRBC’s) were prepared as 
follows for use as antigen in the PBMC assay which was set up in a 96 well U-bottom plate. 
Cryopreserved stocks of nRBC’s and pRBC’s were allowed to thaw on ice and then adjusted to a 
working concentration of 9x10
6
 nRBC’s or pRBC’s/ml in complete media. 25µl of this working 
stock was then added into each corresponding well (for a final concentration of 1x10
6
 nRBC’s or 
pRBC’s/ml). As a positive control, 25µl of a mitogen, phytohaemagglutinin (PHA, final 
concentration 10µg/ml, Sigma-Aldrich, Castle Hill, NSW, Australia) was added into corresponding 
wells. After all antigens and mitogens had been plated out, 200µl of PBMC’s (final concentration 
4x10
5
 cells/well) was added to each respective well. The following blocking antibody treatments 
were then added: Human anti-Interferon-α/ß Receptor Chain 2 antibody (clone MMHAR-2, final 
concentration: 5µg/ml, Merck Pty Ltd, Bayswater, VIC, Australia) or its mouse IgG2A isotype 
control (clone 20102, final concentration: 5µg/ml, Bio-scientific Pty Ltd, Kirrawee, NSW, 
Australia); Human anti-IL-10 antibody (clone 25209, final concentration: 20µg/ml, Sapphire 
Bioscience Pty Ltd, Redfern, NSW, Australia), or its mouse IgG2B isotype control (clone 20116, 
final concentration: 20µg/ml, Sapphire Bioscience Pty Ltd) and Ultra-LEAF™ Purified anti-human 
HLA-DR antibody (clone L243, final concentration 20µg/ml, Biolegend, San Diego, CA, USA) or 
its Ultra-LEAF™ purified mouse IgG2a, κ isotype control antibody (clone: MOPC-173, final 
concentration 20µg/ml, Biolegend). The plate was then placed in a humidified incubator at 37°C, 
5% (v/v) CO2 for 24-72 hours. Culture supernatants were harvested at 24 and 72 hours post- PBMC 
re-stimulation and stored at -20°C until required.  
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3.3.4 Flow cytometry  
 
72 hours post PBMC re-stimulation, intracellular cytokine analysis for IFNγ and IL-10 was 
performed. Briefly, for detection of ex vivo IFNγ alone, 10µg/ml of Brefeldin A (BFA, Sigma-
Aldrich) was prepared in complete media (with 10% FBS) and added to each well, for the 
remaining 3 hours (at 69 hours) of re-stimulation. To detect Tr1 cells (IFNγ+IL-10+), 10µg/ml of 
BFA, 25ng/ml phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich), 500ng/ml of ionomycin 
calcium salt (Sigma-Aldrich) was prepared in complete media (with 10% FBS) and added to each 
well, for the remaining 3 hours of re-stimulation. 72 hours post re-stimulation; PBMC’s were 
washed with HBSS (Life Technologies) and centrifuged at 338xg for 3 minutes at 4°C. 1µg/ml (in a 
final volume of 50µl) of Zombie NIR™ fixable viability kit (Biolegend) was diluted in HBSS, 
added to each well and incubated for 15-20 minutes at room temperature, protected from light. 
PBMC’s were washed with HBSS and centrifuged at 338xg for 3 minutes at 4°C. 1-5µg/ml (in a 
final volume of 50µl) of surface antibodies (Table 4) were diluted in FACS buffer, added to each 
well and incubated for 15-20 minutes on ice, protected from light. PBMC’s were then washed twice 
with 150 – 200µl of FACS buffer and centrifuged at 338xg for 3 minutes at 4°C. 100µl of BD 
cytofix buffer (BD Biosciences) was added to each well and incubated on ice for 20 minutes, 
protected from light. PBMC’s were then washed twice with 100 - 200µl of 1x BD perm buffer (BD 
Biosciences) and then centrifuged at 338xg for 3 minutes at 4°C. 2µg/ml (final volume of 50µl) of 
intracellular antibody (IFNγ PeCy7 and IL-10 PE), diluted in BD perm buffer was then added per 
well and incubated on ice for 60 minutes, protected from light. PBMC’s were then washed twice 
with 150 - 200µl of 1x BD perm buffer (BD Biosciences) and then centrifuged at 338xg for 3 
minutes at 4°C. PBMC’s were resuspended in a final volume of 100µl of 1% PFA (MP Biomedicals 
Pty Ltd), stored at 4°C and protected from light until acquisition on a Fortessa 5 (BD Biosciences). 
Samples were generally acquired within 12-24 hours post staining.  
 
Cell populations of interest were defined as follows: 
 
 CD4+ T cells: CD16-CD56-CD3+CD4+ 
 CD8+ T cells: CD16-CD56-CD3+CD8+ 
 NK cells: CD16-CD56+CD3- 
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Table 4: Human monoclonal antibodies used for flow cytometry  
Specificity  Clone Fluorophore Dilution  Supplier 
BDCA-1 L161 PerCP/Cy5.5 1 in 50 Biolegend 
CD3 SK7 Alexa Fluor 700 1 in 50 Biolegend 
CD3 SK7 FITC 1 in 200 Biolegend 
CD4 RPA-T4 APC Cy7 1 in 25 BD 
CD4 RPA-T4 Horizon V500 1 in 30  BD 
CD8 SK1 PerCP/Cy5.5 1 in 80 Biolegend 
CD11c B-ly6 Alexa Fluor 700 1 in 50 BD 
CD14 TüK4 Qdot®605 1 in 100 Invitrogen 
CD16 3G8 Alexa Fluor 700 1 in 50 Biolegend 
CD19 H1B19 BV605 1 in 20 Biolegend 
CD19 SJ25C1 FITC 1 in 20 BD 
CD45RA HI100 PeCy7 1 in 20 BD 
CD56 NCAM16.2 Brilliant Violet 421 1 in 20 BD 
CD123 6H6 PeCy7 1 in 50 Biolegend 
CXCR3 1C6/CXCR3 Brilliant Violet 421 1 in 20 BD 
CXCR5 RF8B2 Brilliant Violet 421 1 in 20 BD 
HLA-DR L243 APC Cy7 1 in 30 BD 
IFNγ 4S.B3 PeCy7 1 in 100 BD 
IL-6 MQ2-13A5 PE 1 in 20 BD 
IL-10 JES3-19F1 PE 1 in 100 BD 
Live/dead  APC/Cy7 (NIR) 1 in 100 Biolegend 
PD1  EH12.2H7 APC 1 in 20 Biolegend 
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3.3.5 MACS purification of CD4
+
 CD8
+
 CD56
+
 cells from whole blood 
 
PBMC’s were isolated as described in 3.3.2. PBMC’s were then washed in 10ml of sterile 
Dulbecco’s PBS (Life Technologies) and centrifuged at 392xg for 10minutes at 4°C, to remove any 
FBS carryover from the complete media. Using the MACS Miltenyi bead kits (Miltenyi Biotec 
Australia Pty Ltd, Macquarie Park, NSW, Australia) for positive selection of CD4
+
, CD56
+
 and 
CD8
+
 each sample was divided such that half was allocated for isolation of CD4
+
 cells and the other 
half underwent 2 isolations, CD56
+
 followed by CD8
+ cells, as per manufacturer’s instructions 
(Table 5). For the positive selection of CD4
+ 
and CD8
+
 cells, after the first elution, the sample was 
then loaded onto a fresh column and underwent a second round of elution in order to increase purity 
of selected population. Purity was  95-99%. Cells were then washed with 9ml of Dulbecco’s PBS, 
centrifuged at 392xg for 10 minutes at 4°C and the pellet was gently re-suspended in 500µl of 
RNA-later® (Sigma-Aldrich). Samples were transferred to 4°C overnight and then stored at -80°C 
for long term storage until RNA was extracted. 
 
Table 5: Magnetic labelling of CD4
+
, CD8
+
 and CD56
+
 cells 
Blood 
volume 
# PBMC Beads  MACS buffer  Total volume 
10ml 2×10
7
 40 μl 160 μl 200 μl 
20ml 4×10
7
 80 μl 320 μl 400 μl 
30ml 6×10
7
 120 μl 480 μl 600 μl 
40ml 8×10
7
 160 μl 640 μl 800 μl 
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3.3.6 Whole blood gene array  
 
From May 2012 – October 2012 blood samples were collected from the following cohorts: 
QP12C02 Cohort 1 (2012, Larium, n=3), QP12C02 Cohort 2 (2012, Larium, n=8), QP12C02 
Cohort 3 (2012, Larium, n=8), QP12C10 Cohort 1 (2012, OZ439, n= 7), QP12C10 Cohort 2 (2012, 
OZ439, n=7). A total of 33 paired samples were collected at day 0 and day 7 post challenge. 8ml of 
whole blood was collected from each subject into PAXgene® Blood RNA tubes (QIAGEN, Pty 
Ltd, Chadstone, VIC, Australia) and stored at -20°C within 2 hours after blood withdrawal. 
PAXgene tubes were thawed for 4 hours at room temperature before processing for RNA 
extractions. Automated RNA extractions were performed on the QIAcube (QIAGEN Pty Ltd, 
Valencia, CA, USA) using the PAXgene Blood miRNA kit (QIAGEN Pty Ltd, VIC, Australia) as 
per manufacturer’s instructions. RNA integrity and concentration was determined using the Agilent 
RNA 6000 Nano LabChip (Agilent Technologies, Pacific Laboratory Products, Blackburn, VIC, 
Australia) on an Agilent 2100 Bioanalyzer (Agilent Technologies Inc, Santa Clara, CA, USA). 
RNA samples were stored at -80°C before processing for RNA amplification and biotinylation. The 
Illumina® TotalPrep RNA Amplification kit (Thermo Fisher, Scoresby, VIC, Australia) was used 
to amplify and label RNA for direct hybridization onto Illumina array platforms, as per 
manufacturer’s instructions. Briefly, an input of 500ng of RNA was used in the first strand of 
cDNA synthesis (2 hours at 42°C) by reverse transcription, followed by the second strand (2 hours 
at 16°C). cDNA was purified using magnetic beads and eluted in water (heated to 55°C). In vitro 
transcription (IVT) was then used to synthesise the biotin-labelled cRNA by incubating cDNA with 
the IVT master mix for 14 hours at 37°C. cRNA was then purified using cRNA binding mix and 
cRNA binding beads, followed by 2 washes with cRNA wash solution. Finally, cRNA was eluted in 
40µl of cRNA elution buffer (heated to 55°C). Labelled cRNA concentration was determined using 
the NanoDrop ND-1000 UV-Vis Spectrophotometer (Thermo Scientific, Wilmington, DE, USA). 
The Illumina® Whole-Genome Gene Expression Direct Hybridization Assay system (Direct 
Hybridization Assay) (Illumina Australia, Pty Ltd, Scoresby, VIC, Australia) was used to detect 
gene expression in our samples, as per manufacturer’s instructions. Briefly, the labelled cRNA is 
hybridized to the bead on the BeadChip containing the complementary gene-specific sequence.  A 
total of 6 Illumina® Human BeadChips (HumanHT-12_V4) were used for direct hybridization of 
all 33 paired samples. Samples were randomised in order to avoid sample bias, prior to loading onto 
the BeadChips and incubating the RNA-loaded BeadChips in an Illumina Hybridization Oven for 
16 hours at 58°C. RNA-loaded BeadChips were then removed from the overnight hybridization and 
subsequently immersed and washed in 250ml of E1BC wash buffer, where the BeadChip cover-
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seals were gently removed using tweezers. BeadChips were then washed in 1x High-temp was 
buffer (set to warm to 55°C, the day before) for 10 minutes before transferring back into fresh 
250ml E1BC wash buffer for 5 minutes at room temperature. BeadChips were subsequently washed 
in 250ml of fresh 100% Ethanol for 10 minutes and then transferred into 250ml of E1BC wash 
buffer for 2 minutes at room temperature. Each BeadChip was then incubated in 4ml of Block E1 
buffer for 10 minutes at room temperature on a rocker mixer to ensure even spread of block buffer 
across the surface of the chip. 1µg/ml (final volume of 2ml) of Cy3-Strepavidin (kindly supplied by 
Dr. Glen Boyle, QIMR Berghofer Medical Research Institute), diluted in Block E1 buffer was 
added per BeadChip and incubated at room temperature on the rocker mixer (set to medium) for 10 
minutes, protected from light. All BeadChips were subsequently immersed and washed in fresh 
250ml of E1BC wash buffer for 5 minutes. All BeadChips were then dried by centrifuging at 392xg 
for 4 minutes at room temperature (Eppendorf Centrifuge 5810R). Finally, BeadChips were scanned 
on the iScan microarray scanner (Illumina Inc, San Diego, CA, USA) which uses a laser to excite 
the Cy3 of the single base extension product on the beads of the BeadChip sections. Data was 
collected as TIFF files after appropriate calibration and quality control measures.  
 
 
3.3.7 Gene array analysis  
 
Agilent Genespring (Agilent Technologies Inc) was used to examine any statistical 
differences between day 0 and day 7 using a paired t-test with corrections for multiple testing 
(Benjamini-Hochberg method) and the fold change cut off set at 1.25
298, 299, 300, 301
. Ingenuity 
Pathway Analysis (IPA) (QIAGEN, Redwood City, CA, USA) was performed to determine the top 
10 signalling pathways that were predominantly represented in our dataset with the fold change cut 
off set at 1.25. 
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3.3.8 Fluidigm® - micro fluidic RT qPCR (real time quantitative PCR) system 
 
RNA was extracted from PAXgene tubes using the QIAcube as described above. RNA 
concentration and quality was determined on the NanoDrop ND-1000 UV-Vis Spectrophotometer 
(Thermo Scientific). RNA was reverse transcribed into cDNA using Taqman Reverse Transcription 
Reagents (Life Technologies Pty Ptd, Mulgrave, VIC, Australia) and quantified on the Nanodrop 
ND-1000 UV-Vis Spectrophotometer (Thermo Scientific). Specific Target Amplification (STA) 
was carried out as per Fluidigm’s recommendations (PN 68000133 Rev C) in order to increase 
target concentration. Fluidigm technology uses micro-volumes and in order to detect specific targets 
a minimum of 500 – 1,000 copies (of a specific target) is required in the original 5µl loading 
volume. Briefly, all 48 Taqman assays (Life Technologies Pty Ltd) of interest were pooled and 
diluted (final concentration 0.2x) in Tris-EDTA buffer (Sigma-Aldrich). 1.25µl of the pooled assay 
mix was mixed with 2.5µl of Taqman PreAmp master mix (Life Technologies Pty Ltd) and 1.25µl 
of cDNA. Reactions were cycled at the following conditions shown in Table 6. 
 
Table 6: Thermal cycling conditions for Specific Target Amplification (STA) 
 Temperature Time No. of cycles 
Hold  95°C 10 minutes 1 
Cycling Step 1 95°C 15 seconds 17 
Cycling Step 2 60°C 4 minutes 
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After cycling samples were diluted 1:4 by adding 15µl of Tris-EDTA buffer (final volume of 20µl 
post STA). Samples were then assayed on the same day as per manufacturer’s instructions (PN 
68000089 H1) using the 48.48 Dynamic Array
TM 
chips (Millennium Science Pty Ltd, Mulgrave, 
VIC, Australia). Briefly, 48.48 chips were primed by injecting 300µl of control line fluid into the 
accumulators on either side of the chip and was subsequently loaded into the Fluidigm MX 
Integrated Fluidic Circuit (IFC) controller (Millennium Science Pty Ltd), were the ‘Prime 113x’ 
script was selected and run for 10 minutes. Samples and Taqman assays were then pipetted into 
respective wells on the chip which was then loaded back into the MX IFC controller for 1 hour to 
allowing for sample and assay mixing, using the ‘Load Mix (113x) script. Once the Load Mix script 
finished running, the chip was carefully removed and any dust particles or debris on the surface 
were removed prior to loading chip into the Biomark HD
TM
 (Millennium Science Pty Ltd). The 
48.48 chips were cycled at the following conditions shown in Table 7. Gene expression was 
determined using the 2
-ΔΔCT
 method and the GeoMean of the following three house-keeping genes: 
RPL13a, GAPDH and 18S, as reference. 
 
Table 7: Thermal cycling conditions for Fluidigm® RT qPCR  
 Temperature Time No. of cycles 
Hold 1 50°C 2 minutes 1 
Hold 2 95°C 10 minutes 1 
Cycling Step 1 95°C 15 seconds 50 
Cycling Step 2 60°C 1 minute 
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3.3.9 Calculating Area Under the Curve (AUC) 
 
To determine if there were any associations between cytokines and parasite growth, 
parasitemia was expressed as Area Under the Curve (AUC) to determine a more accurate indicator 
of parasite growth. Retrospective PCR parasitemia values were tested in duplicate and on the day of 
treatment, parasitemia was tested in triplicate. Importantly, AUC was only determined up until drug 
treatment. The limit of detection (LOD) was assumed to be 64parasites/ml
297
. After initial data 
checks for potential outliers, values below the LOD (between: 2 - 63) were substituted with LOD/2 
(32) and values that were not-detected (ND) were set to 1. All parasitemia values were log-10 
transformed, and the mean of the log-10 transformed parasitemia was used as a summary measure 
per time-point per participant. All regression analyses were performed using the mean log-10 
parasitemia values and performed separately per participant. The parasitemia growth can be 
modelled as a sine-wave function, though it requires a minimum of 6 data points. As the majority of 
subjects (67%) had parasitemia data for less than 6 time-points, the area under the curve was 
estimated using the trapezoid rule, using GraphPad Prism version 6. 
 
 
 
3.3.10 Statistical Analysis 
 
Statistical differences between groups were determined using the Wilcoxon matched-pairs 
signed rank test (day 0 vs day 7 or day 0 vs day 14) and the linear regression function was used to 
analyse associations between IL-10 levels and Area Under the Curve (AUC) by GraphPad Prism 
version 6 for Windows (GraphPad, San Diego, CA, USA); p<0.05 was considered statistically 
significant. All data are presented as the mean ± SE, unless otherwise stated.  
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3.4 RESULTS 
 
3.4.1 Whole blood gene array revealed a dominant type I IFN signature 
 
Type I IFN’s have been reported to suppress anti-parasitic CD4+ T cell responses during 
blood-stage Plasmodium infections
67, 68
. Consistent with these findings in mice, here in malaria-
naive individuals we observed a significant up-regulation of genes associated with the type I IFN 
signalling pathway, 7 days post challenge with P. falciparum (Fig 2a, b). Similarly, a recent study 
involving whole-blood transcriptional analysis in Rwandan adults with mild P. falciparum infection 
showed an up-regulation of the type I IFN pathway
302
. In these CHMI studies, the up-regulation of 
the type I IFN signalling pathway appeared to be associated with a down-regulation of genes in the 
T cell receptor signalling pathway (Fig 2 b-d). In order to validate results from the microarray, we 
employed use of the Fluidigm® 48.48 Chip platform to assess gene expression by RT qPCR, where 
we noted increases in irf3, irf7 and ifitm3 expression 7 days post challenge (Fig 2 e). Although 
these results show a similar pattern of gene expression as measured in gene array studies, it was 
critical that we functionally validated the link between the up-regulation of type I IFN genes and 
down-regulation of TCR signalling during  blood-stage P. falciparum infection. To this end, we 
next performed a series of PBMC assays with or without type I IFN blockade, to assess the 
contribution of type I IFN to the suppression of immune responses during blood-stage P. falciparum 
infection. 
 
 
 
 
 
 
Chapter 3 
 
 41758573  92 
 
Figure 2: Whole blood gene array revealed a dominant type I IFN signature. 
 
a) Whole blood from 33 participants (outlined in Table 1) was collected before and 7 days after infection 
with blood-stage P. falcipaurm (clone 3D7; drug sensitive strain) and processed for microarray analysis on 
GeneSpring®, heat map shows clustering analysis, fold change cut off  set at ±1.25. Paired t-test matched for 
multiple test corrections using the Benjamini-Hochberg method. (QP12C02 C1, C2, C3, QP12C10 C1 and 
C2) b), c) Canonical pathway analysis tool in Ingenuity Pathway Analysis® used to analyse top 10 signalling 
pathways with a fold change cut off at ±1.25 (QP12C02 C1, C2, C3, QP12C10 C1 and C2). d) Genes 
selected for validation in GeneSpring (QP12C02 C1, C2, C3, QP12C10 C1 and C2). e) Preliminary 
validation of microarray data using whole blood RNA samples from 18 participants (outlined in Table 2, 
using the Fluidigm® platform for RT qPCR (QP13C05 C1, C2 and QP13C14). b) and c) enlarged in 
Appendix 2 
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3.4.2 Suppression of T cell responses during blood-stage P. falciparum infection  
 
To gain an insight into the magnitude of CD4
+
 T cell responses following first exposure to 
P. falciparum, PBMC’s were isolated before and 7, 14 and 28-35 days after challenge. Blood 
parasitemia was monitored daily beginning at day 5 post challenge by PCR as described in Rockett 
et al.,
297
. Once parasite biomass had reached a physiological threshold of  1,000 pRBC’s/ml 
(generally 7-8 days post challenge) (Fig 3a), individuals were treated with experimental drug (see 
Table 2) at day 7 or 8 and rescue drug (Riamet®) at 28-35 days post challenge. Overall frequencies 
of CD4
+
 and CD8
+
 T cells remained relatively unchanged between day 0 and day 7 post challenge 
(Fig 3b). This suggests that the decreased TCR signalling observed in the gene array could 
potentially result from intrinsic changes in the T cell populations, rather than changes in cell 
frequencies (Fig 2c, Fig 3b). Upon phenotypic analysis of CD4
+
 T cell responses with particular 
focus on Th1 and Tfh cells, we noted a decrease in Th1 cells at day 7, whereas Tfh frequencies 
significantly increased at day 7 (Fig 3c). The early emergence of Tfh cells suggests the preferential 
selection of Tfh to Th1 given that the latter cell type promotes cellular immunity rather than 
humoral immunity which is required for long-term protection.  
 
To determine if the reduced Th1 frequencies at day 7 resulted in a defect in production of the Th1 
signature cytokine IFNγ, we first measured IFNγ levels in culture supernatants from PBMC’s 
stimulated with P. falciparum antigen. Previous reports have shown cross reactive T cell responses 
in individuals who have never been exposed to malaria
303, 304
 and consistent with these reports,  we 
also detected significantly elevated IFNγ levels at day 0 (Fig 3d).72 hours post antigen re-
stimulation we found that levels of IFNγ produced by PBMC’s in response to parasite antigen 
declined from day 0 to day 7 post challenge (Fig 3d), suggesting T cell responses were suppressed 
upon first exposure to blood-stage P. falciparum infection. Parasite-specific IFNγ levels increased 
after drug treatment and were sustained up until at least day 28 post challenge (Fig 3d). CD4
+
 T 
cells appeared to be the major source of IFNγ, since HLA-DR blockade resulted in significantly 
reduced IFNγ levels, 7 days post challenge (Fig 3e). 
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Figure 3: CD4
+
 T cell responses are suppressed during blood-stage P. falciparum infection.  
 
a) Participants were injected with 1,800 – 2,800 pRBC’s/ml and blood parasitemia monitored by PCR 
beginning at 5 days post challenge (QP13C14) b) PBMC’s isolated from participants before and 7 days post 
challenge and frequencies of CD4
+ 
and CD8
+ 
T cells were measured by flow cytometry (QP12C02 C1, C2, 
C3, QP12C10 C1, C2) c) PBMC’s isolated from participants before and 7, 9, 14 and 28 days post challenge 
and frequencies of Tfh (CXCR5
+
) and Th1 (CXCR3
+
) cells measured at each time point by flow cytometry 
(QP13C14). d) PBMC’s were isolated from participants throughout infection and cultured in the presence of 
nRBC’s or pRBC’s at 37°C, 5%CO2 in an incubator for 72 hours, when culture supernatants were harvested 
and IFNγ levels were detected using the BD Human cytometric bead array (CBA) kit as per manufacturer’s 
recommendations (QP13C14). e) PBMC’s were isolated from participants 7 days post challenge and cultured 
in the presence of pRBC’s and anti-HLADR antibody or its isotype control for 72 hours when culture 
supernatants were then harvested and IFNγ levels were detected using the BD Human CBA kit as per 
manufacturer’s recommendations (QP14C12 C1 and QP14C11). Mean  SEM, **=p<0.01, *= p<0.05, 
Wilcoxon matched-pairs signed rank test.  
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3.4.3 CD4
+
 T cells are the predominant source of IFNγ during blood-stage P. falciparum 
infection 
 
In order to ascertain the cell type responsible for the predominant source of parasite-specific 
IFNγ, we performed intracellular cytokine staining in PBMC cultures 72 hours post antigen re-
stimulation (Fig 4a). Horowitz et al., showed that while NK cells were the main producers of IFNγ 
12-18 hrs post antigen re-stimulation, T cells were the main producers of IFNγ 2-6 days post 
antigen re-stimulation
55
. Consistent with these results, we noted that CD3
+ 
CD56
-
 (T cells) 
dominated the IFNγ response with minor contributions from CD56+ CD3- (NK cells) and 
CD56
+
CD3
+
 (potentially NKT cells, γδ T cells and other activated T cells) 72 hours post antigen re-
stimulation (Fig 4b). While γδ T cells have been shown to produce IFNγ in response to parasite 
antigen, they were greatly outnumbered by αβ T cells55 and this was observed in our studies (Fig 4 
b). Earlier studies have shown CD4
+
 T cells to be a predominant source of IFNγ in response to 
parasite antigen
48, 55, 56. While the contribution to IFNγ production by CD4+ and CD8+ T cells was 
relatively equal, CD4
+
 T cells were the main producers of IFNγ in response to parasite antigen 14 
days post challenge (Fig 4c). 
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Figure 4: T cells are the predominant source of IFNγ during blood-stage P. falciparum infection. 
 
a) PBMC’s were isolated from participants before and 7, 14 and 35 days post challenge. PBMC’s were 
culture in the presence of nRBC’s or pRBC’s for 72 hours and Brefeldin A was added for the last 3 hours of 
culture. Total frequencies of IFNγ producing cells were measured by flow cytometry, as per the gating 
strategy (left to right): single cells, lymphocytes, live/viable cells, total IFNγ+, Q1:CD3-CD56-, Q2:CD3-
CD56
+
 (NK cells), Q3: CD3
+
CD56
+
, Q4: CD3
+
CD56
-
 (T cells), CD4
+
, CD8
+
, CD4
-
CD8
-
 T cells. b) 
Frequencies of cells (coloured bars) as a percentage of total IFNγ+ cells at  0, 7, 14 and 35 days post 
challenge from isolated PBMC’s cultured in the presence of nRBC’s or pRBC’s for 72 hours. c) Frequencies 
of IFNγ+ CD3+ cells showing proportion of CD4+ and CD8+ T cells within the T cell compartment, 
throughout the course of infection. Representative of 2 independent cohorts (QP13C05 3A and 3B), data is 
shown from QP13C05 3A.  
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3.4.4 Type I IFN’s were induced upon first exposure to P. falciparum and suppressed IFNγ 
production 
 
Various studies have reported on the induction of type I IFN’s during Plasmodium infection 
in various experimental malaria models
67, 68, 274, 305, 306, 307
 as well as humans
308, 309
. Recently, type I 
IFN’s have been reported to suppress CD4+ T cell-derived IFNγ production, via DC’s in a model of 
severe malaria
67, 68
. In accordance with these findings, we found significantly elevated levels of 
IFNα in response to parasite antigen, 7 days post challenge (Fig 5a). Importantly, blockade of type I 
IFN signalling showed a significant increase in IFNγ by PBMC’s in response to parasite antigen, 7 
days post challenge (Fig 5b). Collectively, these results suggest that type I IFN’s suppressed anti-
parasitic IFNγ responses. 
 
 
Figure 5: Blood-stage P. falciparum induces a type I IFN response that suppresses IFNγ production. 
 
a) Isolated PBMC’s cultured in the presence of nRBC’s or pRBC’s for 72 hours when culture supernatants 
were harvested and IFNα levels were measured by using the eBioscience Human IFNα detection kit 
(QP14C12 C1). b) PBMC’s were isolated from participants 7 days post challenge and cultured in the 
presence of nRBC’s, pRBC’s or pRBC’s + anti-IFNAR antibody or its isotype control for 72 hours and IFNγ 
levels were detected using the BD Human CBA kit (QP13C14 and QP13C05 3A).  ***=p<0.001, *= p<0.05, 
Wilcoxon matched-pairs signed rank test. 
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3.4.5 Type I IFN’s inhibit monocyte derived IL-6 production in response to P. falciparum 
 
The dramatic increase in IFNγ levels, following type I IFN blockade, prompted us to 
investigate whether other cytokines might also be affected by IFN-I, during blood-stage P. 
falciparum infection. Notably, upon type I IFN signalling blockade IL-6 levels were significantly 
elevated throughout the course of infection (Fig 6). Interestingly, following type I IFN signalling 
blockade, IL-6 levels were highest prior to infection, during, suggesting that type I IFN’s were 
potentially suppressing IL-6 production by innate cells
310
 (Fig 6). Cellular sources of IL-6 were 
assessed by flow cytometry (Fig 7a-d), where IL-6 production by plasmacytoid DC’s (pDC’s) and 
myeloid DC’s (mDC’s) was found to be comparable between day 0 and day 7 (Fig 7b, c). However, 
IL-6 production by monocytes was significantly elevated upon type I IFN signalling blockade at 
day 0 (Fig 7d). Elevated IL-6 levels have been observed in patients with inflammatory diseases 
such as rheumatoid arthritis, Castleman’s disease and systemic juvenile idiopathic arthritis311. 
Collectively, these results suggest that type I IFN’s suppresses monocyte derived IL-6 production 
upon first exposure to P. falciparum infection.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Type I IFN signalling blockade enhances IL-6 production in response to P. falciparum. 
 
PBMC’s were isolated from participants on 0, 7, 14 and 28 days post challenge and cultured in the presence 
of nRBC’s, pRBC’s or pRBC’s + anti-IFNAR antibody or its isotype control for 72 hours and IL-6 levels 
were detected using the BD Human CBA kit, as per manufacturer’s recommendations (QP13C14 and 
QP13C05 3A). Mean SEM, ***=p<0.001, Wilcoxon matched-pairs signed rank test. 
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Figure 7: Type I IFN’s suppress monocyte derived IL-6 production in response to P. falciparum. 
 
a) Gating strategy shown for pDC’s, mDC’s (top row) and monocytes (bottom row) measured by flow 
cytometry (QP13C14). b) Isolated PBMC’s were cultured in the presence of pRBC’s + anti IFNAR or its 
isotype control for 24 hours and Brefeldin A added for the last 3 hours and IL-6 was measured by 
intracellular cytokine staining by flow cytometry. IL-6 Mean Fluorescence Intensity (MFI) shown on pDC’s 
at day 0 and 7 post challenge (QP13C14). c) IL-6 MFI shown on mDC’s at day 0 and 7 post challenge 
(QP13C14). d) IL-6 MFI shown on monocytes at day 0 and 7 post challenge (QP13C14). Median + Min and 
Max, **=p<0.01, Wilcoxon matched-pairs signed rank test. 
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3.4.6 Type I IFN’s suppress early inflammatory cytokines in response to P. falciparum 
 
Given that members of the type I IFN signalling pathway are involved in the regulation of 
inflammatory cytokine responses
312, 313
, we next tested whether type I IFN blockade would affect 
other inflammatory cytokines. Strikingly, we observed significantly elevated levels of IL-1β and IL-
17A production by PBMC’s in response to parasite antigen, upon type I IFN signalling blockade, 7 
days post challenge (Fig 8 a, b). It was interesting to note that the effects type I IFN signalling 
blockade was specific to IL-6, IL-1β and IL-17A, but not TNF (Fig 6, Fig 8c). Taken together, 
these data suggest that type I IFN’s suppress major inflammatory networks early during P. 
falciparum infection.  
 
Figure 8: Type I IFN’s suppress IL-1β, IL-17 but not TNF production in response to P. falciparum. 
 
a) Isolated PBMC’s were cultured in the presence of nRBC’s, pRBC’s, pRBC’s + anti-IFNAR antibody or 
its isotype control for 72 hours when culture supernatants were harvested and levels of IL-1β, b) IL-17 or c) 
TNF were detected using the BD Human CBA kit, as per manufacturer’s recommendations. Data shown 
from QP13C14 and QP13C05 3A, Mean  SEM, ***=p<0.001, *=p<0.05, Wilcoxon matched-pairs signed 
rank test. 
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3.4.7 First exposure to P. falciparum induces parasite-specific Tr1 cells and IL-10 production 
7 days post drug treatment 
 
Earlier studies have shown that circulating levels of IFNγ and IL-10 were significantly 
higher in patients with severe malaria
314, 315
. More recently, it was shown that Tr1 cells emerge as 
the dominant CD4
+
 T cell response in highly exposed children living in malaria endemic regions
47, 
48, 232
. The gating strategy for Tr1 cells, in our CHMI studies is shown in Fig 9. Similar to field 
studies, in our CHMI studies, we found a significant increase in IL-10 production by PBMC’s in 
response to parasite antigen throughout the course of infection (Fig 10a). IL-10 levels peaked 14 
days post challenge (7 days post drug treatment) (Fig 10a), suggesting the generation of IL-10 
occurred in response to increased antigen available as a result of parasite killing by drug. Recent 
studies have confirmed CD4
+ 
T cells as a major source of IL-10 production during Plasmodium 
infections
47, 74, 316
. Similarly, in our studies, this increase in IL-10 production by PBMC’s in 
response to parasite antigen appeared to HLA-DR restricted (Fig 10b), suggesting that CD4
+
 T cells 
were a major source of IL-10 during blood-stage P. falciparum infection. In addition to this increase 
in IL-10 production, we observed a significant increase in the frequency of Tr1 cells in response to 
parasite antigen 14 days post challenge (Fig 10c, d). Similar to total IL-10 production, the induction 
of Tr1 cells also appeared to be HLA-DR restricted (Fig 10c, d). Together these data indicate that a 
significant proportion of IL-10 production by PBMC’s in response to parasite antigen was by CD4+ 
T cells, 7 days post drug treatment (14 days post challenge), indicating the development of Tr1 cells 
during first exposure to blood-stage P. falciparum infection. 
 
Figure 9: Gating strategy for Tr1 cells, 72 hours post Pf antigen re-stimulation. 
 
a) Isolated PBMC’s were cultured in the presence of nRBC’s or pRBC’s (Pf) for 72 hours and Brefeldin A, 
PMA/Ionomycin was added for the remaining 3 hours of culture before frequencies of Tr1 cells were 
analysed by flow cytometry. Gating strategy from left to right shows: single cells, lymphocytes, live/viable 
cells, CD16
-
CD56
-
 (exclusion of NK and γδ T cells), CD3+, CD4+, IFNγ+ IL-10+ (QP13C05 3A).  
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Figure 10: Blood-stage P. falciparum induces HLA-DR restricted Tr1 cells and IL-10 production. 
 
a) PBMC’s were isolated from participants at 0, 7, 14 and 28 days post challenge and cultured in the 
presence of nRBC’s or pRBC’s for 72 hours, when culture supernatants were harvested and levels of IL-10 
were measured using the BD Human CBA kit (QP13C14). b) PBMC’s were isolated from participants 14 
days post challenge (7 days post drug treatment) and cultured in the presence of nRBC’s, pRBC’s or pRBC’s 
+ anti HLADR antibody or its isotype control for 72 hours, when culture supernatants were harvested and 
levels of IL-10 were measured using the BD Human CBA kit (QP14C12 C1 and C2). c) PBMC’s were 
isolated from participants 14 days post challenge (7 days post drug treatment) and cultured in the presence of 
nRBC’s, pRBC’s or pRBC’s + anti HLADR antibody or its isotype control for 72 hours and Brefeldin A, 
PMA/Ionomycin was added for the remaining 3 hours of culture before d) frequencies of Tr1 cells were 
measured by flow cytometry (QP14C12 C1 and C2). a Mean ±SEM, b and d, Median + Min and Max, 
**=p<0.01, *=p<0.05, Wilcoxon matched-pairs signed rank test. 
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3.4.8 Type I IFN dependent IL-10 production and Tr1 cell induction, during blood-stage 
Plasmodium infection 
 
Interestingly, type I IFN’s have been shown to induce IL-10 production in 
monocytes/macrophages, dendritic cells, B and T cells, via STAT3-dependent or independent 
pathways
272, 273
. We confirmed this, showing that upon blockade of type I IFN signalling, IL-10 
production by PBMC’s in response to parasite antigen was significantly reduced 7 days post drug 
treatment (Fig 11a). Interestingly, type I IFN’s were also required for the induction of Tr1 cells (Fig 
11b). Linear regression analysis showed a significant positive correlation between IL-10 levels and 
parasitemia, as determined by AUC at day 7 post challenge (Fig 11c). While IL-10 plays a key role 
in immunoregulation, this may contribute to suppression of anti-parasitic responses and thus impede 
parasite control. However, an alternative mechanism might be that higher parasite levels promote 
greater IL-10 production. To investigate this further, we neutralised IL-10 and observed significant 
increases in the production of pro-inflammatory cytokines IFNγ and TNF, 7 days post drug 
treatment (Fig 11d, e). Given the positive correlation between IL-10 and AUC and the significant 
increases in IFNγ and TNF levels upon neutralisation of IL-10, we investigated whether there was 
any association between IFNγ and AUC. Linear regression analysis showed a significant inverse 
correlation between IFNγ levels and parasitemia, as determined by AUC at day 7 post challenge 
(Fig 11f).   Collectively, these data suggest that parasite-induced IL-10 can suppress the generation 
of potent anti-parasitic responses, contributing to increased parasitemia. 
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Figure 11: Emergence of immunoregulatory networks is type I IFN-dependent and may contribute to 
enhanced parasite growth. 
 
a) PBMC’s were isolated from participants 14 days post challenge (7 days post drug treatment) and cultured 
in the presence of nRBC’s, pRBC’s or pRBC’s + anti-IFNAR antibody or its isotype control for 72 hours 
and IL-10 levels were detected using the BD Human CBA kit (QP13C14 and QP13C05 3A). b) PBMC’s 
were isolated from participants 14 days post challenge (7 days post drug treatment) and cultured in the 
presence of nRBC’s, pRBC’s or pRBC’s + anti IFNAR antibody or its isotype control for 72 hours and 
Brefeldin A, PMA/Ionomycin was added for the remaining 3 hours of culture before frequencies of Tr1 cells 
were analysed by flow cytometry (QP13C05 3A). c) Linear regression analysis performed to determine 
correlations between log-transformed IL-10 levels 14 days post challenge and parasitemia using area under 
the curve (AUC) (QP13C14, QP13C05 3A, 3B, QP14C11 and QP14C12). d) PBMC’s were isolated from 
participants 14 days post challenge (7 days post drug treatment) and cultured in the presence of nRBC’s, 
pRBC’s or pRBC’s + anti-IL-10 antibody or its isotype control for 72 hours when d) IFNγ levels (QP13C05 
3A and 3B) and e) TNF levels were detected using the BD Human CBA kit (QP13C05 3A and 3B). f) Linear 
regression analysis performed to determine correlations between log-transformed IFNγ levels 7 days post 
challenge and parasitemia using area under the curve (AUC) (QP13C14, QP13C05 3A, 3B, QP14C11 and 
QP14C12).  Median + Min and Max, ***=p<0.001, **=p<0.01, *=p<0.05, Wilcoxon matched-pairs signed 
rank test. c, f  Linear regression function (goodness of fit).  
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3.4.9 Type I IFN-dependent IL-10 production in patients with natural P. falciparum exposure 
 
To test whether type I IFN  induced IL-10 production was limited to our CHMI studies we 
obtained PBMC samples from P. falciparum malaria patients from Timika, Papua, Indonesia 
(Table 3, 3.3.3) and measured IL-10 levels in response to parasite antigen. In these individuals, day 
0 refers to the time of admission to the clinic, where parasites were detectable in the blood and day 
7 refers to 7 days post-drug treatment. Upon type I IFN signalling blockade, IL-10 levels were 
significantly reduced 7 days post treatment (Fig 12). These data suggests that in individuals who 
have natural P. falciparum infection, type I IFN’s were also required for inducing IL-10 production 
by PBMC’s in response to parasite antigen. 
 
 
 
Figure 12: Emergence of immunoregulatory networks is also type I IFN-dependent in patients with 
natural P. falciparum exposure. 
 
Cryopreserved PBMC’s from Timika, Indonesia at day 0 (time of admission into the clinic) and day 7 (7 
days post drug treatment) were thawed and cultured in the presence of nRBC’s, pRBC’s or pRBC’s + anti-
IFNAR antibody or its isotype control for 72 hours and IL-10 levels were detected using the BD Human 
CBA kit. Mean SEM, *=p<0.05, Wilcoxon matched-pairs signed rank test. 
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3.5 DISCUSSION  
 
In this series of CHMI studies, whole blood gene array analysis revealed a dominant type I 
IFN signature associated with suppressed TCR signalling 7 days post challenge, relative to pre-
challenge. Consistent with previous studies, parasite-specific IFNα levels were significantly 
elevated 7 days post challenge
308, 309
. Reduced T cell receptor signalling was not caused by reduced 
T cell frequencies, since CD4
+
 and CD8
+
 T cell frequencies were comparable between day 0 and 
day 7, thereby indicating intrinsic changes within these T cell sub-populations. Phenotypic analysis 
of Th1 and Tfh frequencies revealed a decrease in Th1 frequencies, but significant increase in Tfh 
frequencies at day 7 post challenge. While an increase in Tfh frequencies was observed at day 7 and 
28 post challenge, despite a type I IFN-mediated reduction of IL-6, it is possible that other 
cytokines such as IL-21 play a compensatory role in the induction/maintenance of Tfh cells, since 
they both signal via STAT3
82, 317
. The induction of cellular immune responses induced by 
vaccination plays a key role in the activation of effector CD4
+
 T cell subsets, including Th1 and Tfh 
cells
287
. Th1 cells mediate parasite killing, while Tfh cells provide B cell help in the generation of 
protective antibody responses
283, 284, 318
. Interestingly, Obeng-Adjei et al., demonstrated that in 
children with acute malaria, Plasmodium preferentially activates Th1-like CXCR3
+
 Tfh cells that 
are unable to provide adequate B cell help
287
. Taken together with our results, this suggests that 
Plasmodium impedes the generation of protective immunity by manipulating the host’s cellular and 
humoral immune responses early on in infection.  
 
While there has been no direct evidence for a protective role for IFNγ during human 
Plasmodium infections, numerous studies have demonstrated associations between IFNγ levels and 
protection from disease. For example, previous studies have shown that  CD4
+
 T cell derived TNF 
and IFNγ induced by RTS,S vaccination has been associated with protection in naturally exposed 
children and experimentally challenged adults
319, 320, 321
,  suggesting that inflammatory CD4
+
 T cell 
responses may contribute to protection from clinical disease
48
. We and others have shown CD4
+
 T 
cells are the main source of IFNγ during blood-stage Plasmodium infection48, 55, 56. In line with 
previous studies
68
, together these data suggest that upon first exposure to P. falciparum, type I 
IFN’s suppress anti-parasitic CD4+ T cell responses.  
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Field studies involving infants and young children, as well as these CHMI studies, provide 
substantial evidence that upon early or first exposures to Plasmodium, immunoregulatory networks 
emerge in response to the parasite. IL-10 production and Tr1 cell development seem to be induced 
in order to limit inflammation, but this has the additional effect of impeding the generation of anti-
parasitic immune responses. The establishment of immunoregulatory networks in young children 
seems to increase their susceptibility to developing severe disease in the absence of effective 
treatment. Additionally, a recent study in western Kenya (holoendemic malaria region), showed that 
when IFNγ and IL-10 responses were both present in response to the merozoite surface protein 1 
(MSP142), the protective effect of IFNγ was abrogated
35
. Taken together with our studies, this 
suggests that the induction of IL-10 limits the potentially protective effect of IFNγ and thus leads to 
parasite persistence and disease. On the other hand, a majority of adults living in malaria endemic 
regions, with repeated exposures to Plasmodium have high levels of IFNγ along with TNF, which 
ultimately serve to control parasite growth, such that these individuals are often asymptomatic. 
Indeed, while high levels of inflammatory cytokines do result in clinical symptoms, it has been 
shown  in field studies, that over time and over a series of multiple exposures, adults have 
developed mechanisms to limit inflammation from causing pathology while maintaining low 
parasitemia levels [reviewed in
32, 258, 322
].  
 
By using PBMC samples collected from Timika, Indonesia, where 125 million people live 
in malaria-endemic regions
323
, we found that IL-10 production was dependent on type I IFN’s, post 
drug treatment. The early emergence of immunoregulatory networks may provide an explanation 
for the limited efficacy of the RTS,S/AS01 vaccine and highlights the need for targeted therapeutic 
interventions to improve vaccine efficacy, possibly by manipulating immunoregulatory networks. In 
addition to this, a more comprehensive understanding of how Tr1 cells are induced in response to 
Plasmodium is required. Mapping the requirements and pathways for Tr1 cell induction during 
infection will provide mechanistic insights as to how these networks can be modulated when 
developing a vaccine. IL-27 has been shown to drive the generation of Tr1 cells in both humans and 
mice
209, 324, 325, 326
. Recently, Tyrosine kinase 2 (Tyk2) was reported to modulate IL-27 gene 
expression and release via a type I IFN dependent mechanism
327
. Tyk2-deficient mice exhibited 
significantly reduced IL-27 levels in the plasma following endotoxic shock or polymicrobial sepsis 
induced by cecal ligation puncture (CLP)
327
. While Tyk2 did not appear to be required to mediate 
the effects of IL-27 on target gene expression in CD4
+
 T cells, the authors suggest that the 
association of Tyk2 with gp130 may not be required in CD4
+
 T cells for IL-27 signalling
327
. 
Nonetheless, it would be interesting to investigate pathways involving type I IFN’s and IL-27 and 
how they interact to induce Tr1 cells. 
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While vaccines currently in clinical trials have demonstrated excellent efficacy rates in 
healthy volunteers, it is unclear as to why this efficacy decreases dramatically, when tested in 
malaria endemic areas. Factors contributing to this reduced efficacy rate in malaria patients have 
been attributed to, transmission rates, degree of exposure to Plasmodium species, underlying 
medical conditions and age. A model of anti-malaria immunity proposed by Artavanis-Tsakonas et 
al., suggests that in infants from malaria endemic areas, low TNF and IFNγ levels are induced via 
an innate pathway and antigen-specific T cells are primed at the same time
322
. Upon re-infection, 
antigen-specific T cells expand and produce large amounts of IFNγ which synergises with TNF to 
control parasite growth, however, this inflammatory cascade increases their risk to developing 
severe malaria
322
. Further infections induce effective anti-parasitic immunity resulting in reduced 
parasite load and therefore the concomitant level of antigenic stimulation dampens the pro-
inflammatory cascade
322
. Similar to recent field studies involving children in a high transmission 
setting, our findings show that in healthy adults from non-endemic areas with no previous history or 
exposure to malaria, anti-parasitic immune responses were suppressed and instead parasite-specific 
IL-10 production and Tr1 cells were induced
47, 48, 232, 235
. Boyle et al., suggest that in a low 
transmission setting, both children and adults predominantly produce IFNγ and TNF48. 
Contrastingly, in a high transmission setting, children have higher frequencies of parasite-specific 
CD4
+
 T cells producing IL-10, whereas the CD4
+
 T cells in adults produce IFNγ and TNF48. 
Furthermore, in highly exposed children, the dominant CD4
+
 T cell response includes Tr1 cells
47, 
232
. These data, along with the dramatic reduction of vaccine efficacy in field trials, strongly suggest 
that Plasmodium preferentially induces the immunoregulatory pathways to suppress the 
development of anti-parasitic immunity.   
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Collectively, these recent findings and the data described in this Chapter may provide 
insights into the limited efficacy of the current RTS, S/AS01 vaccine. We show that in healthy adult 
volunteers, upon first exposure to P. falciparum, type I IFN’s promote the establishment of 
immunoregulatory networks. Given that these immunoregulatory networks also appear to be 
induced in young children living in malaria endemic areas who have not yet acquired an adequate 
level of immunity to malaria
47, 232, 235, 276
, this suggests that first and/or early exposures to 
Plasmodium induces immunoregulatory responses rather than anti-parasitic responses . While these 
immunoregulatory networks may provide protection against pathology, they may also impede the 
generation of anti-parasitic immune responses. However, in order for this to be empirically 
demonstrated, participants from these CHMI studies would have to be re-infected with P. 
falciparum and their immune responses measured to determine if Tr1 cells still emerge after a 
second exposure to P. falciparum. 
 
 
To understand how these immunoregulatory networks are established and regulated, the next 
Chapter investigates the requirements for the generation of Tr1 cells during parasitic infections 
including Plasmodium, but also examines whether Tr1 cells are induced in other parasitic diseases 
such as Leishmania, thereby probing the broader significance of these findings. 
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4.1 INTRODUCTION 
 
Polyclonal CD4
+
 T cell responses against Plasmodium and Leishmania infections have 
provided valuable insights into host-parasite interactions, however, the study of antigen-specific 
CD4
+ 
T cell responses, particularly in infectious diseases, provide a more accurate insight into host-
parasite interplay.  From a vaccine development perspective, understanding the emergence and 
subsequent magnitude of antigen-specific CD4
+
 T cell responses is imperative for the development 
of effective vaccines.  The integrins CD11a and CD49d have been reported to aid the phenotypic 
identification of cells which have recently encountered antigen
328, 329
. CD11a is expressed on all 
leukocytes and is an important adhesion molecule involved in lymphocyte and granulocyte 
function
330, 331
, while CD49d is directly involved in mononuclear leukocyte trafficking and is 
expressed by T cells, B cells, eosinophils and basophils
332, 333
. The utility of using CD11a and 
CD49d to track antigen-specific T cell responses has been confirmed in Plasmodium
328, 334
, 
Leishmania
335
, LCMV
329
 and Listeria infections
336
. CD11a and CD49d expression requires the 
presence of cognate antigen and is not altered via TLR stimulation or an inflammatory 
environment
329
, and therefore has been widely used to identify antigen-specific T cell responses.  
 
Plasmodium and Leishmania infections elicit potent Th1 responses that promote parasite 
clearance via the production of IFNγ which activates macrophages156, 337, 338. An emerging paradigm 
is that in the presence of persisting pathogens, Th1 cells acquire the capacity to become 
immunoregulatory by transitioning into IL-10-producing Th1 cells, now commonly known as Tr1 
cells. This transition involves the emergence of master transcription factors that determine cell fate. 
While various master transcription factors have been identified for the development of Th1, Th2, 
Th17, Tfh and Treg cells, as well as the environmental conditions and extrinsic factors that further 
promote their differentiation, other transcriptional regulators have been shown to play important 
roles in fine-tuning this process. For example, Th1 cell development requires Tbet, while Blimp1, c-
maf, Ahr and Egr2 are all thought to play key roles in the development of Tr1 cells
206, 209, 216, 217
. 
Blimp1 has been shown to play key roles in T cell function, differentiation and homeostasis
339, 340
. 
In T cells, prdm1 mRNA encoding the Blimp1 protein is induced upon antigen-dependent activation 
of naïve CD4
+
 and CD8
+
 T cells via IL-2-, activator protein (AP)-1, nuclear factor kappa (NFκ)B 
and IRF4-dependent signals
339, 340
.  
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Several studies have demonstrated a strong association between Blimp1 expression and IL-
10 production, where in conventional CD4
+
 T cells Blimp1 induces IL-10 production
215, 216, 217, 251
 
whereas Blimp1 and IRF4 were both required for inducing IL-10 production by CD4
+ 
Foxp3
+
 Treg 
cells
181
. This suggests that while Th cells have unique differentiation pathways, the mechanisms of 
IL-10 induction for each subset has been integrated within their differentiation program
201, 341
. The 
effects of IL-10 induction are of particular interest, given its immunoregulatory role during 
Plasmodium infections, suppressive role in Leishmania infections and how this influences disease 
outcome. In an effort to modulate infection-induced inflammatory responses, IL-10 is produced, but 
there is a delicate balance between the tissue protective role of IL-10 and the unwanted suppression 
of anti-parasitic immunity
37, 280
. In addition to IFNγ and IL-10 expression, the surface markers, 
CD49b and LAG3 have been reported to potentially aid in the phenotypic identification of Tr1 
cells
200
. CD49b is an integrin which mediates adhesion and lymphocyte activation, and is expressed 
by NK cells, a subset of splenic CD4
+
 T cells, NKT cells, intestinal intraepithelial and lamina 
propria lymphocytes, epithelial cells and platelets
200
. LAG3 is a CD4 homolog, binds with high 
affinity to MHCII and is up-regulated in T cells that have recently been activated, as well as 
exhausted T cells, in comparison to expression on effector or memory T cells
342
. LAG3 is not 
expressed by resting T cells
343
. Furthermore, a recent study reported an increase in the frequency of 
CD49b
+ 
LAG3
+
 Tr1 cells in HIV patients; however, it was unclear as to whether elevated IL-10 
levels had a beneficial or detrimental impact on disease progression
344
. The development of Tr1 
cells during Plasmodium
47, 75, 235
,  Leishmania
214, 234, 345
, LCMV
215
 and Toxoplasma
216
  infections 
provides an insight into how these pathogens  modulate IL-10 to aid their survival by causing 
immunosuppression of the host. Further study into the effects of Blimp1 induced IL-10 production 
and Tr1 cells will provide a greater understanding of the suppression of anti-parasitic CD4
+ 
T cell 
responses, which consequently leads to the establishment of parasite persistence and pathology. 
 
This chapter examines the roles for Blimp1 in the development of CD4
+
 T cell responses 
during Plasmodium and Leishmania infections, with a particular focus on Th1 and Tr1 cells. 
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4.2 MATERIALS AND METHODS 
 
The material and methods presented here are specific to this chapter 
 
4.2.1 Mice 
 
Female C57BL/6J mice 8-12 weeks old were purchased from either the Australian Resource 
Centre (Canning Vale, Perth, WA, Australia) or the Walter and Eliza Hall Institute (WEHI) 
(Parkville, Melbourne, VIC, Australia) and were maintained in the animal house facility at the 
QIMR Berghofer Medical Research Institute under conventional conditions. T cell specific Blimp1 
deficient mice: C57BL/6J.Lck-Cre
+
 x Prdm1
fl/fl
 = Prdm1
ΔT
 (Cre positive), Lck-Cre
-
 x Prdm1
fl/fl
 = 
Prdm1
fl/fl 
(Cre negative) and prdm1
gfp 
(GFP reporter)
 
mice were bred in-house under specific-
pathogen free conditions. All animal procedures were approved and monitored by the QIMR 
Berghofer Animal Ethics Committee. This work was conducted under QIMR Berghofer animal 
ethics approval numbers: A02-633M and A02-634M, in accordance with the “Australian Code of 
Practice for the Care and Use of Animals for Scientiﬁc Purposes” (Australian National Health and 
Medical Research Council).
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4.2.2 Parasites and infection 
4.2.2.1 Plasmodium infections 
 
PcAS and PbA strains were used in all experiments after one in vivo passage in a C57BL/6J 
mouse. Please see Chapter 2, 2.3.1 and 2.3.2 for preparation of inoculums. All mice received a 
standard dose of 1x10
5
 pRBC’s in RPMI/PS i.v. via the lateral tail vein. Thin blood smears from tail 
bleeds were stained with Clini Pure- stains (HD Scientific Supplies, Willawong, QLD, Australia). 
Parasitemia was used to monitor the course of infection and was determined by flow cytometry.  
 
4.2.2.2 Leishmania infections 
 
L. donovani parasites were maintained by passage in B6.RAG1
-/-
 mice and amastigotes were 
isolated from the spleens of chronically infected mice. Mice were infected with 2x10
7
 L. donovani 
amastigotes in RPMI/PS i.v. via the lateral tail vein. Spleen and liver impression smears were used 
to determine parasite burdens and were expressed as Leishman Donovan Units (LDU; number of 
amastigotes per 1000 host nuclei multiplied by the organ weight (in grams)) 
 
4.2.3 Monitoring parasitemia (during Plasmodium infections) by flow cytometry  
Briefly, 1-2 drops of blood, from a tail bleed was diluted and mixed in 250 μl RPMI/PS 
containing 5 U/ml heparin sulphate. Diluted blood was stained simultaneously with Syto84 (5 μM; 
Life Technologies) to detect RNA/DNA and Hoechst33342 (10 μg/ml; Sigma-Aldrich) to detect 
DNA for 30 minutes at room temperature, protected from light. 2 ml RPMI/PS was added to stop 
the reaction, and samples were immediately placed on ice until acquisition on a BD FACSCanto II 
Analyzer (BD Biosciences). Data was analysed using FlowJo software (Treestar), where pRBC 
were readily detected as being Hoechst33342
+
 Syto84
+
, with lymphocytes excluded on the basis of 
size, granularity, and higher levels of Hoechst33342/Syto84 staining compared with pRBC’s (Fig 
1a,b) 
 
Chapter 4 
 
 41758573  115 
 
Figure 1: Monitoring peripheral parasitemia during PcAS infection. 
 
a) C57BL/6J mice infected with 1x10
5
 PcAS pRBC’s i.v. and parasitemia (1-2 drops of blood collected from 
the tail) was monitored by flow cytometry by gating on (top, left to right) 1: single cells, 2: RBC’s and 3: 
Syto84
+ 
Hoechst
+
 pRBC’s to identify parasite nucleic acid/DNA within RBC’s. b) Representative 
Syto84/Hoechst staining profiles in naïve mice and Prdm1
fl/fl
 (WT equivalent) and Prdm1
ΔT
 PcAS-infected 
mice 8 days p.i. when parasitemia peaks in the WT controls. Representative of 5 independent experiments, n 
= 5 mice per group. 
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4.2.4 Monitoring PbA infection and clinical scoring of ECM symptoms 
A transgenic PbA line (clone 231c11) expressing luciferase (PbA-luc) and GFP under the 
control of the ef1-α promoter was used for all PbA experiments unless otherwise stated. From day 5 
post-infection with PbA, mice are monitored twice daily to assess their level of infection/illness. 
When mice showed signs of experimental cerebral malaria (ECM), monitoring was increased to 2-
3hr intervals. Monitoring mice involved assigning them a clinical score at each time point. 
Mice were scored subjectively according to the following criteria: 
1 Ruffling of fur 
2 Hunched, still some mobility 
3 Wobbly gait 
4 Limb paralysis 
5 Convulsions, coma, death 
Each of the above criteria received a score of 1, and these symptoms usually presented in the order 
described above. A cumulative score of 4 and above required that mice were sacrificed.  The next 
time point for sacrificed mice was a score of 5. 
 
4.2.5 in vivo bioluminescence imaging 
The in vivo imaging system 100 (Xenogen, Alameda, CA, USA) was used to detect the level 
of bioluminescence as a measure of whole body parasite burden in each mouse. At selected time-
points, PbAluc-infected mice were anaesthetised with isofluorane and injected with 150mg/kg i.p. 
of D-luciferin (Xenogen) 5 minutes prior to imaging. Bioluminescence was measured in p/s/cm²/sr 
using Living Image Software (Xenogen). 
4.2.6 Flow cytometry 
List of antibodies used summarised in Table 1. Cell populations of interest were defined as follows: 
 
 pRBC’s: Syto84+ Hoechst+ 
 Activated CD4+ T cells: CD11a+ CD49d+ CD4+ TCRβ+ 
 Activated Th1 cells: CD11a+ CD49d+ CD4+TCRβ+ Tbet+ IFNγ+ 
 Activated Tr1 cells: CD11a+ CD49d+ CD4+ TCRβ+ IL-10+ IFNγ+ 
 Treg cells: CD4+ TCRβ+ Foxp3+ IL-10+ 
 Plasma cells: B220+ CD19+ CD138+ Blimp1 (GFP)+ 
 
Chapter 4 
 
 41758573  117 
Table 1: Mouse monoclonal antibodies used for flow cytometry  
Specificity  Clone Fluorophore Dilution Supplier 
B220  RA3-6B2 APC  1 in 200 Biolegend 
CD4 GK1.5 PerCPCy.5.5 1 in 200 Biolegend 
CD4 GK1.5 FITC 1 in 200 Biolegend 
CD8α 53-6.7 Alexa Fluor 700 1 in 200 Biolegend 
CD19 6D5 Biotin 1 in 200 Biolegend 
CD19 6D5 PerCP/Cy5.5 1 in 100 Biolegend 
CD11a M17/4 FITC 1 in 50 Biolegend 
CD49b DX5 APC 1 in 100 Biolegend 
CD49d R1-2 Biotin  1 in 50 Biolegend 
CD138 281-2 PE 1 in 100 Biolegend 
Foxp3 MF-14 APC or AF488 1 in 100 Biolegend 
Hoechst 33342*  Pacific Blue 1 in 500 Sigma-Aldrich 
IFNγ XMG1.2 APC 1 in 200 BD 
IFNγ XMG1.2 BV421 1 in 200 Biolegend 
IFNγ XMG1.2 PE 1 in 200 Biolegend 
IL-10 JES5-16E3 PE 1 in 200 Biolegend 
LAG3 C9B7W Biotin 1 in 200 Biolegend 
Live/Dead   Aqua (Amcyan) 1 in 200 Invitrogen 
Streptavidin  PE 1 in 100 Biolegend 
Streptavidin  AF700 1 in 100 Biolegend 
Streptavidin  PeCy7 1 in 200/ 
1 in 400 
Biolegend 
Syto84*  PE 1 in 500 Life Technologies 
Tbet Ebio4B10 efluor 660 (APC) 1 in 10 Ebioscience 
Tbet Isotype control 
(mouse IgG1κ) 
P3.6.2.8.1 efluor 660 (APC) 1 in 10 Ebioscience 
TCRβ H57-597 APC 1 in 200 Biolegend 
TCRβ H57-597 BV421 1 in 200 Biolegend 
TCRβ H57-597 PerCP/Cy5.5 1 in 200 Biolegend 
TNF MP6-XT22 PE 1 in 400 Biolegend 
TNF MP6-XT22 PeCy7 1 in 400 Biolegend 
*RNA/DNA dyes for detecting pRBC’s in blood. 
 
Chapter 4 
 
 41758573  118 
4.2.8 Antibodies for in vivo neutralisation of IL-12  
 
For IL-12 neutralisation experiments, mice were administered 500µg of rat IgG (Sigma or 
Invitrogen) or anti-IL-12 (clone: C17.8, BioXcell, West Lebanon, NH, USA) i.p on the day of 
infection and every 3 days p.i. until day 14 p.i. (see Fig 11a) 
 
4.2.9 Human VL patient samples 
 
All patients in this study presented with symptoms of VL at the Kala-azar Medical Research 
Center (Muzaffarpur, Bihar, India). Diagnosis of VL was confirmed either by the microscopic 
detection of amastigotes in splenic aspirate smears or by the rk39 dipstick test. In total, 10 patients 
were enrolled in the study with their prior consent and ethical clearance from the Institutional 
Ethical Committee of Banaras Hindu University (Varanasi, Uttar Pradesh, India). Blood was 
collected from patients before and 28 days after commencement of drug treatment, and PBMC were 
isolated by Ficoll-Hypaque (GE Healthcare, NJ, USA) gradient centrifugation and used for the 
positive selection of CD4
+
 T cells using magnetic beads and columns (Miltenyi Biotech, Bergisch 
Gladbach, Germany).  After MACS purification, cells were transferred directly into RNAlater® 
(Sigma-Aldrich), and stored at -70°C until RNA was extracted. Total RNA was isolated using 
RNeasy mini kits and QiaShredder homogenizers (Qiagen, Valencia, CA), as per manufacturers 
protocol. The quality of RNA was assessed by denaturing agarose gel electrophoresis. cDNA 
synthesis was performed in 20 µL reactions on 0.5–1.0 µg RNA using High-Capacity cDNA 
Archive kit (Applied Biosystems, CA, USA). Real-time PCR was performed on an ABI Prism 7500 
sequence detection system (Applied Biosystems) using cDNA-specific FAM–MGB labelled 
primer/probe sets for human PRDM1. The relative quantification of products was determined by the 
number of cycles over 18S mRNA endogenous control required to detect PRDM1 gene expression. 
Patient clinical data is shown in Table 2. 
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Table 2: Human VL patient clinical data 
 
Patient Information Recorded data 
Number of individuals per group (n) 10  
Gender (M/F)  5 males, 5 females  
Age (years)  28.90+ 18.19 (24)  
Duration of illness (days)  29.75 + 26.41 (22)  
WBC counts (pre treatment)  4160 + 1257 (3700)  
WBC counts (post treatment)  9440 + 2777 (10000)  
Spleen size (cm), (pre treatment)  2.6 + 1.5 (3)  
Spleen size (cm), (post treatment)  0.1 + 0.31 (0)  
Values are given as mean + SD 
Median values are given within brackets. 
Post treatment values are 28 days post treatment. 
 
 
4.2.10 Statistical Analysis 
 
Statistical differences between groups were determined using the Mann-Whitney U test or 
the Log -rank (Matel-Cox) test (survival)  for mouse studies and the Wilcoxon matched-pairs signed 
rank test was used in the human studies by GraphPad Prism version 6 for Windows (GraphPad, San 
Diego, CA); p<0.05 was considered statistically significant. All data are presented as the mean ± 
SEM, unless otherwise stated. 
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4.3 RESULTS 
 
4.3.1 Characterisation of CD4
+
 T cell responses during Plasmodium infections 
C57BL/6J mice infected with PcAS develop mild, uncomplicated malaria where peak 
parasitemia occurs 7-8 days p.i., and then resolves by day 12-13 p.i.. After this time, mice establish 
immunity to re-infection
346
. Common symptoms observed throughout the course of infection include 
ruffled fur and hunching, whereas anaemia and haemoglobinuria are observed at peak parasitemia or 
as parasitemia begins to resolve
347
. During blood-stage Plasmodium infections, CD4
+
 T cells 
provide help for B cell responses, as well as producing IFNγ which is critical for parasite control45, 
54, 76, 348
. CD4
+
 T cell help is not restricted to the blood-stage of infection, but is also required during 
the liver stage, where CD4
+
 T cells help activate parasite-specific CD8
+
 T cells, thus aiding control 
of infected hepatocytes
349, 350
. To better understand CD4
+
 T cell responses during the course of 
Plasmodium infections, we employed the use of the integrins CD11a and CD49d, as reported by 
Butler et al., to monitor activated CD4
+
 T cell responses
328
, with a particular focus on Th1 and Tr1 
cells, throughout the acute phase of PcAS infection (Fig 2a-f). We noted that the frequency of 
CD11a
+ 
CD49d
+
 cells peaked 15 days p.i. in C57BL/6J mice and by day 34 p.i. had declined to 
almost similar frequencies in naive mice (day 0 p.i.) (Fig 2a, b). The frequency of Th1 cells (CD4
+ 
TCRβ+ CD11a+ CD49d+ IFNγ+ Tbet+) reached a maximum at 7 days p.i. (Fig 2c, d), whereas a 2-fold 
increase was observed in Tr1 cell (CD4
+
 TCRβ+ CD11a+ CD49d+ IFNγ+ IL-10+) frequencies from 
day 7-15p.i., and then stabilised (Fig 2e, f). Importantly, we noted that at day 7 p.i., when 
parasitemia had reached its maximum, Th1 cells all resided within the CD11a
+
CD49d
+
 gate, 
indicating they were highly activated, recently antigen experienced cells (Fig 2g). The frequency of 
splenic CD4
+
 Foxp3
+
  Treg cells initially declined between day 5 to day 7 p.i., but then stabilised 
(Fig 3a, b). The relatively small frequency of CD4
+
 Foxp3
+
 IL-10
+
 Tregs increased slightly between 
days 5-7 p.i., and then steadily declined from day 7 to day 34 p.i. (Fig 3a, c), suggesting a limited 
role for Tregs and Treg-derived IL-10 production during PcAS infection. 
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Figure 2 
 
Figure 2: Characterisation of Th1 and Tr1 CD4
+
 T cell responses during PcAS infection. 
 
a) C57BL/6J mice infected with 1x10
5
 PcAS pRBC’s i.v. and splenic CD4+ T cells assessed for CD11a and 
CD49d expression 5, 7, 15 and 34 days p.i. by flow cytometry. b)  CD11a
+ 
CD49d
+
 CD4
+
 T cell frequencies 
in PcAS-infected mice. c) CD11a
+ 
CD49d
+
 IFNγ+ Tbet+ expression on CD4+ T cells and d) frequencies of 
Th1 cells throughout PcAS infection. e) CD11a
+ 
CD49d
+
 IFNγ+ IL-10+ expression on CD4+ T cells and f) 
frequencies of Tr1 cells throughout PcAS infection. g) Overlay of Th1 cells on CD11a
+ 
CD49d
+
 gate 7 days 
p.i.. Representative of 2 independent experiments, mean  SEM, n=5 mice per group. 
 
 
 
 
 
 
 
 
Chapter 4 
 
 41758573  122 
 
Figure 3: CD4
+
 Foxp3
+
 Treg cell kinetics during PcAS infection. 
 
a) C57BL/6J mice infected with 1x10
5
 PcAS pRBC’s i.v. and splenic CD4+ T cells assessed for IL-10 and 
Foxp3 expression 5, 7, 15 and 34 days p.i. by flow cytometry. b) Total CD4
+
Foxp3
+
 Treg cell frequencies in 
PcAS-infected mice. c) CD4
+ 
Foxp3
+
 IL-10
+ 
Treg cell frequencies in PcAS-infected mice. Representative of 2 
independent experiments, mean  SEM, n=5 mice per group. 
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4.3.2 Blimp1 is required for IL-10 production by CD4
+
 T cells during infection 
 
We next examined IL-10 induction during infection. Recent studies indentified the 
transcriptional regulator Blimp1 as an inducer of IL-10 production by T cells. To study the kinetics 
of Blimp1 expression, we used Blimp1-GFP reporter mice, as described by Kallies et al., where they 
genetically targeted the Blimp1 locus to insert an IRES-GFP cassette 3’ to exon 6 to produce the 
prdm1
gfp 
 allele (Fig 4a)
242
. The targeted allele encodes a truncated Blimp1 protein lacking exons 7-
8 and GFP from the same mRNA transcript. Thus, the truncated protein provides an effective way of 
measuring prdm1 transcription, using GFP as a readout (Fig 4a, b)
242
. It is important to note that this 
truncated protein is transcriptionally inactive and unable to bind to any promoters or regulatory 
elements. Early studies in B cell differentiation showed a requirement for Blimp1 in plasma cell 
development, where increased Blimp1 expression was observed as plasmablasts matured into long-
lived antibody-secreting cells (ASCs)
242
. Plasma cells (CD19
+ 
B220
+ 
CD138
+
) constitutively express 
high levels of Blimp1 and therefore to validate Blimp1 GFP expression in our studies, we first 
measured Blimp1 GFP levels in these cells (Fig 4b, c). Plasma cells exhibited 3-5 fold higher levels 
of Blimp1 expression compared to T cells during PcAS infection (Fig 4c). Consistent with 
published reports
215, 216, 251
, we were able to demonstrate that IL-10 producing CD4
+ 
T cells 
exhibited the highest level of Blimp1 expression (Fig 4c). Importantly, we showed that these IL-10
+ 
CD4
+
 T cells express high Blimp1 levels throughout the course of PcAS infection (Fig 4c). IFNγ 
and to a far lesser extent, TNF producing CD4
+ 
T cells also expressed medium to low levels of 
Blimp1 (Fig 4c). This hierarchical expression of Blimp1 in CD4
+
T cells highlighted the positive 
association between Blimp1 and IL-10. Consequently, IL-10
+
 and IL-10
+ IFNγ+ CD4+  T cells 
exhibited the highest Blimp1 expression, relative to 
 
CD4
+
 T cells producing IFNγ or TNF (Fig 4c, 
d). 
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Figure 4: Kinetics of Blimp1 expression in plasma cells and cytokine producing CD4
+
 T cells during 
PcAS infection. 
 
a) Generation of prdm1
gfp
 reporter mice as reported by Kallies et al., 2004, JEM, 200 8: 967-977  permission 
number 3765180709708 b) Verification of Blimp1 GFP expression in plasma cells identified as B220
+ 
CD19
+ 
CD138
+ 
Blimp1(GFP)
+
 by flow cytometry. c) prdm1
gfp
 and WT mice infected with 1x10
5
 PcAS pRBC’s i.v. 
Comparison of Blimp1 expression profiles in plasma cells (purple), IL-10
+
 (blue), IFNγ+ (green) and TNF+ 
(red) CD4
+
 T cells 5, 7, 15 and 34 days p.i.. Grey-filled histogram (WT) and black-filled histogram 
(prdm1
gfp
) shows Blimp1 expression by cytokine producing CD4
+
 T cells 15 days p.i.. d) Blimp1 Mean 
Fluorescence Intensity (MFI) in IL-10
+, IFNγ+ and IL-10+ IFNγ+ CD4+ T cells in the spleen 15 days p.i.. 
Representative of 3 independent experiments, mean  SEM, n=3-5 mice per group. 
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4.3.3 Blimp1 regulates parasite growth and effector CD4
+
 T cell responses during Plasmodium 
infections 
 
The positive association between Blimp1 and IL-10 and the negative association between 
Blimp1 and TNF, suggested a potential role for Blimp1 in regulating inflammation, since TNF 
promotes inflammation while IL-10 limits this process. Therefore, since Blimp1 positively 
associated with IL-10, we hypothesised that Blimp1 dependent IL-10 played a key role in 
inflammation during infection. T cell specific, Blimp1-deficient (Prdm1
∆T
) mice spontaneously 
develop inflammatory disease characterised by the infiltration of activated T cells into tissues as a 
result of significant alterations in T cell homeostasis
339, 340
. This highlights the contribution of 
Blimp1 to the regulation of tissue pathology, primarily driven by inflammation. Given that both 
Plasmodium and Leishmania elicit potent inflammatory responses we next assessed the contribution 
of Blimp1 mediated regulation of CD4
+
 T cells on disease outcome. Prdm1
∆T
 mice, infected with 
PcAS exhibited significantly reduced parasitemia levels throughout the course of infection, 
compared with Prdm1
fl/fl
 litter mate control mice (Fig 5a), implicating a role for Blimp1 in parasite 
control. To assess splenic CD4
+
 T cells with an activated phenotype, we used CD11a and CD49d 
expression to detect CD4
+
 T cells that had recently encountered antigen
328
. The gating strategy for 
Th1 and Tr1 cells for this Chapter and Chapter 5 is shown in Fig 6. Blimp1 has been shown to play 
a fundamental role in T cell differentiation and homeostasis and consistent with these reports
339, 340
, 
we observed a dramatic increase in the frequency of activated CD4
+
 T cells (Fig 5b, c) and Th1 cells 
(Fig 5 b, d), but a severe impairment in the generation of Tr1 cells in the Prdm1
ΔT mice 15 days 
after PcAS infection (Fig 5 b, e). Despite the increased inflammatory responses observed in the 
Prdm1
ΔT mice, they showed very little if any signs of symptoms such as anaemia and 
haemoglobinuria, compared to the Prdm1
fl/fl
 litter mate control mice which did display these 
symptoms. Since the deletion of Blimp1 using Cre under the control of the Lck promoter with the 
Cre-loxP system will also impact on CD8
+
 T cells due to the CD4
+
CD8
+
 double positive stage in 
thymic development, we also measured IFNγ and IL-10 production by CD8+ T cells during PcAS 
infection. CD8
+ 
T cells displayed significantly increased Tbet and IFNγ expression (Fig 7a) and an 
impaired ability to produce IFNγ and IL-10 simultaneously (Fig 7b). While these results trended in 
a similar manner to CD4
+
 T cells, it should be noted that the frequencies of Tbet
+ IFNγ+ and IL-10+ 
IFNγ+ CD8+ T cells were 2-3 fold less, compared to CD4+ T cells. These results confirmed the 
requirements for Blimp1 in IL-10 production by T cells
215, 216
. However, we found no such 
dependence on Blimp1-dependent IL-10 production by Treg cells during PcAS infection (Fig 7c). 
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Figure 5: Blimp1 influences parasite control and is required for CD4
+
 T cell-derived IL-10 production 
during PcAS infection. 
 
a) Prdm1
ΔT 
(T cell specific Blimp1 deficient) and Prdm1
fl/fl 
(littermate controls) mice were infected with 
1x10
5
 PcAS pRBC’s i.v. and peripheral parasitemia was monitored by flow cytometry beginning at 4 days 
p.i.. b) Splenic CD4
+
 T cell responses assessed at day 15 p.i.. c) Frequencies and numbers of activated 
(CD11a
+ 
CD49d
+
) CD4
+
 T cells were measured by flow cytometry 15 days p.i.. d) Frequencies and numbers 
of Th1 (IFNγ+ Tbet+) CD4+ T cells were measured by flow cytometry 15 days p.i.. e) Frequencies and 
numbers of Tr1 (IFNγ+ IL-10+) CD4+ T cells were measured by flow cytometry 15 days p.i..  Representative 
of 3 independent experiments, mean  SEM, n=5 mice per group, **=p<0.01, *= p<0.05, Mann-Whitney U 
test. 
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Figure 6: Gating strategy for identifying Th1 and Tr1 cells  
 
Order of gating: left to right, beginning with single cells, lymphocytes, live/viable cells, CD4
+
 T cells, 
CD11a
+ 
CD49d
+
 CD4
+
 T cells, isotypes for identifying Th1 (IFNγ+ Tbet+) and Tr1 (IFNγ+ IL-10+) CD4+ T 
cells in the spleens of Prdm1
ΔT 
and Prdm1
fl/fl 
mice. Representative of 5 independent experiments, n=5 mice 
per group. 
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Figure 7: Blimp1 has a minor impact on CD8
+
 T cells and Foxp3
+ 
IL-10
+
 CD4
+ 
Treg cells during PcAS 
infection. 
 
a) Prdm1
ΔT 
and Prdm1
fl/fl 
mice were infected with 1x10
5
 PcAS pRBC’s i.v. Frequencies and numbers of 
CD8
+
 T cells expressing IFNγ and Tbet in the spleen at day 15 p.i.. b) Frequencies and numbers of CD8+ T 
cells expressing IFNγ and IL-10 at day 15 p.i.. c) Frequencies and numbers of CD4+ T cells expressing Foxp3 
and IL-10 at day 15 p.i.. Representative of 3 independent experiments, mean  SEM, n=5 mice per group, 
**=p<0.01, Mann-Whitney U test.  
 
Since PcAS infections do not result in extensive tissue pathology, to assess the potential 
contribution of the Th1 response to pathology, we employed the use of a severe malaria model 
caused by infection with PbA. Prdm1
∆T
 mice infected with PbA exhibited significantly reduced 
whole body parasite burdens at day 6 p.i. (onset of neurological symptoms in Prdm1
fl/fl
 litter mate 
controls), and reduced blood parasitemia at day 4 p.i. (Fig 8a). Prdm1
∆T
 mice had a small survival 
advantage compared to Prdm1
fl/fl
 litter mate controls (Fig 8b), but when monitored for clinical 
scores, Prdm1
∆T 
mice all eventually succumbed to the neurological complications associated with  
PbA infection (Fig 8c).  
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Interestingly, despite no beneficial impact on disease outcome, a significant increase in Th1 
frequencies and numbers was observed in the absence of Blimp1 in T cells, and a severe impairment 
in the Tr1 response was observed (Fig 8 d, e).  
 
Figure 8: Blimp1 regulates CD4
+
 T cell responses but does not result in protection against severe 
symptoms during PbA infection. 
 
a) Prdm1
ΔT 
and Prdm1
fl/fl 
mice were infected with 1x10
5
 PbA-luc pRBC’s i.v. At day 6 p.i. when Prdm1fl/fl 
littermate mice
 
controls began to exhibit symptoms such as ruffled fur and hunching, all mice were injected 
with 5mg/kg of D-luciferin to determine parasite biomass using an in vivo bioluminescence imaging system 
(Xenogen IVIS). Peripheral parasitemia was measured by flow cytometry b) Survival curves for Prdm1
ΔT 
and Prdm1
fl/fl 
PbA-infected mice c) All mice were assigned a clinical score beginning at 5 days p.i. and a 
score of 4-5 indicated euthanasia or death, respectively. d) Splenic CD4
+
 T cell responses were assessed 4 
days p.i. prior to the onset of symptoms. Frequencies and numbers of Th1 cells were measured by flow 
cytometry 4 days p.i.. e) Frequencies and numbers of Tr1 cells measured by flow cytometry at day 4 p.i..  
Representative of 3 independent experiments, mean  SEM, n=5-9 mice per group, ***=p<0.001, 
**=p<0.01, *= p<0.05, Mann-Whitney U test. 
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4.3.4 Blimp1 expression is negatively associated with TNF producing CD4
+ 
T cells  
 
Low Blimp1 expression in TNF producing CD4
+
 T cells suggested an opposite and negative 
association between Blimp1 and TNF expression, relative to the relationship between Blimp1 and 
IL-10 (Fig 4c). B6.TNF
-/-
 mice infected with L. donovani  exhibited  3-fold higher parasite burdens 
with 100% mortality 11 weeks p.i.
351
. To date, TNF-deficient mice are one of the only genetically 
modified mouse strains to succumb to VL, suggesting that TNF plays a critical role in the survival 
of the host against the parasite. TNF has been shown to be required for controlling parasite growth 
during Leishmania infections, but is also a major contributor to splenic pathology
129
. To examine 
this intriguing association between Blimp1 and TNF more extensively, we infected prdm1
gfp
 mice 
with L. donovani and measured Blimp1 expression by CD4
+
 T cells in the spleen and liver 14 days 
p.i. (Fig 9a, b). A similar Blimp1 expression profile to that found during PcAS infection was 
observed during L. donovani infection, whereby in both liver and spleen, IL-10 producing CD4
+
 T 
cells displayed the highest levels of Blimp1 expression (Fig 9a, b). However, given that the liver is 
a site of acute infection and the spleen being a site of chronic infection
352
, it was interesting to note 
that very similar Blimp1 expression profiles were observed in both tissues, which might suggest a 
requirement for Blimp1 expression in both acute and chronic experimental VL.  
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Figure 9: Positive associations between Blimp1, LAG3, CD49b and Tr1 CD4
+ 
T cells during L. 
donovani infection. 
 
a) prdm1
gfp 
and WT mice infected with 2x10
7
 L. donovani amastigotes i.v. Blimp1 GFP expression by IL-10
+
, 
IFNγ+ or TNF+ CD4+ T cells measured at day 7 and 14 p.i. in the spleen and b) liver by flow cytometry. c) 
Tr1 (IFNγ+ IL-10+) CD4+ T cells were measured at day 14 p.i. in the spleen and d) liver. e) Blimp1 MFI on 
IFNγ- IL-10+, IFNγ+ IL-10+ (Tr1) and IFNγ+ IL-10- CD4+ T cells was measured in both spleen and f) liver, 14 
days p.i.. g) LAG3 and CD49b MFI on IFNγ- IL-10+, IFNγ+ IL-10+ (Tr1) and IFNγ+ IL-10- CD4+ T cells were 
also measured by flow cytometry in both the spleen and h) liver at day 14 p.i.. Representative of 3 
independent experiments, mean  SEM, n=5 mice per group. 
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4.3.5 Tr1 preferentially cells express CD49b and LAG3 in the spleen during L. donovani 
infection 
 
Recent reports have shown IL-10
+ IFNγ+ Tr1 cells to express high amounts of Blimp1251 and 
this was notably observed in the spleen, 14 days p.i. with L. donovani (Fig 9c, e). In the liver, 
however, comparable levels of Blimp1 expression was found between IL-10
+
 single producing 
CD4
+
 T cells and Tr1 cells (Fig 9d, f), suggesting that Blimp1 is not preferentially expressed solely 
by Tr1 cells and may potentially be expressed by other IL-10 producing T cell populations, such as 
Tregs. Tr1 cells have been predominantly characterised on the basis of their co-expression of IL-10 
and IFNγ47, 199, 201. Recent reports, however, have identified surface markers that may aid the 
phenotypic characterisation of these cells. For example, CD49b and LAG3 co-expression has been 
reported in mouse and human Tr1 cells
200
. In an effort to identify specific surface markers to detect 
Tr1 cells, CD49b
+
 and LAG3
+
 T cells were tested for IL-10 expression, as previously reported
200
. In 
the spleen 14 days p.i., Tr1 cells exhibited the highest levels of LAG3 and CD49b, compared to IL-
10 and IFNγ single producing CD4+ T cells (Fig 9g), which is consistent with published literature200. 
However, in the liver, LAG3 and CD49b expression was comparable between IL-10 single 
producing CD4
+
 T cells and Tr1 cells (Fig 9h), highlighting potential different tissue requirements 
for Blimp1, LAG3 and CD49b during L. donovani infection. These results support the notion that 
Blimp1 expression during Plasmodium and Leishmania infections is required for the generation of 
Tr1 cells to potentially suppress parasite-induced inflammatory responses. 
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4.3.6 VL patients have increased PRDM1 expression in PBMC’s and CD4+ T cells  
 
After establishing a hierarchical expression pattern for Blimp1 in two models of parasitic 
infections, we next determined if there was any clinical relevance for Blimp1 expression in humans 
with active VL disease.  Importantly, we found that PRDM1 mRNA expression was higher in total 
PBMC’s (Fig 10a), as well as CD4+ T cells (Fig 10b) in active VL patients, compared to levels 
found 28 days after drug treatment. It is interesting to note that human VL patients that report to this 
clinic are all at different stages of disease and despite this, PRDM1 mRNA levels were elevated in 
most patients (Table 1). While it would have been interesting to investigate the expression levels of 
other transcription factors, due to limitations associated with human samples, no other transcription 
factors were analysed in these studies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: PRDM1 mRNA is up-regulated in PBMC’s and CD4+ T cells isolated from VL patients. 
 
a) Human PRDM1 mRNA measured by qPCR from PBMC’s and b) MACS purified CD4+ T cells isolated of 
patients before and 28 days after drug treatment. n= 10 patients per group as shown by the individual black 
lines, *= p<0.05, Wilcoxon matched-pairs signed rank test. 
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4.3.7 IL-12 induces Blimp1 expression during L. donovani infection 
 
The IL-12 cytokine family plays central roles in the regulation of CD4
+ 
T cell responses, 
whereby Th1 differentiation is largely driven by Tbet expression, resulting in IFNγ production156, 
157
. The CD4
+
 T cell differentiation pathway is dependent on IL-12 produced by DC’s156, 353. L. 
donovani infection induces a potent Th1 response which aids the activation of microbicidal killing 
mechanisms in macrophages
108, 354, 355
. In support of the notion that Tr1 cells emerge from a 
terminally differentiated Th1 cell subset, we investigated the relationship between IL-12, Blimp1 
and Tr1 induction during L. donovani infection. We administered prdm1
gfp 
mice with control rat IgG 
or anti-IL-12 on the day of infection and every 3 days after, until 14 days p.i. (Fig 11a). IL-12 
neutralisation significantly reduced hepatosplenomegaly (Fig 11b, c), and this was associated with a 
significant reduction in IFNγ producing CD4+ T cells and increases in parasite burdens (Fig 11d-g). 
Prdm1
gfp 
mice treated with anti-IL-12 also had significantly reduced Tr1 frequencies, and Blimp1 
expression on these Tr1 cells was also impaired (Fig 11h, i).  Together, these results demonstrate a 
requirement for IL-12 in the induction of Blimp1 expression by Tr1 cells, as well as IL-10 
production by these cells.   
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Figure 11: IL-12 is required for Blimp1 expression and Tr1 induction during L. donovani infection. 
 
a) prdm1
gfp 
and WT mice treated with 1 dose of 500μg rat IgG or anti-IL-12 (C17.8) prior to infection with 
2x10
7
 L. donovani amastigotes i.v. and every 3 days following infection (* denotes 1 dose). b) Spleen and c) 
liver weights measured at day 14 p.i.. d) Mean parasite burdens expressed as LDU were measured in the 
spleen and e) liver at day 14 p.i.. f) Frequencies of IFNγ+ CD4+ T cells were measured by flow cytometry in 
both spleen and g) liver 14 days p.i.. h) Frequencies of Tr1 cells as well as Blimp1 MFI (GFP) on Tr1 cells 
were measured in the spleen and i) liver by flow cytometry 14 days p.i.. Representative of 1 independent 
experiment, mean  SEM, n=5 mice per group, **=p<0.01, *= p<0.05, Mann-Whitney U test.  
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4.4 DISCUSSION  
 
Our data presented here demonstrates that the transcriptional regulator Blimp1 modulates 
CD4
+
 T cell responses during Plasmodium and Leishmania infections. Specifically, PRDM1 mRNA 
was up-regulated in CD4
+
 T cells from VL patients. Employing experimental models of malaria we 
were able to show that Blimp1 limited the generation of Th1 cells, but promoted Tr1 cell 
development. Furthermore, the observation that Blimp1 expression was strongly associated with IL-
10 production, suggests that Blimp1 promotes immunoregulatory functions, as opposed to 
inflammatory responses. Notably, IFNγ and TNF producing CD4+ T cells exhibited lower Blimp1 
expression compared to IL-10 single producing CD4
+
 T cells and Tr1 cells, suggesting that Blimp1 
expression promotes immunoregulatory activity during infection-induced inflammation as a means 
of limiting host-tissue damage. 
 
PbA infected control mice develop severe malaria symptoms as a result of CD4
+
  and CD8
+
 
T cells promoting parasite sequestration in vital organs, including the lungs, liver, brain and 
spleen
37
. Interestingly, T cell specific Blimp1-deficient mice succumbed to PbA infection, at a time 
when neurological complications began during infection, potentially suggesting that the intrinsic 
inflammatory response in these mice is either only protective for a short term, before parasite 
biomass exceeds the immune system’s capacity to exert control or this inflammatory response aids 
parasite sequestration via an alternate mechanism. Collectively, these results show a cell intrinsic 
requirement for Blimp1 in modulating T cell responses during Plasmodium infections. While it was 
tempting to speculate that the increased Th1 frequencies and numbers were the cause of reduced 
parasitemia levels, and therefore played a protective role, we cannot exclude the possibility that this 
potent Th1 response may also promote pathology. Given that PbA infected mice rapidly develop 
severe neurological symptoms, it may be difficult to detect differences in malarial pathogenesis, in 
this model. As such, in a model of uncomplicated malaria (PcAS), the significant reduction in 
parasitemia in the absence of T cell Blimp1 expression was associated with a strong Th1 response 
which could potentially contribute to protection. However, this same response in the more severe 
malaria model (PbA) had minimal impact on the final outcome of disease. This may reflect different 
requirements of CD4
+
 T cells in both models. CD4
+
 T cells have been shown to play protective roles 
in PcAS infections
45
, whereas in the PbA model, have been shown to contribute to pathology
37
. The 
vastly different requirements for CD4
+
 T cells in lethal and non-lethal experimental malaria 
emphasises the delicate balance between protective responses that result in control of parasite 
growth versus inflammatory responses that contribute to disease. 
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Upon parasite invasion, inflammation forms the first line of defence against the spread of 
infection. However, inflammation can also damage host-tissues
37, 129
. Infection-induced 
inflammation is a major driver of parasitic disease, and we employed an experimental VL model 
caused by L. donovani infection, where pathology and parasite control, particularly in the spleen, is 
largely driven by TNF
129
. Understanding the factors that modulate these inflammatory processes 
during infection is critical to limit the subsequent immunopathology associated with excessive 
inflammation. Importantly, we found that Tr1 cells expressed the highest levels of Blimp1, 
compared to IL-10
+ 
IFNγ- and IFNγ+ IL-10- CD4+ T cells in the spleen. The hierarchical distribution 
in Blimp1 expression in CD4
+
 T cells during Plasmodium and Leishmania infections suggested that 
Blimp1 expression is more strongly associated with immunoregulatory responses. Cimmino et al., 
reported that Blimp1 repressed Th1 differentiation
247
, which was associated with pro-inflammatory 
functions, including IFNγ and TNF production. The strong association between Blimp1 expression 
and IL-10 production in our studies and others
215, 216, 251
, supports the notion that this transcriptional 
regulator is important in promoting the emergence of immunoregulatory pathways during infection-
induced inflammation to counteract pro-inflammatory environments, and thus aid in the prevention 
of host tissue damage. 
 
For many years, IL-10 signalling has been known to play important roles in limiting 
immunopathology in the host
74, 214, 225, 226, 356
. In the absence of this regulatory mechanism, tissue 
damage occurs
74, 357
. IL-10 can be produced by multiple cell types, including conventional CD4
+
 T 
cells and Foxp3
+
 Tregs
181, 214, 356, 358
. Depletion studies of Treg cells during PbA infections have 
identified a protective requirement for IL-10 against severe malaria
46
. However, adoptive transfer 
studies of CD4
+
T cells from Foxp3Tg mice (Foxp3 is over-expressed in these mice) or CD4
+ 
CD25
+
 
T cells from wild-type (WT) mice into naive control recipients compromised parasite control during 
uncomplicated experimental malaria caused by PcAS
359
. While Foxp3
+
 CD4
+
 Tregs have been 
shown to be a cellular source of IL-10 during Plasmodium infections
360
, recent studies have 
identified Tr1 cells as a more critical source of IL-10 required to protect against severe 
immunopathology during PcAS infection
74
. B cells and macrophages/monocytes are also a 
predominant source of IL-10, but only T cell specific, IL-10 deficient mice exhibited significantly 
reduced survival and exacerbated pathology, relative to controls
74
.  Similarly, during Leishmania 
infections, Tr1 cells, and not CD4
+ 
Foxp3
+ 
Treg cells, were also the predominant source of IL-10
214, 
234, 345
.  
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Additionally, other studies have shown that Tr1 cells, and not Foxp3
+
 Treg cells, were the main 
suppressors of inflammation
361
, further supporting a role for Blimp1-induced IL-10 in limiting 
immunopathology via Tr1 cells. While Blimp1 expression was not measured in Treg cells, data from 
our group suggests that depletion of Treg cells during infection results in a complementary increase 
Tr1 cell numbers. Studies have shown that IRF4 is induced in Treg cells, which acts downstream of 
Foxp3 to target Blimp1 to then induce IL-10 production
181
. While the role of Treg cells has been 
extensively studied in many disease settings, Tr1 cells and their role in immunoregulation, and how 
this differs from Treg cell-mediated regulation, is less well understood. Our data here and studies by 
others in different inflammatory and disease settings, demonstrate that Tr1 cells exhibit high levels 
of Blimp1 expression during Plasmodium and Leishmania infections. In malaria endemic regions, 
recent field studies have suggested that while Tr1 cells display immunoregulatory characteristics, 
they were not independently associated with protection against future malaria infections and may in 
fact be associated with increased risk
47
, implying a suppressive role for Tr1 cells during 
Plasmodium infections. Data presented in this Chapter supports this idea because mice lacking 
Blimp1 expression by T cells generated few Tr1 cells, and this was associated with improved 
control of non-lethal PcAS, lethal PbA and L. donovani growth. Thus, Tr1 cells are induced in 
response to human and mouse Plasmodium and Leishmania infections and their ability to produce 
IL-10 is an important mechanism for limiting inflammation, but may also suppress anti-parasitic 
CD4
+
 T cell responses. 
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The extrinsic and intrinsic requirements for the generation of Tr1 cells have been widely 
reported
196, 200, 209, 251
. Consistent with these findings, our data shows that IL-12 and Blimp1 were 
required for the generation of Tr1 cells. In addition, IL-27 is required for driving IL-10 production 
by Tr1 cells, and also belongs to the IL-12/IL-23 family of cytokines
208
. Iwasaki et al., showed that 
IL-12 and IL-23 only modestly induced Blimp1 expression, compared to IL-27, suggesting that a 
more severe impairment in Tr1 generation would be expected with IL-27 blockade
217
. Given that IL-
12 and IL-27 contribute to Th1 differentiation, a recent study using a model of M. tuberculosis 
showed that IL-27Rα-/- mice do not display major defects in IFNγ-mediated responses, suggesting 
that where IL-12 is not limiting, IL-27 is most likely redundant for this function
362
. These studies 
imply that IL-12 and Blimp1 are sufficient to induce Th1 cells that have the potential to become 
self-regulatory and give rise to Tr1 cells. Collectively, the data reported in this Chapter and by other 
groups suggest that Tr1 cells emerge from Blimp1-dependent, terminally differentiated effector Th1 
cells, rather than an independent CD4
+
 T cell lineage
216, 251
.  
 
The plasticity of CD4
+
 T cell responses during Plasmodium and Leishmania infections is 
essential for survival of the host, and numerous feedback mechanisms in response to infection-
induced inflammation promote the emergence of Tr1 cells preferentially over Th1 cells when 
parasites persist. Current studies aim to gain a better understanding about what factors controls the 
emergence of Tr1 from Th1 cells at the transcriptional level and under what conditions. Our studies 
here have shown that Blimp1 plays a key role in modulating the emergence of both Th1 and Tr1 
responses, and the next Chapter provides a mechanistic insight into the subsequent effects on splenic 
pathology as a result of Tr1 induction.  
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Blimp1-dependent IL-10 production by CD4
+
 T 
cells protects against TNF-mediated pathology 
during Leishmania infections 
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“It is the pervading law of all things organic and inorganic, of all things physical and metaphysical, 
of all things human and all things superhuman, of all true manifestations of the head, of the heart, of 
the soul, that the life is recognizable in its expression, that form ever follows function...  
This is the law”  
 
 – Louis Sullivan 1896 –   
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5.1 INTRODUCTION 
 
A key function of Tr1 cells, involves protecting host tissue against inflammation-induced 
pathology
200, 203, 363
. Harnessing the therapeutic potential of Tr1 cells has quickly gained interest and 
thus a better understanding of Tr1 induction during disease will aid the development of novel 
therapeutic strategies against chronic inflammatory diseases. Infection-induced inflammation has 
been reported to contribute to host tissue remodelling
129, 364
. It is thought that Tr1 cells may help 
preserve tissue integrity by limiting inflammatory-mediated pathology, but Tr1 cells may also 
suppress anti-parasitic CD4
+
 T cell responses, thus allowing pathogen persistence. These different 
roles for Tr1 cells emphasises the need to better understand their functions, and in particular, the 
transcriptional regulators that determine their development and function. 
 
Leishmania infections cause potent CD4
+
 T cell responses, including the secretion of pro-
inflammatory cytokines aimed at killing intracellular parasites and limiting parasite spread. TNF is a 
potent pro-inflammatory cytokine that alters epithelial cell barrier permeability, and also initiates 
tissue remodelling, macrophage activation and cellular recruitment during inflammation, particularly 
in response to pathogen invasion
365
. While TNF serves to limit the spread of infection and rid the 
host from the invading pathogen, excess production can be detrimental to host tissue. Infliximab, 
and adalimumab (anti-TNF monoclonal antibodies) and Enbrel (soluble TNF receptor Fc fusion 
protein) were amongst the first TNF inhibitors licensed to treat chronic inflammatory disorders such 
as rheumatoid arthritis, psoriasis, ankylosing spondylitis, inflammatory bowel disease and ulcerative 
colitis
366, 367, 368, 369, 370, 371, 372, 373
. While TNF blockade can reduce inflammation, it can also increase 
susceptibility to established and opportunistic pathogens. Thus, in order to develop TNF blocking 
therapies with increased specificity, a greater understanding of how TNF is regulated during 
inflammation is required. 
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The architecture of the spleen reflects its function and role in orchestrating immune 
responses against invading pathogens. The spleen is a site for the removal of old RBC’s from the 
bloodstream, as well as the removal of pathogens and cellular or foreign debris
119, 126
. Importantly, 
the highly organised lymphoid compartment allows for the effective interaction between T cells and 
B cells. In addition, the spleen comprises specialised macrophage populations which help maintain 
splenic architecture by allowing efficient trafficking of lymphocytes into and out of the organ
119, 129
. 
The two main areas in the spleen are the red pulp, which is involved in filtering the blood, recycling 
iron and removing pathogens and other foreign materials, and the white pulp, where T and B cell 
responses are initiated and maintained. The organisation of the white pulp is controlled by the 
chemokines CCL19, CCL21 and CXCL13, which guide T cells and B cells to their respective 
zones
120, 121, 122. Within the T cell zone, T cells interact with DC’s , while in B cell zones, activated 
B cells undergo clonal expansion and maturation through isotype switching and somatic 
hypermutation
119
. The MZ, also known as a transit area for cells entering the white pulp from the 
bloodstream, is home to various cells that work together to maintain the integrity of the spleen
119
. In 
particular, specialised subsets of macrophages can be found in the MZ, including MZM’s which 
form the outer ring around the white pulp and the MMM’s which comprise the inner ring of the 
white pulp
119, 127
. In between these macrophage populations reside the MZ B cells and DC’s374, 375. 
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During L. donovani infection, TNF is required for parasite control, but can also contribute to 
the disruption of the splenic architecture, resulting in the characteristic splenomegaly observed in 
VL patients. TNF causes the selective destruction of MZM’s and gp38+ stromal cells lining the 
splenic white pulp areas, and consequently, this contributes to splenomegaly observed 28 days p.i. in 
C57BL/6J mice infected with L. donovani
128, 129
. The functional consequence of this breakdown in 
splenic architecture involves impaired lymphocyte trafficking
129
. These changes in splenic 
organisation are associated with impaired immune function, and as such, are thought to contribute to 
parasite persistence. In contrast to parasite control in the liver, which is a site of acute, resolving 
infection, parasites persist in the spleen contributing to chronic infection. Disruptions in tissue 
organisation are also evident in other chronic inflammatory diseases, including cancer, autoimmune 
diseases, a range of other infectious diseases and other disorders where vascular remodelling occurs 
during the chronicity of inflammation
132, 364
. In fact, vascular remodelling  is thought to contribute to 
splenomegaly associated with leishmaniasis
376
. Therefore, a better understanding about how TNF is 
regulated during inflammatory settings may allow for more selective approaches to modulate TNF 
activity, where host tissue is preserved without compromising protection against intracellular 
pathogens. 
 
This Chapter investigates the requirements for the development of Blimp1-dependent Tr1 
cells during Leishmania infections, which appears to impair the control of parasite growth, but limit 
TNF-mediated pathology, thus helping to preserve splenic architecture during L. donovani infection. 
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5.2 MATERIALS AND METHODS 
 
The material and methods presented here are specific to this chapter 
5.2.1 Mice 
 
Female C57BL/6J mice 8-12 weeks old were purchased from either the Australian Resource 
Centre (Canning Vale, Perth, WA, Australia) or the WEHI (Parkville, Melbourne, VIC, Australia) 
and were maintained in the animal house facility at the QIMR Berghofer Medical Research Institute 
under conventional conditions. C57BL/6J.IFNγR-/- mice were maintained in the animal house 
facility at the QIMR Berghofer Medical Research Institute under conventional conditions. T cell 
specific Blimp1 deficient mice: C57BL/6J.Lck-Cre
+
 x Prdm1
fl/fl
 = Prdm1
ΔT
(Cre positive), Lck-Cre
-
 
x Prdm1
fl/fl
 = Prdm1
fl/fl 
(Cre negative), T cell specific IL-10R deficient mice: C57BL/6J.Lck-Cre
+
 x 
Il10R
fl/fl
 = Il10R
ΔT
 (Cre positive) , Lck-Cre
-
 x il10R
fl/fl
 = Il10R
fl/fl 
(Cre negative)
 
, myeloid-derived 
specific IL-10R deficient mice: C57BL/6J.LysM-Cre
+
 x Il10R
fl/fl
 = Il10R
ΔM
 (Cre positive) , LysM-
Cre
-
 x Il10R
fl/fl
 = Il10R
fl/fl 
(Cre negative)
 
, T cell specific IL-10 deficient mice: C57BL/6J.Lck-Cre
+
 x 
Il10R
fl/fl
 = Il10
ΔT
 (Cre positive) , Lck-Cre
-
 x Il10
fl/fl
 = Il10
fl/fl 
(Cre negative) mice were bred in-house 
under specific-pathogen free conditions. Treg cell specific Blimp1 deficient mice: C57BL/6J.Foxp3-
Cre
+
 x Prdm1
fl/fl
 = Prdm1
ΔF
 (Cre positive), Foxp3-Cre
-
 x Prdm1
fl/fl
 = Prdm1
fl/fl 
(Cre negative) mice 
were sourced from the WEHI and maintained at QIMR Berghofer Medical Research Institute under 
conventional conditions. All animal procedures were approved and monitored by the QIMR 
Berghofer Animal Ethics Committee. This work was conducted under QIMR Berghofer animal 
ethics approval number A02-634M, in accordance with the “Australian Code of Practice for the 
Care and Use of Animals for Scientiﬁc Purposes” (Australian National Health and Medical Research 
Council). 
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5.2.2 Parasites and infection 
 
L. donovani parasites were maintained by passage in B6.RAG1
-/-
 mice and amastigotes were 
isolated from the spleens of chronically infected mice. Mice were infected with 2x10
7
 L. donovani 
amastigotes in RPMI/PS i.v. via the lateral tail vein. Spleen and liver impression smears were used 
to determine parasite burdens and were expressed as LDU; number of amastigotes per 1000 host 
nuclei multiplied by the organ weight (in grams). 
 
5.2.3 Preparation of L. donovani amastigotes for use as antigen 
 
L. donovani infected spleens were prepared as per Chapter 2, 2.3.3. Parasites were 
resuspended in 5ml of 4% PFA (MP Biomedicals Pty Ltd) and placed on ice for 30 minutes. 
Parasites were then washed once with 50ml RPMI/PS and centrifuged at 1800xg for 15 minutes at 
room temperature. Parasites were resuspended in 1ml of RPMI/PS and passed through a blunt 26” 
gauge needle and 10ml syringe in order to minimise parasite clumping.  Parasites were then counted 
using the Helber counting chamber (Weber Scientific, Teddington, UK). Concentration was 
adjusted to 1x10
8
 parasites/ml in appropriate volumes of freezing medium (Chapter 2, 2.1) and 1ml 
aliquots were frozen and stored at -80°C, until required. 
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5.2.4 L. donovani antigen re-stimulation assay 
 
Spleens were collected aseptically into 10ml RPMI/PS and subsequently passed through a 
BD Falcon-100μm cell strainer (BD Biosciences, San Jose, CA, USA) to obtain a single cell 
suspension. Splenocyte suspensions were then centrifuged at 338xg for 7 minutes at room 
temperature. To obtain splenic mononuclear cells, supernatants were decanted; pellets were 
resuspended in 1ml of RBC lysis buffer (Sigma-Aldrich) and incubated at room temperature for 8 
minutes to ensure complete lysis of RBC’s. 9ml of RPMI/PS was added to wash lysis buffer and 
then centrifuged at 338xg for 7 minutes at 4°C, to inhibit any further lysis. Supernatants were 
decanted and pellets were resuspended in a final volume of 10ml RPMI/PS for counting. Splenic 
mononuclear cells were then counted on a haemocytometer (BLAUBRAND
® 
counting 
chamber Neubauer, Blackburn, VIC, Australia) after a 1:5 to 1:20 dilution in 0.1% Trypan Blue 
solution in PBS (0.4%, MP Biomedicals Pty Ltd).  Splenic mononuclear cells were then adjusted to 
a concentration of 2 x 10
6
 cells/ml. L. donovani fixed amastigotes (4% PFA) were thawed and 
washed in RPMI/PS and then counted and adjusted to a final concentration of 4 x 10
7
/ml. Cells and 
parasites were plated into a 96 well U-bottom plate at a 1:20 ratio, where each well contained 1 x 
10
5
 cells and 2 x 10
6
 parasites. Cells were cultured in the presence of antigen for a period of 24 and 
72 hours. Culture supernatants were harvested at 24 to 72 hours and intracellular cytokine staining 
was performed at both time points (Table 1). 
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5.2.5 Flow cytometry 
 
Splenic and hepatic mononuclear cells were stained using antibodies in Table 1. 
 
Cell populations of interest were defined as follows: 
 
 Activated CD4+ T cells: CD11a+ CD49d+ CD4+ TCRβ+ 
 Activated Th1 cells: CD11a+ CD49d+ CD4+TCRβ+ Tbet+ IFNγ+ 
 Activated Tr1 cells: CD11a+ CD49d+ CD4+ TCRβ+ IL-10+ IFNγ+ 
 Treg cells: CD4+ TCRβ+ Foxp3+  
 Inflammatory monocyte-like populations: B220- CD11b+Ly6Chi 
 Conventional dendritic cells (cDC’s): B220- CD11chi MHCIIhi 
 B cells: CD19+B220+ 
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Table 1: Mouse monoclonal antibodies used for flow cytometry or immunofluorescence* 
Specificity  Clone Fluorophore Dilution Supplier 
B220  RA3-6B2 APC  1 in 200 Biolegend 
B220  RA3-6B2 APC/Cy7 1 in 200 Biolegend 
B220*  RA3-6B2 PE 1 in 40 Biolegend 
CD3* 17A2 biotin 1 in 100 Biolegend 
CD4 GK1.5 PerCPCy.5.5 1 in 200 Biolegend 
CD4 GK1.5 FITC 1 in 200 Biolegend 
CD8α 53-6.7 Alexa Fluor 700 1 in 200 Biolegend 
CD19 6D5 Biotin 1 in 200 Biolegend 
CD19 6D5 PerCP/Cy5.5 1 in 100 Biolegend 
CD11a M17/4 FITC 1 in 100 Biolegend 
CD11b M1/70 PerCP/Cy5.5 1 in 200 Biolegend 
CD11c N418 APC 1 in 200 Biolegend 
CD49b DX5 APC 1 in 100 Biolegend 
CD49d R1-2 Biotin  1 in 100 Biolegend 
Foxp3 MF-14 APC or AF488 1 in 100 Biolegend 
IFNγ XMG1.2 APC 1 in 200 BD 
IFNγ XMG1.2 BV421 1 in 200 Biolegend 
IFNγ XMG1.2 PE 1 in 200 Biolegend 
IL-10 JES5-16E3 PE 1 in 200 Biolegend 
LAG3 C9B7W Biotin 1 in 200 Biolegend 
Live/Dead   Aqua (Amcyan) 1 in 200 Invitrogen 
Ly6C HK1.4 FITC 1 in 200 Biolegend 
MHCII (I-A/I-E) M5/114-15.3 Pacific Blue 1 in 200 Biolegend 
Streptavidin  PE 1 in 100 Biolegend 
Streptavidin*  AF594 1 in 100 Biolegend 
Streptavidin  AF700 1 in 100 Biolegend 
Streptavidin  PeCy7 1 in 200/ 
1 in 400 
Biolegend 
Tbet Ebio4B10 efluor 660 (APC) 1 in 50 Ebioscience 
Tbet Isotype control 
(mouse IgG1κ) 
P3.6.2.8.1 efluor 660 (APC) 1 in 50 Ebioscience 
TCRβ H57-597 APC 1 in 200 Biolegend 
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Specificity  Clone Fluorophore Dilution Supplier 
TCRβ H57-597 BV421 1 in 200 Biolegend 
TCRβ H57-597 PerCP/Cy5.5 1 in 200 Biolegend 
TNF MP6-XT22 PE 1 in 400 Biolegend 
TNF MP6-XT22 PeCy7 1 in 400 Biolegend 
 
5.2.6 Antibodies for in vivo TNF blockade 
 
For TNF blockade experiments, mice were administered 200µg of Human Normal 
Immunoglobulin (INTRAGAM® P; CSL, Melbourne, VIC, Australia) or anti-TNF (Enbrel
TM
; 
Amgen, Thousand Oaks, CA, USA) i.p., on the day of infection and every 2 days p.i. until day 14 
p.i.. 
 
5.2.7 Fluorescence Microscopy  
 
Mice were injected with 100µg i.v. of FITC dextran (Life Technologies, Melbourne, 
Australia) one day prior to collection of organs. Spleen tissue was collected into 4% PFA, incubated 
at room temperature for 1-2 hours and then transferred to a 30% sucrose solution (in MilliQ water) 
(Sigma-Aldrich, Sydney, Australia) overnight at 4°C. Fixed spleen tissue was then preserved in 
Tissue-Tek O.C.T. compound (Sakura, Torrance, CA, USA). Splenic architecture and distribution of 
MZM’s were analysed in 20 µm sections counter-stained with DAPI and imaged on the Aperio FL 
slide scanner (Leica Biosystems, North Ryde, NSW, Australia).  Image analysis was performed 
using Image Scope v11.2.0.780 (Leica Biosystems) to determine area of the sections and 
Metamorph® v7.8 (Integrated Morphometry analysis tool; Molecular Devices, Sunnyvale, CA, 
USA) to count the MZM’s. For lymphocyte trafficking experiments, mice were injected i.v. with 2 x 
10
7
 naïve splenocytes labelled with Cell Trace Far Red DDAO-SE (Life Technologies, Mulgrave, 
Australia), 2 hours prior to sacrifice. 20 µm  sections were used to assess cell trafficking, where 
sections were stained with CD3 biotin (5 µg/ml) + SA AF594 (5 µg/ml), B220 PE (5 µg/ml) 
(Biolegend, San Diego, CA, USA), counter-stained with DAPI (1:25000, Sigma-Aldrich, Castle 
Hill, Australia) and mounted with Pro-Long Gold anti-fade (Life Technologies).  
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5.2.8 Cell trafficking experiments 
 
Spleen tissue was processed as above in 5.2.7. Sections were cut (20µm) and subsequently 
stored at -80°C until processing. Briefly, slides were equilibrated to room temperature for 30 
minutes and an ImmEdge Hydrophobic Barrier Pen (Vector Laboratories, Burlingame, CA, USA) 
was used to encircle the sections. Slides were allowed to dry for 10-15 minutes before washing them 
in 1x PBS for 3 minutes. 100μl of 5% goat serum (in PBS) was added and slides incubated at room 
temperature for 30 minutes in the dark, to block any non-specific binding. Slides were then washed 
once in 1x PBS and 100µl of Avidin (Vector Laboratories) solution was added and slides were 
incubated for 15 minutes at room temperature. Slides were subsequently washed and 100μl of biotin 
solution was added and incubated for 15 minutes at room temperature. 5μg/ml of mouse anti-CD3 
biotin (17A2) was added per slide and incubated for 1 hour at room temperature, protected from 
light. Slides were washed 3 times in 1x PBS (3 minutes per wash) and then incubated in 5μg/ml SA-
AF594 and 5μg/ml of B220 PE for 1 hour at room temperature. After 3 washes, DAPI solution 
(1:25000) was added to each slide and incubated for 10 minutes at room temperature. Slides were 
washed (as before) and then mounted with 100μl of ProLong Gold (Invitrogen) and 22 x 50mm 
cover-slips (Menzel Gläser, Braunschweig, Germany).  
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5.2.9 Microscopy Analysis 
 
5.2.9.1 Quantifying MZM’s 
 
Splenic architecture and distribution of MZM’s were analysed in 20µm sections counter-
stained with DAPI and imaged on the Aperio FL slide scanner under 20x magnification (Leica 
Biosystems).  Image analysis was performed using Image Scope (Leica Biosystems) to determine 
section area in mm
2
 and the ‘Integrated Morphometry analysis tool’ using MetaMorph® v7.8 
software (Molecular Devices, Sunnyvale, CA, USA) to count the MZM’s. Briefly, the AF488 
(FITC) image panel showing only the MZM’s was extracted from Aperio FL software (Spectrum, 
Leica Biosystems).  Using the Integrated Morphometry analysis tool in MetaMorph®, the ‘Measure’ 
function was used to count all MZM’s in each section. For consistency, cell area limits were set 
from 5-500 (based on fluorescence threshold). Section areas were determined by drawing around the 
perimeter of the spleen transverse section and then using the ‘Positive pixel count v9 algorithm’ in 
Image Scope, to measure the area in mm
2
. Finally to normalise MZM counts to splenic area, MZM 
counts were divided by the area to give ‘Number of MZM’s per mm2, (as shown in graphs in 5.3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 
 
 41758573  153 
5.2.9.2 Quantifying MZM’s in white pulp areas – cell trafficking  
 
For cell trafficking experiments, slides were imaged on a Carl Zeiss 780 NLO laser scanning 
confocal microscope (Zeiss, North Ryde, NSW, Australia) under 10x magnification. Image analysis 
was performed using the ‘Counting App and Region Measurement tool’ in MetaMorph® v7.8 
software (Molecular Devices). Briefly, two image panels were extracted from ZEN Black (Imaging 
acquisition software), the first panel comprised of only labelled splenocytes. Once the fluorescence 
threshold was set, the ‘count cells’ app was used to count cells in each field of view (4 FOVs per 
mouse, 5 mice per group = 20 images in total per group) and since each image was identical in size 
(1416.30μm x 1416.30μm), the total number of cells was counted in each image. The second panel 
comprised of T and B cell zones (CD3 and B220 staining, respectively) in the white pulp (WP). The 
drawing tool was used to define T and B cell zones in each image. Defined regions from the second 
panel (WP) were transferred onto the first panel (cells) and the total number of cells in each region 
was also counted. Total cells in T and B cell zones were then normalised to total WP area. To do 
this, pixel calibration was performed by setting the X and Y calibration to 0.692µm, where 1 pixel 
would now be equal to 1mm
2. The ‘Morphometry’ tool was used to determine the WP area (in mm2) 
within each image. Finally, the number of cells in WP per mm
2 
(Fig 13g) equals the total number of 
cells in WP (Fig 13f), divided by the WP area (Fig 13h). 
 
 
 
5.2.10 Statistical Analysis 
 
Statistical differences between two groups were determined using the non-parametric Mann-
Whitney U test. Statistical differences between multiple groups were made using a Kruskal-Wallis 
test (Dunn’s multiple comparisons test) by GraphPad Prism version 6 for Windows (GraphPad, San 
Diego, CA, USA); p<0.05 was considered statistically significant. All data are presented as the 
mean ± SEM, unless otherwise stated. 
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5.3 RESULTS 
 
5.3.1 L. donovani infection results in tissue-specific responses 
 
C57BL/6J mice infected with L. donovani develop experimental VL where the liver, spleen 
and bone marrow are the main sites of infection
352
 as shown in Fig 1a with the aid of a transgenic 
bioluminescent parasite (tdTomato – expressing L. donovani). The liver is a site of acute infection, 
where peak parasite burden occurs around day 14 - 21 p.i., and is largely resolved by day 56 p.i. 
(Fig 1b). Early infection triggers rapid IL-12 production by CD8α+ DC’s, CD4+ and CD8+ T cell 
activation and production of cytokines such as IL-2, IFNγ and TNF377. IL-12 signals to CD4+ Th1 
cells to produce IFNγ and TNF in order to activate macrophages to produce iNOS and ROS108, 354, 
377
. Hepatic infection is generally resolved within 6-8 weeks post-infection, a process that is largely 
driven by granuloma formation around infected KC’s109. The bone marrow and spleen are sites of 
chronic infection characterised by parasite persistence and associated with changes in the splenic 
architecture leading to impaired lymphocyte trafficking
97, 129
. Parasite burdens in the spleen steadily 
increase throughout infection and plateau around day 56 p.i. (Fig 1c). One of the advantages of this 
model of experimental VL is that the kinetics of both acute and chronic infection can be studied 
within the same animal. A hallmark feature observed in VL patients is the progressive distension of 
the abdomen as a result of extensive hepatosplenomegaly. Similarly, the spleen and liver of L. 
donovani infected mice progressively enlarge throughout the course of infection (Fig 1d). As 
infection progresses, the acute infection resolves in the liver (Fig 1b), but a chronic infection 
becomes established in the spleen (Fig 1c). It is unclear why potent inflammatory responses 
promote parasite clearance in the liver but not in the spleen. 
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Figure 1: Immune responses during L. donovani infection are tissue-specific. 
 
a) C57BL/6J mice infected with either 2x10
7
 tdTomato- expressing L. donovani bioluminescent amastigotes 
or WT – L. donovani amastigotes i.v.. Main sites of infection observed in the liver, spleen and bone marrow. 
In vivo bioluminescent imaging of infected mice performed on the Xenogen IVIS 100 imaging system. b) 
Liver impression smears taken from infected mice at indicated time-points and mean parasite burden 
expressed in LDU. c) Spleen impression smears taken from infected mice at indicated time-points and mean 
parasite burden expressed in LDU. d) Liver and spleen weights recorded in grams from infected mice at 
indicated time-points, throughout the course of infection. Representative of 5 independent experiments, n= 5 
mice per time-point. Figure source: Immunology and Infection Lab, QIMR Berghofer   
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5.3.2 Blimp1 impairs parasite control and regulates CD4
+
 T cell responses during L. donovani 
infection 
 
Data presented in Chapter 4 demonstrated a requirement for Blimp1 in the development of 
Th1 and Tr1 responses during Plasmodium infections. These results were consistent with previous 
reports for Blimp1 in regulating CD4
+ 
T cell responses
215, 216, 247
, and we next sought to examine 
whether Blimp1 also played a key role in modulating Th1 and Tr1 responses in another important 
parasitic disease to establish the broad relevance of these findings to infection. T cell specific 
Blimp1-deficient (Prdm1
ΔT
) mice infected with L. donovani had significantly reduced parasite 
burdens in the spleen 28 days p.i. (Fig 2a), which was associated with significant increases in the 
frequencies of activated Th1 cells (Fig 2b), and a severe impairment in the generation of Tr1 cells 
(Fig 2c). Parasite persistence in the spleen leads to a breakdown in the splenic architecture, and as a 
functional consequence, impedes the generation, priming and maintenance of effective immune 
responses
106, 129
. Surprisingly, Prdm1
ΔT
 mice had significantly larger spleens, indicative of extensive 
splenomegaly throughout the course of infection (Fig 2d), and was associated with a significant 
increase in the frequency of CD4
+
 T cells producing TNF (Fig 2e). Similar responses were observed 
in the livers of Prdm1
ΔT
 mice infected with L. donovani (Fig 3). The significant reduction in parasite 
burdens (Fig 3a), was associated with increases in Th1 cell frequencies (Fig 3b) and impaired Tr1 
cell responses (Fig 3c), in the Prdm1
ΔT
 mice. Hepatomegaly (Fig 3d) in the Prdm1
ΔT
 mice was also 
associated with a significant increase in TNF production by CD4
+
 T cells, particularly 14 days p.i. 
(Fig 3e). Collectively, these results implicate a broader role for Blimp1 in parasitic diseases, where 
in a second parasitic model Blimp1 impaired parasite control, modulated effector CD4
+
 T cell 
responses, but was required to limit pathology during L. donovani infection. Therefore, these results 
suggested that Blimp1-dependent IL-10 production by CD4
+
 T cells was required to limit tissue 
pathology, but may also contribute to impaired parasite clearance. 
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Figure 2: Blimp1 impairs parasite control in the spleen and regulates CD4
+
 T cell responses during L. 
donovani infection. 
 
a) Prdm1
ΔT 
and Prdm1
fl/fl 
mice were infected with 2x10
7
 L. donovani amastigotes i.v. and spleen parasite 
burdens expressed in LDU. b) Frequency of Th1 cells (CD4
+ TCRβ+ CD11a+ CD49d+ IFNγ+ Tbet+) measured 
by flow cytometry at indicated time-points. c) Frequency of Tr1 cells (CD4
+ TCRβ+ CD11a+ CD49d+ IFNγ+ 
IL-10
+
) measured by flow cytometry at indicated time-points. d) Spleen weights recorded in grams at 
indicated time-points. e) Frequency of TNF producing CD4
+
 T cells in the spleen were assessed by flow 
cytometry at indicated time-points. Representative of 6 independent experiments, mean   SEM, n= 4-6 mice 
per group, **=p<0.01, *= p<0.05, Mann-Whitney U test. 
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Figure 3: Blimp1 impairs parasite control in the liver and regulates CD4
+
 T cell responses during L. 
donovani infection. 
 
a) Prdm1
ΔT 
and Prdm1
fl/fl 
mice were infected with 2x10
7
 L. donovani amastigotes i.v. and liver parasite 
burdens expressed in LDU. b) Frequency of Th1 cells (CD4
+ TCRβ+ CD11a+ CD49d+ IFNγ+ Tbet+) measured 
by flow cytometry at indicated time-points. c) Frequency of Tr1 cells (CD4
+ TCRβ+ CD11a+ CD49d+ IFNγ+ 
IL-10
+
) measured by flow cytometry at indicated time-points. d) Liver weights recorded in grams at 
indicated time-points. e) Frequency of TNF producing CD4
+
 T cells in the liver were assessed by flow 
cytometry at indicated time-points. Representative of 6 independent experiments, mean   SEM, n= 4-6 mice 
per group, **=p<0.01, *= p<0.05, Mann-Whitney U test. 
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5.3.3 Blimp1 modulates parasite-specific inflammatory responses during L. donovani infection 
 
The pro-inflammatory cytokines, TNF and IFNγ play critical roles in parasite clearance by 
activating macrophages to kill resident parasites
354, 378, 379
. While TNF is a potent mediator of 
parasite killing, it has also been shown to contribute to pathology, particularly in the spleen
129
. L. 
donovani infected Prdm1
ΔT
 mice exhibited significantly elevated levels of TNF and IFNγ in the 
serum at day 14 p.i. (Fig 4a). We next tested whether the increase in the frequencies of Th1 cells 
was parasite-specific by culturing splenocytes in the presence of fixed L. donovani amastigotes for 
24 hours and subsequently assessing the frequencies of Th1 cells by flow cytometry (Fig 4b). 
Similar to the responses observed in Figs 2 and 3; we observed a significant increase in Th1 cells in 
response to parasite antigen 14 days p.i. (Fig 4b). Additionally, cytokine analysis of culture 
supernatants revealed that Blimp1 deficiency resulted in significant increases in parasite-specific 
TNF and IFNγ levels (Fig 4c), and significantly reduced IL-10 levels 14 days p.i. (Fig 4d). Taken 
together, these data indicate that Blimp1 is required for regulating parasite-induced inflammation 
and promoting antigen-specific Th1 cell responses during L. donovani infection. 
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Figure 4: Blimp1 modulates parasite-specific inflammatory responses during L. donovani infection. 
 
a) Prdm1
ΔT 
and Prdm1
fl/fl 
mice were infected with 2x10
7
 L. donovani amastigotes i.v.. Serum TNF and IFNγ 
levels measured by using a BD Flex set cytometric bead array (CBA) kit, as per manufacturer’s instructions 
at day 14 and 28 p.i.. b) Splenocytes from L. donovani-infected Prdm1
ΔT 
and Prdm1
fl/fl 
mice were cultured in 
the presence of fixed L. donovani (4% PFA) amastigotes for 24 hours before ICCS was performed to 
measure frequencies of Th1 cells by flow cytometry at day 7 and 14 p.i.. c) Splenocytes from L. donovani-
infected Prdm1
ΔT 
and Prdm1
fl/fl 
mice were cultured in the presence of fixed L. donovani (4% PFA) 
amastigotes for 24 hours (TNF and IFNγ) or d)  72 hours (IL-10) when culture supernatants were collected 
and cytokine levels measured by using a BD Flex set CBA kit. Representative of 2 independent experiments, 
mean   SEM, n= 4-5 mice per group, **=p<0.01, *= p<0.05, Mann-Whitney U test. 
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5.3.4 Blimp1 deficiency in Treg cells does not influence parasite control or CD4
+
 T cell 
responses during L. donovani infection 
 
Previous reports demonstrated a requirement for Blimp1 in conjunction with interferon 
regulatory factor (IRF) 4 to induce IL-10 production by Treg cells
181
. T cell derived IL-10 plays a 
suppressive role in Leishmania infections
205, 214
. Given that Treg cell derived IL-10 can act as a 
potent immunoregulator
380, 381
, we investigated whether Blimp1 was required by Treg cells for 
inducing IL-10 production during infection. L. donovani infected Prdm1
ΔT 
mice exhibited 
significantly reduced frequencies of IL-10
+ 
Foxp3
-
 CD4
+
 T cells (Fig 5a), 28 days p.i. in the spleen 
(Fig 5b) and liver (Fig 5c). Consistent with previous reports, we found a significant reduction in IL-
10
+ 
Foxp3
+
 CD4
+ 
Treg cell frequencies in the spleens of Prdm1
ΔT 
mice (Fig 5b); suggesting Blimp1 
is required for IL-10 production by Treg cells
181
. Interestingly, Prdm1
ΔT 
mice had significant 
increases in the frequencies of IL-10
- 
Foxp3
+ 
CD4
+
 T cells in the liver (Fig 5c). Since Treg cells 
required Blimp1 to produce IL-10, we next investigated whether Treg cell specific Blimp1 
deficiency influenced control of parasite growth and/or development of tissue pathology. 
Interestingly, organ weights (Fig 6a), spleen and liver parasite burdens (Fig 6b), were comparable 
between the Treg cell specific Blimp1 deficient (Prdm1
ΔF
) mice and their littermate controls 28 days 
p.i.. Furthermore, the frequency of Th1 cells in both the spleen and liver were similar in Prdm1
ΔF
 
mice and controls (Fig 6c), suggesting Blimp1 deficiency in Treg cells does not influence the 
generation of Th1 cells during L. donovani infection. While no difference in the frequency of Tr1 
cells was observed in the spleen, a significant increase in Tr1 cells was observed in the liver in the 
absence of Blimp1 in Treg cells at day 28 p.i. (Fig 6d). This latter observation suggests that in the 
absence of Blimp1 in Treg cells, a compensatory immunoregulatory mechanism emerges, whereby 
Tr1 cells develop from a conventional CD4
+
 T cell population to counteract the reduced Treg cell 
function due to the absence of IL-10. This data is supported by the significant increase in IL-10
- 
Foxp3
+
 CD4
+
 Treg cells in the liver, 28 days p.i. in the Prdm1
ΔT 
mice (Fig 5c). Importantly, Treg 
cell-specific Blimp1 deficiency did not alter IFNγ or TNF serum levels at day 28 p.i. (Fig 6e). 
Collectively, these results suggest Blimp1-dependent IL-10 production by Treg cells does not 
influence control of parasite growth or regulate anti-parasitic immune responses during L. donovani 
infection.  
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Figure 5: Blimp1 is required for IL-10 production by Treg cells during L. donovani infection. 
 
a) Prdm1
ΔT 
and Prdm1
fl/fl 
mice were infected with 2x10
7
 L. donovani amastigotes i.v. and frequencies of IL-
10 producing Foxp3
+
 CD4
+
 T cells were measured by flow cytometry in the spleen and liver, 28 days p.i.. b) 
Frequencies of IL-10
+
 (single positive), IL-10
+
 Foxp3
+
 (double positive) and IL-10
-
 Foxp3
+
 (single positive) 
CD4
+
 T cells were measured in the spleen by flow cytometry 28 days p.i.. c) Frequencies of IL-10
+
 (single 
positive), IL-10
+
 Foxp3
+
 (double positive) and IL-10
-
 Foxp3
+
 (single positive) CD4
+
 T cells were measured 
in the spleen by flow cytometry 28 days p.i.. Representative of 2 independent experiments, mean   SEM, n= 
4-5 mice per group, *= p<0.05, Mann-Whitney U test. 
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Figure 6: Blimp1 deficiency in Treg cells does not influence parasite control or CD4
+
 T cell responses 
during L. donovani infection. 
 
a) Prdm1
ΔF 
(Treg cell specific Blimp1 deficient) and Prdm1
fl/fl 
(littermate controls) mice were infected with 
2x10
7
 L. donovani amastigotes i.v. Spleen and liver weights recorded in grams, 28 days p.i.. b) Spleen and 
liver parasite burdens expressed in LDU c) Frequency of Th1 cells in the spleen and liver measured by flow 
cytometry 28 days p.i.. d) Frequency of Tr1 cells in the spleen and liver, measured by flow cytometry 28 
days p.i.. e) Serum IFNγ and TNF levels measured using a BD Flex set CBA kit at day 28 p.i.. 
Representative of 1 independent experiment, mean   SEM, n= 4-5 mice per group, *= p<0.05, Mann-
Whitney U test. 
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5.3.5 Blimp1-dependent IL-10 production by T cells is required to limit pathological changes 
in the spleen during L. donovani infection 
 
TNF-producing CD4
+
 T cells displayed a much lower level of Blimp1 expression compared 
to IL-10 producing CD4
+
 T cells (Chapter 4 Fig 9a, b), and in addition to this, mice lacking Blimp1 
specifically in T cells exhibited significantly higher levels of serum TNF, antigen-specific TNF 
production, as well as higher frequencies of TNF-producing CD4
+
 T cells in both the spleen and 
liver (Fig 2e, 3e, 4a, 4c). A recent study demonstrated that TNF blockade induced IL-10 expression 
in human CD4
+
 T cells
382
, supporting earlier reports of IL-10 mediated regulation of TNF
383, 384, 385
. 
Together, these data suggest that Blimp1 in T cells regulates TNF production during L. donovani 
infection via IL-10. The architecture of the spleen is highly organised and by taking a transverse 
cross-section of the spleen (Fig 7a), it is possible to delineate the white pulp areas by fluorescence 
microscopy using FITC dextran and DAPI molecular probes. In a normal WT, un-infected mouse, 
white pulp areas are clearly visible (Fig 7b), whereas 28 days p.i., the spleen enlarges and 
destruction of the white pulp areas is clearly evident (Fig 7c). The white pulp is surrounded by the 
MMM’s, and outside of this layer the MZM’s, form the outermost perimeter of the white pulp (Fig 
7d). To investigate the effects of TNF-mediated tissue pathology and how IL-10 may regulate this 
process, we employed the use of the T cell specific Blimp1-deficient and IL-10-deficient (Il10
ΔT
) 
mice. Prdm1
ΔT
 and Il10
ΔT
 mice infected with L. donovani exhibited significantly reduced parasite 
burdens (Fig 8a), and significant increases in spleen weights (Fig 8b), indicative of pathology 14 
days p.i.. Furthermore, associated with improved parasite control, but increased pathology, we also 
observed significant increases in the frequencies of Th1 cells in both the Prdm1
ΔT
 and Il10
ΔT
 mice 
(Fig 8c), suggesting that Blimp1 induced IL-10 is required to regulate inflammatory responses in 
order to limit pathology. To examine the extent of architectural disruption, a process that is largely 
mediated by TNF
129
, we injected mice with FITC dextran i.v. to determine whether the MZM’s 
lining the white pulp areas of the spleen would be disrupted in the Prdm1
ΔT
 and Il10
ΔT
 mice. Given 
that in a WT mouse, loss of these MZM’s occurs at day 28 p.i., it was interesting to observe a 
significant reduction in number of MZM’s per mm2 of tissue in both Prdm1ΔT and Il10ΔT mice as 
early as day 14 p.i. (Fig 8d), suggesting that both Blimp1 and IL-10 in T cells were required to 
protect against TNF-mediated pathology in the spleen. These observations are consistent with 
previous reports for a protective role for IL-10 against tissue damage mediated by parasite-induced 
inflammation
74, 356, 386, but also identifies loss of MZM’s as a specific manifestation of this 
pathology.  
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Figure 7: L. donovani infection results in disruption of the splenic architecture 28 days p.i.. 
 
a) Transverse cross-section of the spleen. Image source: Body Scientific International LLC website: 
http://www.semayjohnston.com/ b) C57BL/6J mice (un-infected) were injected with 100µg of FITC-dextran 
(in saline) i.v. spleens harvested and fixed in 4% PFA (1-2 hours) followed by overnight incubation at 4°C in 
30% sucrose solution (in MilliQ water) before freezing in Tissue Tek OCT. 20µm sections were cut and 
stained with DAPI, mounted with Pro-Long Gold and imaged on the Aperio FL slide scanner under 20x 
magnification, scale bar 3mm. c) C57BL/6J mice were infected with 2x10
7
 L. donovani amastigotes i.v. and 
27 days p.i. were subsequently injected with 100µg of FITC-dextran (in saline) i.v., spleen tissue was 
processed and imaged on the Aperio FL slide scanner under 20x magnification, scale bar 4mm. d) Schematic 
representation of the splenic MZ, adapted from Georg Kraal, 1992, Int Rev Cytol. 132: 31-74, permission 
number 3763951413543 
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Figure 8: Blimp1-dependent IL-10 production by T cells limits pathological changes in the spleen 
during L. donovani infection. 
 
a) Prdm1
ΔT
, Prdm1
fl/fl 
mice and Il10
ΔT 
(T cell specific IL-10 deficient), Il10
fl/fl 
(littermate controls) mice were 
infected with 2x10
7
 L. donovani amastigotes i.v. and spleen parasite burdens were expressed in LDU, 14 
days p.i.. b) Spleen weights were recorded in grams c) frequency of Th1 cells were measured by flow 
cytometry in the spleen 14 days p.i.. d) number of MZM’s per mm2 was determined by injecting mice with 
100µg of FITC-dextran 13 days p.i. and spleen tissue was processed for imaging on the Aperio FL slide 
scanner under 20x magnification, scale bars 500µm, 14 days p.i.. Representative of 2 independent 
experiments, mean  SEM, n= 5-6 mice per group, **=p<0.01, *= p<0.05, Mann-Whitney U test. 
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5.3.6 Blimp1is required to regulate TNF production by CD11b
+
Ly6C
hi
 cells in the spleen 
during L. donovani infection 
 
During remodelling of the MZ, the distribution of TNF production by various cells is 
widespread, where monocytes, macrophages, DC’s, B cells and T cells can all produce varying 
amounts of TNF
135, 136, 137, 138
. It remains unclear whether a particular cellular source of TNF plays 
protective and or pathogenic roles. Previously, we had shown that Blimp1 was required for 
regulating TNF production by CD4
+
 T cells (Fig 2, 3). We next investigated whether Blimp1 was 
also involved in modulating TNF production by non-T cell populations, including inflammatory 
monocyte-like populations (CD11b
+ 
Ly6C
hi
), B cells (B220
+ 
CD19
+) and cDC’s (CD11chi MHCIIhi) 
(Fig 9). For the purposes of this basic analysis, the CD11b
+ 
Ly6C
lo
 population was not analysed due 
to the absence of the Ly6G surface marker, to discriminate between neutrophils and patrolling 
monocytes. Interestingly, Blimp1 impaired TNF production by CD11b
+
 Ly6C
hi
 cells in the spleen 
14 days p.i. (Fig 10a), similar to CD4
+
 T cells (Fig 2e), but did not suppress TNF production by B 
cells (Fig 10b) or cDC’s (Fig 10c) 14 days p.i.. These findings suggest that there are cell-specific 
requirements for Blimp1-mediated regulation of TNF production, at a time when there is accelerated 
disruption to the splenic architecture. We next assessed levels of chemokines and cytokines involved 
in monocyte recruitment and function
387, 388
 in supernatants of splenocytes from Prdm1
ΔT 
mice and 
their littermate controls cultured in the presence of fixed L. donovani amastigotes for 72 hours. 
Prdm1
ΔT 
mice exhibited significantly elevated levels of parasite-specific MCP-1 (Fig 10d), modest 
increases in IL-1β (Fig 10e) and significantly elevated levels of IL-6 (Fig 10f), further supporting 
the idea that Blimp1 regulates inflammatory responses during L. donovani infection. Taken together, 
these data suggest that at 14 day p.i., when the early loss of MZM’s is observed in the Prdm1ΔT 
mice, CD11b
+
 Ly6C
hi
 cells from these mice produce significantly more TNF, compared with 
controls, which along with CD4
+
 T cell-derived TNF may contribute to MZM loss. Furthermore, 
significant increases in parasite-specific MCP-1 and IL-6 production by splenocytes from Prdm1
ΔT 
mice, compared to controls, also points to the involvement of monocytes in the early MZM loss in 
the spleen.  
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Figure 9: Gating strategy for B cells, monocytes and cDC’s in the spleen during L. donovani infection. 
 
Left to right: Single cells, lymphocytes, viable (live) cells, 1. (From live cells gate): B cells (B220
+ 
CD19
+
), 
2. (From live cells gate): B220
-
 (exclusion of B cells and pDC’s), 3. (From B220- gate): inflammatory 
monocyte-like cells (CD11b
+ 
Ly6C
hi
) and cDC’s (CD11chi MHCIIhi). 
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Figure 10: Blimp1 regulates TNF production by CD11b
+
Ly6C
hi
 cells in the spleen during L. donovani 
infection. 
 
a) Prdm1
ΔT 
and Prdm1
fl/fl 
mice were infected with 2x10
7
 L. donovani amastigotes i.v. and frequency of 
CD11b
+ 
Ly6C
hi
 (inflammatory monocyte-like cells), b) B cells (B220
+ 
CD19
+
) and c) conventional DC’s 
(CD11c
hi
 MHCII
hi
) were measured by flow cytometry on days 7 and 14 p.i.. Splenocytes from L. donovani-
infected Prdm1
ΔT 
and Prdm1
fl/fl 
mice were cultured in the presence of fixed L. donovani (4% PFA) 
amastigotes for 72 hours when culture supernatants were collected and d) MCP-1, e) IL-1β and f) IL-6 levels 
measured by using a BD Flex set CBA kit at 7 and 14 days p.i.. Representative of 2 independent 
experiments, mean  SEM, n= 4-5 mice per group, **=p<0.01, Mann-Whitney U test. 
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5.3.7 IL-10 signalling to T cells and myeloid-derived cells protects MZM’s against TNF 
mediated killing during L. donovani infection 
 
The accelerated loss of MZM’s in the absence of IL-10 (Fig 8d), prompted us to investigate 
whether IL-10 signalling  to macrophages or other myeloid derived populations provided protection 
against exacerbated tissue pathology. Myeloid-specific IL-10R deficient (Il10R
ΔM
) mice infected 
with L. donovani exhibited significantly reduced parasite burdens (Fig 11a), and pronounced 
splenomegaly 14 days p.i. (Fig 11b), compared to litter mate controls. Improved parasite control and 
pathology was associated with impaired generation of Tr1 cells (Fig 11c), significantly increased 
frequencies of Th1 cells (Fig 11d), as well as significantly elevated levels of serum TNF and IFNγ 
(Fig 11e). Additionally, accelerated loss of MZM’s was evident in the Il10RΔM mice (Fig 11f) and 
was associated with a significant increase in the frequency of TNF producing CD11b
+
 Ly6C
hi
 cells, 
14 days p.i. (Fig 11g).  We then asked whether IL-10 was signalling to the T cells themselves to 
protect host tissue from exacerbated pathology by infecting T cell specific IL-10R deficient 
(Il10R
ΔT
) mice with L. donovani. Il10R
ΔT 
mice also exhibited improved parasite control (Fig 12a), 
pronounced splenomegaly (Fig 12b), impaired Tr1 responses (Fig 12c) and significantly increased 
Th1 cell frequencies (Fig 12d). Interestingly, Il10R
ΔT 
mice did not have elevated serum TNF and 
IFNγ production (Fig 12e), yet displayed accelerated MZM loss 14 days p.i.(Fig 12f), which was 
associated with significant increases in TNF production by CD11b
+
 Ly6C
hi 
(Fig 12g), suggesting 
that IL-10 signalling in T cells and myeloid-derived cells was required to limit TNF production by 
myeloid populations. Collectively, these results suggest that Blimp1-dependent IL-10 produced by 
Tr1 cells acts on the T cells themselves, as well as myeloid cells, possibly including MZM’s, in 
order to protect the host tissue against TNF-mediated pathology. 
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Figure 11: IL-10 signalling to myeloid-derived cells protects MZM’s against TNF mediated killing 
during L. donovani infection. 
 
a) Il10R
ΔM 
(Myeloid-specific IL-10R deficient) and Il10R
fl/fl 
(littermate controls) mice were infected with 
2x10
7
 L. donovani amastigotes i.v. and spleen parasite burdens were expressed in LDU, 14 days p.i.. b) 
Spleen weights recorded in grams c) Frequency of Tr1 cells measured by flow cytometry in the spleen 14 
days p.i.. d) Frequency of Th1 cells measured by flow cytometry in the spleen 14 days p.i.. e) Serum TNF 
and IFNγ levels measured at day 14 p.i. using a BD Flex CBA set kit f) number of MZM’s per mm2 
determined as above and imaged on the Aperio FL slide scanner under 20x magnification 14 days p.i.. g) 
Frequency of TNF
 producing TCRβ- CD11b+ Ly6Chi cells measured by flow cytometry in the spleen 14 days 
p.i.. Representative of 2 independent experiments, mean   SEM, n= 5 mice per group, **=p<0.01, *= 
p<0.05, Mann-Whitney U test. 
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Figure 12: IL-10 signalling to T cells protects MZM’s against TNF mediated killing during L. donovani 
infection. 
 
a) Il10R
ΔT 
(T cell specific IL-10R deficient), Il10R
fl/fl 
(littermate controls) mice were infected with 2x10
7
 L. 
donovani amastigotes i.v. and spleen parasite burdens were expressed in LDU. b) Spleen weights recorded in 
grams c) Frequency of Tr1 cells measured by flow cytometry in the spleen 14 days p.i.. d) Frequency of Th1 
cells measured by flow cytometry in the spleen 14 days p.i.. e) Serum TNF and IFNγ levels measured at day 
14 p.i. using a BD Flex set CBA kit f) number of MZM’s per mm2 determined as above and imaged on the 
Aperio FL slide scanner under 20x magnification 14 days p.i.. g) Frequency of TNF
 producing TCRβ- 
CD11b
+ 
Ly6C
hi
 cells measured by flow cytometry in the spleen 14 days p.i.. Representative of 1 independent 
experiment, mean   SEM, n= 5 mice per group, **=p<0.01, *= p<0.05, Mann-Whitney U test. 
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5.3.8 Early MZM loss in the absence of IL-10 is TNF-dependent during L. donovani infection 
 
Earlier studies demonstrated TNF was a major factor involved in the killing of splenic 
MZM’s leading to a breakdown of the highly organised structure of the spleen and thereby 
impairing the trafficking of lymphocytes
129
. In order to test whether this early loss of MZM’s in the 
Prdm1
ΔT
 mice was TNF-dependent, we infected Prdm1
ΔT 
mice with L. donovani and administered 
200µg of Enbrel
TM
 (anti-TNF) or control Intragam® (HuIgG) on the day of infection and every 2 
days until day 14 p.i.. Prdm1
ΔT 
mice that underwent TNF blockade displayed significantly higher 
parasite burdens compared to the control HuIgG-treated mice (Fig 13a). In addition, TNF blockade 
resulted in Prdm1
ΔT 
mice exhibiting significantly reduced splenomegaly, relative to controls (Fig 
13b), and this was associated with a significant increase in the number of MZM’s per mm2 at 14 
days p.i. (Fig 13c, d). Thus, these data confirm that the early loss of MZM’s in the absence of 
Blimp1 in T cells was TNF-dependent. 
 
To address whether the breakdown in splenic architecture impaired the trafficking of 
lymphocytes in the Prdm1
ΔT 
mice, we transferred fluorescently-labelled splenocytes (grey) and 
employed the use of fluorescence microscopy to image T and B cell areas using CD3(blue) and 
B220 (yellow) antibodies to mark T and B cell zones, respectively (Fig 13e). Prdm1
ΔT 
mice treated 
with control HuIgG had significantly lower numbers of total lymphocytes, while TNF blockade 
partially restored the ability to retain lymphocytes in the spleen (Fig 13e, panel 1, 13f). 
Additionally, we found that TNF blockade also improved the trafficking of lymphocytes to the T 
and B cell areas (white pulp) in these mice (Fig 13e panel 2, 13g). Measurement of total white pulp 
areas showed that all areas were comparable between different treatment groups (Fig 13h). 
Therefore, the increase in the number of labelled-cells trafficking to these white pulp areas 
following TNF blockade did not result from changes in white pulp areas. Taken together, these 
results show that Blimp1-dependent IL-10 protects against TNF-mediated MZM loss, thereby 
preserving trafficking of lymphocytes through the T and B cell zones of the spleen. Furthermore, 
increased parasite burdens following TNF blockade, suggests that while Blimp1-dependent IL-10 
protected against pathology, it also impaired parasite control. 
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Figure 13: Early MZM loss in the absence of IL-10 is TNF-dependent during L. donovani infection. 
 
a) Prdm1
ΔT 
and Prdm1
fl/fl 
mice were infected with 2x10
7
 L. donovani amastigotes i.v. and administered with 
200µg of control HuIgG or anti-TNF (Enbrel
TM
) i.p. before infection and every 2 days until day 14 p.i. 
Spleen parasite burdens expressed in LDU. b) Spleen weights recorded in grams 14 days p.i.. c) number of 
number of MZM’s per mm2 determined as above and d)  imaged on the Aperio FL slide scanner under 20x 
magnification 14 days p.i. scale bars 500µm e) Panel 1: mice injected with FITC-dextran 13 days p.i. (one 
day prior to tissue collection). 2x10
7
 DDAO-SE-labelled naive splenocytes (white-grey) were injected i.v. 
into mice 2 hours prior to collection of spleens on day 14 p.i.. Panel 2: All spleens were processed and 20µm 
sections were cut, stained with anti-CD3 (blue) and anti-B220 (yellow) antibodies before being mounted and 
imaged on the Carl Zeiss 780 NLO laser scanning confocal microscope under 10x magnification, scale bars 
200µm. f) Total number of DDAO-SE
+ 
cells (4 fields of view per mouse). g) Number of total cells in white 
pulp (WP) divided by WP area in mm
2
. h) Area of WP in mm
2
 in all sections. Representative of 2 
independent experiments, mean   SEM, n= 5 mice per group (f = 4 images per mouse, therefore: 20 data 
points to obtain an average representation of each section), ***=p<0.001, **=p<0.01, *= p<0.05, Kruskal-
Wallis test. 
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5.3.9 TNF blockade combined with anti-parasitic drug partially rescues pathology while 
maintaining anti-parasitic immunity 
  
Rheumatoid arthritis patients or patients with inflammatory diseases are treated with drugs 
that inhibit TNF activity
389, 390, 391
. One important side-effect in these patients is their susceptibility 
to opportunistic infections
392, 393
. Given that TNF blockade resulted in increased parasite burdens, 
yet preserved splenic architecture, we next asked whether TNF blockade in combination with an 
anti-parasitic drug could serve as a potential therapeutic intervention. We hypothesised that the anti-
parasitic drug, sodium stibogluconate (SSG, pentavalent antimonial) would combat parasite growth 
and the TNF blockade would preserve splenic architecture. C57BL/6J mice were infected with L. 
donovani and treated with TNF blockade or SSG beginning at day 14 p.i. in order to represent a 
situation where VL patients present to clinics in endemic areas with existing disease and or 
pathology. High dose of drug (500mg/kg of SSG) was administered on day 14 and day 21 p.i. and 
TNF blockade was administered every 2 days from day 14 p.i. until day 28 p.i. (Fig 14). Drug 
treatment alone and TNF blockade combined with drug resulted in significantly reduced parasite 
burdens in the liver and spleen 28 days p.i. (Fig 15a, b), but did not reduce splenomegaly (Fig 15c). 
Interestingly, while spleen weights remained unaffected, the number of MZM’s per mm2 was 
significantly improved upon TNF blockade combined with drug treatment, compared to drug alone 
(Fig 15d). Additionally, parasite-specific Th1 responses, measured by flow cytometry, revealed that 
TNF blockade combined with drug did not diminish the anti-parasitic benefit of drug treatment 
alone (Fig 15e). Furthermore, IFNγ levels produced in response to parasite were comparable 
between drug treatment alone and TNF blockade combined with drug (Fig 15f), suggesting that 
while TNF blockade alone would contribute to impaired immune responses, when administered in 
combination with drug, anti-parasitic immune responses could be sustained. Taken together, these 
data show the potential of employing TNF blockade in combination with drug to treat pathology in 
VL patients without compromising parasite control. 
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Figure 14: Combination treatment regimen of anti-TNF (Enbrel
TM
) and drug (SSG).  
 
C57BL/6J mice infected with 2x10
7
 L. donovani amastigotes i.v. and then administered with either 1: 200µg 
of control HuIgG (Intragam), 2: anti- TNF (Enbrel)* beginning at day 14 p.i. and every 2 days until day 28 
p.i.. 3: 50mg/kg of sodium stibogluconate (SSG)
#
 on day 14 p.i. and a second dose administered on day 21 
p.i. or 4: anti-TNF + SSG (at indicated time-points) 
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Figure 15: TNF blockade combined with anti-parasitic drug partially rescues pathology while 
maintaining anti-parasitic immunity. 
 
a) Following the treatments outlined in Fig 14, liver parasite burdens were expressed in LDU, 28 days p.i.. b) 
Spleen parasite burdens also expressed in LDU 28 days p.i.. c) Spleen weights recorded in grams. d) Number 
of MZM’s per mm2 measured (as above) 28 days p.i.. e) Splenocytes from L. donovani infected C57BL/6J 
mice were cultured in the presence (antigen) or absence (media) of fixed L. donovani (4% PFA) amastigotes 
for 24 hours and subsequently, the frequency of Th1 cells was measured by flow cytometry. f) Culture 
supernatants were collected at 24 hours post antigen re-stimulation from (e) and IFNγ levels measured using 
a BD Flex set CBA kit on day 28 p.i.. Representative of 2 independent experiments, mean   SEM, n= 4-5 
mice per group, **=p<0.01, *= p<0.05, Mann-Whitney U test. 
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5.3.10 IFNγ signalling is required for TNF production and consequently drives TNF-mediated 
tissue damage 
 
Prdm1
ΔT mice had significantly higher serum TNF and IFNγ levels following L. donovani 
infection (Fig 4a, c), and following TNF blockade, splenic pathology was greatly reduced (Fig 13). 
Therefore, since improved parasite control and exacerbated pathology in mice lacking Blimp1 or 
IL-10 in T cells was associated with enhanced Th1 responses and elevated IFNγ and TNF levels, we 
examined the contribution of IFNγ signalling to the control of parasite growth and splenic 
pathology during L. donovani infection. Previous reports have shown that IFNγ is critical for 
controlling parasite growth in the liver
394
. Consistent with these reports, we also observed a 
significant increase in parasite burdens in the liver in the absence of IFNγ signalling (Fig 16a). 
Interestingly, while there was a modest decrease in splenic parasite burdens (Fig 16b), 
splenomegaly was significantly reduced in the IFNγR-deficient mice throughout the course of 
infection (Fig 16c). Associated with the reduction in splenomegaly, we also noted that MZM’s were 
clearly retained and preserved in the IFNγR-deficient mice, 28 days p.i. compared to WT controls 
(Fig 16d, e). Furthermore, serum TNF levels were significantly reduced in the IFNγR-deficient 
mice, throughout the course of infection (Fig 16f), whereas IFNγ levels were significantly elevated 
28 days p.i. (Fig 16g). Collectively, these results suggest that IFNγ signalling was required for 
inducing TNF production, and therefore, contributed to splenic pathology during L. donovani 
infection. Importantly, these results show that following L. donovani infection, IFNγ promoted TNF 
production, and this pathway was regulated by Blimp-1-mediated IL-10 production by T cells. 
Importantly, this regulatory pathway determined the balance between control of parasite growth and 
TNF-mediated pathology.  
 
 
 
 
 
 
 
 
 
 
Chapter 5 
 
 41758573  179 
 
Figure 16: IFNγ signalling is required for TNF production and consequently drives TNF-mediated 
tissue damage. 
 
a) WT and IFNγR deficient (IFNγR-/-) mice were infected with 2x107 L. donovani amastigotes i.v. and liver 
parasite burdens expressed in LDU, 28 days p.i.. b) Spleen parasite burdens expressed in LDU, 28 days p.i.. 
c) Spleen weights recorded in grams at day 14 and 28 p.i. d) Number of MZM’s per mm2 were measured as 
described previously and e) imaged on the Aperio FL slide scanner under 20x magnification, scale bars 
400µm 28 days p.i.. f) Serum TNF and g) IFNγ levels measured using a BD Flex set CBA kit 14 and 28 days 
p.i.. Representative of 2 independent experiments, mean   SEM, n= 5-6 mice per group, **=p<0.01, *= 
p<0.05, Mann-Whitney U test. 
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Figure 17: Blimp1-dependent IL-10 production by CD4
+
 T cells protects against TNF-mediated 
pathology in the spleen. 
 
IL-12 produced by DC’s signals and is required to drive Th1 differentiation (Chapter 4) which subsequently 
induces Blimp1 expression in the Th1 cell population and therefore drives the induction of Tr1 cells during 
Plasmodium and Leishmania infections. Tr1 cell derived IL-10 limits the inflammatory cascade by signalling 
to macrophages to protect against TNF- mediated killing during L. donovani infection. Figure drawn by: S. 
Ng, Immunology and Infection Laboratory, QIMR Berghofer. 
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5.4 DISCUSSION 
 
Blimp1 is central to various aspects of immune cell differentiation
395
. First identified in 
plasma cell function, the expanding roles for Blimp1 now includes involvement in T cell 
homeostasis, NK cell and DC maturation
242, 244, 245, 339
. Moreover, Blimp1 is required for the 
induction of T cell and Treg cell derived IL-10 production
181, 215, 216
. Here, we show that Blimp1-
dependent IL-10 production by Tr1 cells is necessary to limit IFNγ-dependent, TNF-mediated tissue 
damage in the spleen during L. donovani infection (summarised in Fig 17). In this model of 
experimental visceral leishmaniasis, where splenomegaly is a TNF-mediated process, our results 
suggest that the highly inflammatory environment mediates control of parasite growth while at the 
expense of contributing host-tissue pathology.  Collectively, these results suggest that while 
parasitic infections such as malaria and leishmaniasis induce potent inflammatory responses which 
are required for parasite control, in the absence of immunoregulatory molecules such as IL-10, 
excess inflammation exacerbates tissue-pathology and thus disrupts the splenic architecture. 
 
IL-10 plays suppressive roles in multiple parasitic diseases, including Leishmania 
infections
218, 280, 385, 396
. T cell-specific Blimp1-deficient and IL-10-deficient mice exhibited 
significantly reduced parasite burdens, suggesting that Blimp1-dependent IL-10 impaired parasite 
control. However, these experiments also showed that the induction of IL-10 was important for 
preserving splenic architecture against inflammatory-mediated destruction. Furthermore, we found a 
significant increase in IL-10
-
 Foxp3
+
 CD4
+
 Treg cells in the liver, 28 days p.i. in the Prdm1
ΔT 
mice. 
Additionally, we observed a significant increase in Tr1 frequencies in the liver of Prdm1
ΔF 
mice 28 
days p.i.. Taken together, these data provide evidence for a compensatory mechanism where in the 
absence of Blimp1 in Treg cells, Tr1 cells emerge to counteract reduced Treg cell function due to 
the lack of IL-10. Mechanistically, this may occur via IL-2 consumption, since Prdm1
ΔT 
mice 
exhibit higher levels of IL-2
397
 and thus contributing to the increase in Foxp3
+
 CD4
+
 Treg cell 
frequencies in the liver, 28 days p.i.. Interestingly, while Treg cell-derived IL-10 is known to play 
immunoregulatory roles in inflammatory settings, our results using the Treg cell-specific Blimp1-
deficient mice showed that parasite burdens, organ weights and TNF and IFNγ levels were 
comparable with littermate controls, and therefore, the striking differences between the Prdm1
ΔT 
and 
littermate control mice were not caused by Blimp1 deficiency in Treg cells. Therefore, given that 
Treg cells appeared to play a minor role during infection, we focused on Tr1 cells and IL-10 
signalling during L. donovani infection. IL-10 signals to T cells and myeloid cells, including 
MZM’s, to provide protection against parasite induced inflammation.  
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In addition, the significant increase in Th1 cell frequencies in the Il10R
ΔT 
and Il10R
ΔM 
mice suggests 
that T cell derived-IFNγ signals to monocytes/macrophages to produce more TNF, and consequently 
contributes to the destruction of MZM’s. TNF has been shown to be a mediator of splenic white 
pulp remodelling during L. donovani infection
129
, and previously Ly6C
+
 inflammatory monocytes 
have been shown to be involved in the vascular remodelling of the spleen during L. donovani 
infection
133
.  
 
We also found that TNF production by inflammatory monocyte-like populations (CD11b
+ 
Ly6C
hi
) 
was significantly elevated in the absence of IL-10 signalling to T cells and myeloid populations, 
suggesting that IL-10-mediated control of TNF production by CD11b
+
 Ly6C
hi
 cells is important in 
minimising tissue damage during infection. However, in order to establish this definitively, studies 
need to be conducted with mice deficient for TNF specifically in myeloid and T cell populations. 
The early loss of MZM’s in the T cell-specific Blimp1-deficient mice resulted in impaired 
trafficking of lymphocytes into the T and B cell areas of the white pulp compartment which was 
rescued by TNF blockade. Consistent with these results, earlier studies have shown MZM’s to be 
key players in directing the trafficking of lymphocytes into white pulp areas
126, 398, 399
. Furthermore, 
in the absence of Blimp1 and IL-10 expression in T cells and IL-10R in T cells and myeloid cells, 
splenomegaly and loss of MZM was accelerated. During experimental VL, splenomegaly is 
accompanied by extensive vascular remodelling
132
, mediated by neurotrophic receptor (Ntrk2) 
expression on splenic endothelial cells and interactions with ligands expressed by F4/80
hi
 CD11b
lo
 
CD11c
+
 macrophages
364
. Moreover, macrophage-derived TNF has been previously reported to be 
involved in angiogenesis and vascular remodelling
400, 401
, and therefore, taken together with our 
data, suggests that vascular remodelling in the spleen caused by TNF is regulated by Blimp1-
dependent IL-10 production by Tr1 cells during L. donovani infection. Given that vascular 
remodelling is induced by inflammation
402, 403, 404
, it is possible that the implications of these 
findings extend beyond infection-induced inflammation, and may apply to other chronic 
inflammatory diseases.  
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The immunoregulatory roles of IL-10 are well known, however, the cellular requirements for 
the induction of IL-10 in CD4
+
 T cells has only recently been investigated in detail. Blimp1 was 
reported to play key roles in inducing IL-10 production by Tr1 cells (in LCMV and T. gondii 
models), which are thought to arise from a Th1 cell precursor that acquires self-regulatory 
capacity
215, 216
. However, these findings mainly focused on the upstream requirements for the 
generation of Tr1 cells, and while the authors discussed the self-regulating capacity of Tr1 cells, the 
biological and physiological consequence of this self-regulation was not studied. Parasitic infections 
such as those caused by Plasmodium and Leishmania species induce robust immune responses to 
kill parasites; however, parasite-induced inflammation also contributes to host tissue damage. Our 
results here show that Tr1 cells are induced in both Plasmodium (Chapter 4) and Leishmania 
infections as a means of limiting inflammation-induced immunopathology. Consistent with these 
findings, other studies have also reported on the induction of  Tr1 cells in Plasmodium
47, 48, 232, 235
 
and Leishmania
214, 233, 234, 345
 infections. A previous study had demonstrated that in the absence of 
IL-10, IL-17 was responsible for mediating immunopathology during L. major infection
405
. 
However, upon assessing serum IL-17 levels, as well as parasite-specific IL-17 production in the T 
cell specific Blimp1 deficient mice, no Blimp1-mediated effects on IL-17 production were observed 
(Appendix 3). Therefore, at least in our VL model, in the absence of Blimp1-dependent IL-10, IL-
17 does not appear to contribute to the exacerbated pathology observed in the T cell-specific 
Blimp1-deficient mice. Furthermore, our data shows that Blimp1 induces IL-10 production by Tr1 
cells which signals to macrophages to protect against TNF-mediated destruction of the splenic 
architecture. While limiting tissue pathology may seem like an obvious function of Tr1 cells, it will 
be important to fully understand the mechanism by which these immunoregulatory pathways 
develop and are maintained. A greater understanding of these pathways and networks will provide 
insight into how Tr1 cells can be modulated to protect against the inflammatory activities of TNF in 
inflammatory disorders.   
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The majority of VL patients that present to clinics exhibit pronounced signs of disease, and 
in particular, splenomegaly is a key pathological feature. We show that TNF is a key promoter this 
pathology, but also show that TNF blockade can exacerbate control of parasite growth. Therefore, 
development of targeted therapies that do not compromise parasite control is required. Given that 
TNF is a main driver of pathology and disease in VL patients
106
, we explored the possibility of 
blocking TNF in conjunction with anti-parasitic drug in order to limit parasite growth, but protect 
host tissue against parasite-induced inflammation. Our results show that while TNF blockade did not 
compromise anti-parasitic immunity when combined with drug, it did not diminish parasite-specific 
IFNγ levels compared to drug alone. Thus, we have shown a potentially promising therapeutic 
application involving anti-TNF treatment combined with anti-parasitic drug. While, we showed a 
significant increase in the number of MZM’s in mice that received drug and TNF blockade, it 
remains to be determined whether this partial preservation of MZM’s is enough to restore 
lymphocyte trafficking to white pulp areas. Various cells are able to produce TNF during infection, 
including monocytes, macrophages, DC’s, B cells and T cells135, 136, 137, 138. We found that disruption 
to the splenic architecture was associated with significant increases in TNF production by CD4
+
 T 
cells and CD11b
+ 
Ly6C
hi
 cells in the absence of Blimp1 and IL-10. Whether these cellular sources 
of TNF play protective and or pathogenic roles remains to be determined, and should be taken into 
careful consideration when developing therapeutic combination treatments against TNF. 
 
Another promising immunotherapy approach being tested to treat inflammatory diseases is 
the use of Treg cells due to their immunoregulatory capacities
363, 406, 407
. However, some challenges 
of this approach include the fact that intranuclear expression of Foxp3 makes Treg cells difficult to 
purify. In addition, their frequencies range between 1-2% of human CD4
+ 
T cells and thus must be 
expanded ex vivo to gain sufficient numbers for therapeutic use and even then, repeated in vitro 
expansion may alter the phenotype and function of these cells
406, 408, 409
. The expansion of Treg cells 
from patients with rheumatoid arthritis or multiple sclerosis indicates there are phenotypic changes 
in the Treg cell populations isolated from these patients, leading to Treg instability
406
. Therefore, in 
a situation where Treg cell-based therapy is not feasible, the use of Tr1 cells may offer an alternative 
solution to treat disease. Data presented in this Chapter identifies Tr1 cells as critical regulators of 
inflammation-induced pathology and provides mechanistic insights into how Blimp1-induced IL-10 
in Tr1 cells protects against TNF-mediated tissue damage. 
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The proposal of the Th1/Th2 paradigm in 1986
410
 offered a simplistic view of CD4
+
 T cell 
differentiation and regulation, based on their opposing actions. However, the discovery of Th1 and 
Th2 cells was only a small insight into the unique plasticity of CD4
+
 T cells. While the Th1/Th2 
paradigm provided a conceptual framework, the discovery of Th17, Tfh and Treg cells has propelled 
the field of CD4
+ 
T cell biology into an era where personalised medicine is becoming an attractive 
approach for the treatment of autoimmune, inflammatory and infectious diseases, as well as cancers. 
Additionally, the identification of IL-10 producing Th1 cells
199, 215, 216, 411, 412
, as well as the ability of 
Treg cells to limit Th cell activity via mechanisms of migratory mimicry of the Th cell in 
question
180, 182, 184, 185
, are examples of the ability of CD4
+
 T cells to respond accordingly to their 
immediate environment.  
 
Plasmodium and Leishmania infections activate potent CD4
+
 T cell subsets that drive a 
myriad of inflammatory responses that mediate parasite control. However, in the absence of 
immunoregulatory mechanisms (IL-10 and Treg cells), the resulting immunopathology can 
influence disease outcome. Today, vaccine development and therapeutic medicine are at the 
forefront of medical research and it is therefore important to differentiate immune responses that are 
beneficial from those that pose detrimental outcomes. Therefore, the use of Treg cells has changed 
the field of immunotherapy by providing options for immunoregulation in a therapeutic setting.  
 
Evidence of CD4
+
 T cell suppression during malaria and VL has been extensively reported, 
thus highlighting the importance of identifying mechanisms to enhance anti-parasitic responses for 
vaccine development
47, 67, 275, 413, 414, 415
. Here, we have shown that type I IFN’s suppress anti-
parasitic CD4
+
 T cell responses during first exposure to P. falciparum infection and instead 
promotes Tr1 cell development. In association with previous studies, results in this thesis show that 
first and/or early exposures induces immunoregulatory responses rather than anti-parasitic 
responses, since these same immunoregulatory networks appear to be established in young children 
living in malaria-endemic regions who have not yet acquired an adequate level of immunity to 
malaria
47, 48, 232, 235
. The implications of these findings extend to the limited efficacy (46%) of the 
RTS,S/A01 vaccine
12
, where the early establishment of these immunoregulatory networks may 
impede anti-parasitic responses that serve to control parasite growth and thus limit disease 
progression .  
Collectively, these findings provide valuable insights into vaccine development for other infectious 
diseases, such as leishmaniasis, but also immunotherapy where the therapeutic potential of Tr1 cells 
can be harnessed to treat inflammatory disease.  
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Recent studies have focused on the requirements (i.e. IL-27, IL-21, Blimp1, IL-10) for the 
generation of Tr1 cells during T. gondii
216
 and LCMV infections
215
. Importantly, the combined 
effects of Tr1 cell induction and their regulatory actions on host tissue have not been studied in great 
detail. It is tempting to speculate on the immunoregulatory functions of Tr1 cells in limiting tissue 
pathology; however, as is the case with various chronic infectious diseases, where host tissue is 
destroyed, it is not clear whether Tr1 cells are able to restore tissue architecture as well as function. 
Tr1 cells limit pathology, however, whether this is enough to rescue protective immune responses at 
effector tissue sites remains to be empirically demonstrated.  
 
In this thesis, it was demonstrated that the generation of Tr1 cells is dependent on IL-12 and Blimp1 
which supports the concept that they represent a terminally differentiated Th1 CD4
+
 T cell subset. T 
cell-specific Blimp1-deficient mice were employed to show the consequences of a failure to 
generate Tr1 cells in both Plasmodium and Leishmania infections. Impaired Tr1 responses were 
associated with extensive hepatosplenomegaly during L. donovani infection. In addition to this, TNF 
has been shown to be a driving force of pathology observed in the spleen
106, 129
, suggesting that Tr1 
cells play a protective role against TNF-mediated pathology. Taken together, these results suggest 
that during infection, DC’s produce IL-12 to drive Th1 CD4+ T cell differentiation. This results in 
an up-regulation of Blimp1 in Th1 cells to induce IL-10 production by these cells such that they 
acquire the capacity to secrete IL-10 in addition to IFNγ. Importantly, we show IL-10 derived from 
Tr1 cells is an important regulator of TNF-associated pathology. Furthermore, the preservation of 
splenic architecture during infection by TNF blockade rescued lymphocyte trafficking, suggesting 
Tr1 cells are involved in limiting pathology as well as restoring functional immune responses to 
homeostatic balance. Collectively, these findings show for the first time that the therapeutic 
potential of Tr1 cells extends beyond limiting inflammation and may be used to restore immune 
responses during infection. Moreover, these findings are of critical importance, where the use of Tr1 
cells may be extended to other chronic inflammatory diseases. 
 
 
 
 
 
 
 
 
Chapter 6 
 
 41758573  188 
TNF blockade as therapy is widely used to treat inflammatory disorders such as rheumatoid 
arthritis ankylosing spondylitis and plaque psoriasis
137
. However, the issue of immunosuppression is 
strikingly evident in patients treated with anti-TNF agents. Given that TNF is a main driver of 
pathology and disease in VL patients
106
, we explored the possibility of blocking TNF in conjunction 
with anti-parasitic drug in order to limit parasite growth, but protect host tissue against parasite-
induced inflammation. Mice that received drug plus anti-TNF exhibited significantly reduced 
parasite burdens, preserved splenic architecture and the frequency of IFNγ-producing Th1 cells was 
also increased relative to the control group. These findings demonstrate that TNF blockade in 
conjunction with drug treatment can potentially serve as a therapeutic strategy, where drug controls 
parasite growth and TNF blockade limits tissue pathology. These findings have broader 
implications, where an alternative strategy may be to distinguish cellular sources of TNF that 
promote pathology from those that control pathogen growth and then specifically target them with 
small molecules such as TNF inhibitors, as being tested by others
137
. 
 
According to the WHO, 80% of chronic disease deaths occur in low-middle income 
countries
416
. The National Institutes of Health (NIH) have identified 80-100 different autoimmune 
diseases and annual health care costs of up to $100 billion (USD) to treat these diseases
417, 418
. 
Furthermore, current first line therapies are not effective in all patients with autoimmune diseases 
and their different mechanisms of action make it difficult to choose the best treatment option for 
each patient
419
. Taken together, this presents an urgent need for the development of better treatment 
options for individuals with chronic infectious diseases such as malaria and leishmaniasis, as well as 
individuals suffering from autoimmune diseases. Importantly, the findings presented in this thesis 
have identified key immunoregulatory pathways in two important parasitic diseases that have the 
potential to be manipulated not only to improve infectious disease outcomes, but also have impacts 
on a broad range of chronic inflammatory diseases.  
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Appendices 
 
Appendix 1: Composition of the RTS,S/AS01vaccine candidate against malaria 
 
The ‘R’ stands for the central repeat region of P. falciparum  circumsporozoite protein (CSP),  the 
‘T’ for the T-cell epitopes of the CSP; and the ‘S’ for hepatitis B surface antigen (HBsAg). These 
are combined in a single fusion protein (‘RTS’) and co-expressed in yeast cells with free HBsAg. 
The ‘RTS’ fusion protein and free ‘S’ protein spontaneously assemble into ‘RTS,S’ particles and 
the AS01 stands for adjuvant system 01
420, 421
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Appendix 2: Enlarged Ingenuity Pathway Analysis – Signalling pathways 
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Appendix 3: In the absence of IL-10, IL-17A appears to play a minor role in contributing to the 
inflammation-induced pathology observed in the T cell specific Blimp1 deficient mice 
 
a) Splenocytes from L. donovani infected Prdm1
ΔT 
and Prdm1
fl/fl 
mice were cultured in the presence of fixed 
L. donovani (4% PFA) amastigotes for 72 hours and culture supernatants were assessed for IL-17A levels 
using a BD Flex set kit at day 7 and day 14 p.i.. b) WT (C57BL/6J), IL-10 deficient (IL-10
-/-
), Prdm1
ΔT 
and 
Prdm1
fl/fl 
mice were infected with 2x10
7
 L. donovani amastigotes i.v. and serum IL-17A levels were 
measured using a BD Flex set kit at day 14 and 28p.i.. 
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